"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOUSSN_SASSARI",2000,2,16,1,0,0,0,1,0,0,0,0.5,0,1,1,0,0,0.5,0.5,0,0,41,0.904458764225952,NA,0,1,0.094,0,0,0,"GIUSEPPINA CASU;IVANA PERSICO;MARIA GIUSEPPA SAROBBA;GIUSEPPE PALMIERI;ENZO IERARDI;ANTONIO COSSU;A. FARRIS;SERGIO CROTTA;MARIA IMENEO;ANDREA ANGIUS;PAOLO COSSU‐ROCCA;MARIO BUDRONI;MARIO PIRASTU;FRANCESCO LUZZA;MARIA FILOMENA DEDOLA;ADDOLORATA MARASCO;AGATA PISANO;SORIN AURELIAN PAȘCA;V MARRAS;GIOVANNI SANNA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ENZO IERARDI;SERGIO CROTTA;MARIA IMENEO;FRANCESCO LUZZA;ADDOLORATA MARASCO;GIOVANNI SANNA;GERARDO NARDONE;SANTINO MARCHI;ROCCO MAURIZIO ZAGARI;FRANCO BAZZOLI;P. USAI;CLARA VIRGILIO;FRANCESCO PERRI;GIUSEPPINA CASU;IVANA PERSICO;MARIA GIUSEPPA SAROBBA;GIUSEPPE PALMIERI;ANTONIO COSSU;A. FARRIS;ANDREA ANGIUS","0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.05;0.05;0.05;0.05;0.05;0.05;0.05","MARIO BUDRONI;GIOVANNI SANNA","1;1","GIOVANNI SANNA;MARIO BUDRONI","0.08;0.05","A. FARRIS;AGATA PISANO;ANDREA ANGIUS;ANTONIO COSSU;FRANCESCO TANDA;GIOVANNINO MASSARELLI;GIUSEPPE PALMIERI;GIUSEPPINA CASU;GRAZIA PALOMBA;IVANA PERSICO;MARIA FILOMENA DEDOLA;MARIA GIUSEPPA SAROBBA;MARINA PISANO;MARIO BUDRONI;MARIO PIRASTU;N. OLMEO;PAOLO COSSU‐ROCCA;SORIN AURELIAN PAȘCA;V MARRAS;ADDOLORATA MARASCO","44;44;44;44;44;44;44;44;44;44;44;44;44;44;44;44;44;44;44;38","MARIO BUDRONI;GIOVANNI SANNA","44;38","GIOVANNI SANNA;MARIO BUDRONI","1;1","MEDICINE;BIOLOGY","2;1","ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;INTERNAL MEDICINE","1;1;1;1;1","ANTIBODY;AREA UNDER THE CURVE;CANCER;CONFIDENCE INTERVAL;GENE;HELICOBACTER PYLORI;POPULATION;PREDICTIVE VALUE;PREDICTIVE VALUE OF TESTS;PROSPECTIVE COHORT STUDY;RECEIVER OPERATING CHARACTERISTIC;SALIVA","1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;EXON;GENOTYPE;IMMUNOASSAY;IMMUNOGLOBULIN G;LIKELIHOOD RATIOS IN DIAGNOSTIC TESTING;LOCUS (GENETICS);MUTATION;POSITIVE PREDICATIVE VALUE;SEROLOGY","1;1;1;1;1;1;1;1;1;1","GERMLINE MUTATION;HAPLOTYPE;IMMUNOGLOBULIN A","1;1;1","HELICOBACTER INFECTIONS;HELICOBACTER PYLORI;IMMUNOGLOBULIN G;BREAST NEOPLASMS;FEMALE;HUMANS;IMMUNOENZYME TECHNIQUES;MALE;NEOPLASM PROTEINS;SALIVA;TRANSCRIPTION FACTORS;ADOLESCENT;ADULT;AGED;AGED, 80 AND OVER;BASE SEQUENCE;BRCA2 PROTEIN;DNA PRIMERS;FOUNDER EFFECT;MIDDLE AGED","3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER","1;1","BRCA2 PROTEIN;BREAST CANCER;FOUNDER EFFECT;HELICOBACTER PYLORI;IDENTITY BY DESCENT;IMMUNOGLOBULIN A;POSITIVE PREDICATIVE VALUE","1;1;1;1;1;1;1","BRCA MUTATION;COMMERCIAL SEROLOGICAL;FOUNDER BRCA;HELICOBACTER PYLORI;SALIVARY IMMUNOGLOBULIN;SEROLOGICAL KIT","1;1;1;1;1;1","BREAST CANCER;CANCER PATIENTS;IDENTITY-BY-DESCENT METHOD;SARDINIAN BREAST;SHARED HAPLOTYPE;ANALYSING PARAFFIN-EMBEDDED;APPLIED SUCCESSFULLY;BLADDER CANCER;BRCA CODING;BRCA LOCUS;BRCA MUTATION;CANCER FAMILIES;CANCER PATIENT;CANCER POPULATION;CANCER RESEARCH;CODING EXONS;CODON DELAG;COMMON HAPLOTYPE;CONTROL NUCLEAR;DELAG CAUSING;DELAG MUTATION;DIRECT SEQUENCING;FAMILIES ORIGINATING;FAMILIES SUGGESTS;FLANKING BRCA;FOUNDER BRCA;FOUNDER MUTATION;FRAME-SHIFT MUTATION;HAPLOTYPE ALLOWED;HAPLOTYPE SHARED","5;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.5,3,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,18,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2001,2,6.5,6.5,1,0.5,1,1,0.666666666666667,0.5,0.666666666666667,0,1,1,0,0,1,0.5,0,0,0.5,25,0.547136594290448,NA,0,0.5,0.423,0,0,0,"A. CONTU;F CARNINO;SILVIA COMIS;P. PRONZATO;LORELLA VESENTINI;LUIGI GALLO;M. BERGAGLIO;LUCIA DEL MASTRO;RITA LIONETTO;GIOVANNI FADDA;DOMENICO GUARNERI;MARCO VENTURINI;RICCARDO ROSSO","1;1;1;1;1;1;1;1;1;1;1;1;1","GIOVANNI FADDA;A. CONTU;F CARNINO;SILVIA COMIS;P. PRONZATO;LORELLA VESENTINI;LUIGI GALLO;M. BERGAGLIO;LUCIA DEL MASTRO;RITA LIONETTO;DOMENICO GUARNERI;MARCO VENTURINI;RICCARDO ROSSO","1;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08","A. CONTU;F CARNINO;SILVIA COMIS;P. PRONZATO;LORELLA VESENTINI;LUIGI GALLO;M. BERGAGLIO;LUCIA DEL MASTRO;RITA LIONETTO;GIOVANNI FADDA;DOMENICO GUARNERI;MARCO VENTURINI;RICCARDO ROSSO","1;1;1;1;1;1;1;1;1;1;1;1;1","GIOVANNI FADDA;A. CONTU;F CARNINO;SILVIA COMIS;P. PRONZATO;LORELLA VESENTINI;LUIGI GALLO;M. BERGAGLIO;LUCIA DEL MASTRO;RITA LIONETTO;DOMENICO GUARNERI;MARCO VENTURINI;RICCARDO ROSSO","1;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08;0.08","A. CONTU;DOMENICO GUARNERI;F CARNINO;LORELLA VESENTINI;LUCIA DEL MASTRO;LUIGI GALLO;M. BERGAGLIO;MARCO VENTURINI;P. PRONZATO;RICCARDO ROSSO;RITA LIONETTO;SILVIA COMIS;GIOVANNI FADDA","40;40;40;40;40;40;40;40;40;40;40;40;10","A. CONTU;DOMENICO GUARNERI;F CARNINO;LORELLA VESENTINI;LUCIA DEL MASTRO;LUIGI GALLO;M. BERGAGLIO;MARCO VENTURINI;P. PRONZATO;RICCARDO ROSSO;RITA LIONETTO;SILVIA COMIS;GIOVANNI FADDA","40;40;40;40;40;40;40;40;40;40;40;40;10","A. CONTU;DOMENICO GUARNERI;F CARNINO;GIOVANNI FADDA;LORELLA VESENTINI;LUCIA DEL MASTRO;LUIGI GALLO;M. BERGAGLIO;MARCO VENTURINI;P. PRONZATO;RICCARDO ROSSO;RITA LIONETTO;SILVIA COMIS","1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE","2","INTERNAL MEDICINE;GASTROENTEROLOGY;ONCOLOGY;PATHOLOGY","2;1;1;1","ADVERSE EFFECT;CANCER;CHEMOTHERAPY;CONCOMITANT;COPD;LUNG;TUBERCULOSIS","1;1;1;1;1;1;1","BREAST CANCER;BRONCHIECTASIS;CYCLOPHOSPHAMIDE;FLUOROURACIL;SPUTUM;TOLERABILITY","1;1;1;1;1;1","EPIRUBICIN;METASTATIC BREAST CANCER","1;1","AMBROXOL;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;ADULT;AGED;CYCLOPHOSPHAMIDE;EPIRUBICIN;EXPECTORANTS;FEMALE;FLUOROURACIL;GRANULOCYTE COLONY-STIMULATING FACTOR;HUMANS;MALE;MIDDLE AGED;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;TERPENES;ADMINISTRATION, ORAL;AGED, 80 AND OVER;DISEASE PROGRESSION;DISEASE-FREE SURVIVAL","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF CHRONIC COUGH","1;1","AMBROXOL;CONCOMITANT;EPIRUBICIN;METASTATIC BREAST CANCER;TOLERABILITY","1;1;1;1;1","ACCELERATED-INTENSIFIED CYCLOPHOSPHAMIDE;AIRWAYS DISEASES;BREAST CANCER;CANCER PATIENTS;CEF COMPARED;COMPARISON VERSUS;CONTROLLED COMPARISON;CYCLOPHOSPHAMIDE EPIRUBICIN;FLUOROURACIL CEF;GRUPPO ONCOLOGICO;III STUDY;INTER GRUPPO;ITALIAN GRUPPO;METASTATIC BREAST;MULTICENTER RANDOMIZED;NORD-OUESTMAMMELLA INTER;OBSTRUCTIVE AIRWAYS;ONCOLOGICO NORD-OUESTMAMMELLA;ORAL NELTENEXINE;PATIENTS RESULTS;PHASE III;RANDOMISED CONTROLLED;RANDOMIZED PHASE;STANDARD CEF;VERSUS SOBREROL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2002,1,5,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,6,0.108757299995285,NA,0,0,0,0,0,0,"ANNA MARIA LISCIA;CARLA MASALA;ROBERTO CRNJAR;A CERBONESCHI;PAOLO SOLARI","1;1;1;1;1","ANNA MARIA LISCIA;CARLA MASALA;ROBERTO CRNJAR;A CERBONESCHI;PAOLO SOLARI","0.2;0.2;0.2;0.2;0.2","A CERBONESCHI","1","A CERBONESCHI","0.2","A CERBONESCHI;ANNA MARIA LISCIA;CARLA MASALA;PAOLO SOLARI;ROBERTO CRNJAR","6;6;6;6;6","A CERBONESCHI","6","A CERBONESCHI","1","BIOLOGY","1","ANATOMY;BIOCHEMISTRY;BOTANY;MICROBIOLOGY;NEUROSCIENCE;ZOOLOGY","1;1;1;1;1;1","ENTAMOEBA HISTOLYTICA;GALEA;LARVA;LEPIDOPTERA GENITALIA;NICOTINE;RECEPTOR;TASTE","1;1;1;1;1;1;1","CHEMORECEPTOR;DISPAR;GYPSY MOTH;LYMANTRIA DISPAR;PYRALIDAE","1;1;1;1;1","","","","1","NEUROSCIENCE AND GENETICS OF DROSOPHILA MELANOGASTER","1","DISPAR;GALEA;GYPSY MOTH;LYMANTRIA DISPAR;ODOR SOURCE LOCALIZATION","1;1;1;1;1","MOTHILYMANTRIA DISPARI","1","CHEMORECEPTOR CELLS;GYPSY MOTH;ABSTRACT TASTE;APPROACHES DOSERESPONSE;BEHAV IOURAL;BEHAVIOURAL APPROACHES;BLE ROLE;CATEGO RIZED;CELLS INVOLVED;CHARACTERIZING CHEMORECEPTOR;DETERRENT SUBSTANCES;DIET COMPONENTS;DOSERESPONSE RELA;ELECTROPHYSIOLOGICAL DATA;GUSTATION RESULTS;IOURAL EFFECTS;LATERAL SENSILLA;LYMANTRIA DISPAR;MARKED SENSITIVITY;MAXILLARY PALPS;MEDIAL SENSILLA;MOTH LYMANTRIA;NACL SUCROSE;NICOTINE SOLUTIONS;POSSI BLE;RELA TIONSHIPS;SENSILLA BASICONICA;SENSILLA STYLOCONICA;SPECIFIC STIMULI;SUGARS MORPHOLOGICAL","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2003,2,8.5,1,0,0,0,1,0,0,0,0.5,0,2,0,0,0,1,0,0,0,24,0.453447033095916,NA,0,1,0.088,0,0,0,"MAURO MANCONI;ANTONIO DURANDO;FRANCO TARRO GENTA;A. CONTU;ORNELLA GARRONE;MARIA ANTONIETTA COLOZZA;CLAUDIA BIGHIN;SALVATORE LORENZONI;GIANPIERO BOATTO;I. STEVANI;A. LAMBIASE;D. SERRA;LUCIA DEL MASTRO;MARIA NIEDDU;ANTONIO CARTA;MARCO VENTURINI;A. PAU","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAURO MANCONI;SALVATORE LORENZONI;GIANPIERO BOATTO;D. SERRA;MARIA NIEDDU;ANTONIO CARTA;A. PAU;ANTONIO DURANDO;FRANCO TARRO GENTA;A. CONTU;ORNELLA GARRONE;MARIA ANTONIETTA COLOZZA;CLAUDIA BIGHIN;I. STEVANI;A. LAMBIASE;LUCIA DEL MASTRO;MARCO VENTURINI","0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1","A. CONTU;SALVATORE LORENZONI","1;1","SALVATORE LORENZONI;A. CONTU","0.14;0.1","A. PAU;ANTONIO CARTA;D. SERRA;GIANPIERO BOATTO;MARIA NIEDDU;MAURO MANCONI;SALVATORE LORENZONI;A. CONTU;A. LAMBIASE;ANTONIO DURANDO;CLAUDIA BIGHIN;FRANCO TARRO GENTA;I. STEVANI;LUCIA DEL MASTRO;MARCO VENTURINI;MARIA ANTONIETTA COLOZZA;ORNELLA GARRONE","27;27;27;27;27;27;27;21;21;21;21;21;21;21;21;21;21","SALVATORE LORENZONI;A. CONTU","27;21","A. CONTU;SALVATORE LORENZONI","1;1","MEDICINE;CHEMISTRY","2;1","BIOCHEMISTRY;CHROMATOGRAPHY;GASTROENTEROLOGY;INTERNAL MEDICINE;MEDICAL EMERGENCY;ORGANIC CHEMISTRY;SURGERY","1;1;1;1;1;1;1","ADVERSE EFFECT;CANCER;CHEMOTHERAPY;EXTRACTION (CHEMISTRY);PHENOL;POISON CONTROL;SOLVENT;STOMACH;URINE","1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;CRESOL;CYCLOPHOSPHAMIDE;DICHLOROMETHANE;DOCETAXEL;MUCOSITIS;NEUTROPENIA","1;1;1;1;1;1;1","CAPECITABINE;EPIRUBICIN;FEBRILE NEUTROPENIA","1;1;1","ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BONE NEOPLASMS;BREAST NEOPLASMS;CRESOLS;DEOXYCYTIDINE;DISINFECTANTS;LIVER NEOPLASMS;PACLITAXEL;PHENOL;ADULT;EPIRUBICIN;FLUOROURACIL;HUMANS;STOMACH;AGED;CAPECITABINE;CHROMATOGRAPHY, GEL;DOCETAXEL;FEMALE;GAS CHROMATOGRAPHY-MASS SPECTROMETRY","3;3;3;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GENOTOXICITY AND CARCINOGENESIS MECHANISMS","1;1","CRESOL;DICHLOROMETHANE;EPIRUBICIN;FORENSIC TOXICOLOGY;MICROTUBULE-TARGETING AGENTS;MUCOSITIS;POSTMORTEM TOXICOLOGY;TOXICITY ASSESSMENT","1;1;1;1;1;1;1;1","ADVANCED BREAST;BREAST CARCINOMA;FATAL POISONING;PREVIOUSLY UNTREATED;UNTREATED ADVANCED","1;1;1;1;1","GRADE ADVERSE;III DISEASE;STAGE III;ACCEPTABLE SAFETY;ADVERSE EVENTS;BREAST CARCINOMA;COMPLETE RESPONSES;IV DISEASE;ORAL CAPECITABINE;SAFETY PROFILE;STAGE IV;TEX CHEMOTHERAPY;ACHIEVED TUMOR;ADVANCED BREAST;ADVANCEDMETASTATIC BREAST;ADVERSE EVENT;AMERICAN CANCER;ANTITUMOR ACTIVITY;CANCER AMERICAN;CANCER SOCIETY;CAPECITABINE MGM;CARCINOMA CANCER;CARCINOMA METHODS;CENTERS TREATMENT;CHEMOTHERAPY DEMONSTRATED;COMBINATION THERAPY;COMMON GRADE;COMPARE TEX;CONCLUSIONS TEX;CYCLE RESULTS","3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2004,2,13.5,1.5,0,0,0,1,0,0,0,0,0,2,0,0,0,1,0,0,0,40.5,0.86072030119885,NA,0.5,1,0.126,0,0,0,"ALFREDO BERRUTI;SUZANNE PARRY;MARIA GIUSEPPA SAROBBA;GIUSEPPE PALMIERI;ANTONIO COSSU;A. FARRIS;SARA LATTUADA;T VOLPE;MICHELA DONADIO;OSCAR BERTETTO;ALBERTO BOTTINI;DIONYSSIOS KATSAROS;CHRIS JONES;PETER T. SIMPSON;S. MANCARELLA;MARIO BUDRONI;SUNIL R. LAKHANI;THEODORA GALE;RAFFAELLA BITOSSI;JORGE S. REIS‐FILHO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SUZANNE PARRY;GIUSEPPE PALMIERI;ANTONIO COSSU;CHRIS JONES;PETER T. SIMPSON;MARIO BUDRONI;SUNIL R. LAKHANI;THEODORA GALE;JORGE S. REIS‐FILHO;DAWN STEELE;ALFREDO BERRUTI;MARIA GIUSEPPA SAROBBA;A. FARRIS;SARA LATTUADA;T VOLPE;MICHELA DONADIO;OSCAR BERTETTO;ALBERTO BOTTINI;DIONYSSIOS KATSAROS;S. MANCARELLA","0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06","MARIA GIUSEPPA SAROBBA;A. FARRIS;MARIO BUDRONI","1;1;1","MARIO BUDRONI;MARIA GIUSEPPA SAROBBA;A. FARRIS","0.1;0.06;0.06","ANTONIO COSSU;CHRIS JONES;DAWN STEELE;GIUSEPPE PALMIERI;JORGE S. REIS‐FILHO;MARIO BUDRONI;PETER T. SIMPSON;SUNIL R. LAKHANI;SUZANNE PARRY;THEODORA GALE;A. FARRIS;ALBERTO BOTTINI;ALFREDO BERRUTI;CINZIA NIGRO;DIONYSSIOS KATSAROS;ELENA BERTONE;FEDERICO CASTIGLIONE;LUIGI DOGLIOTTI;MARIA GIUSEPPA SAROBBA;MICHELA DONADIO","73;73;73;73;73;73;73;73;73;73;8;8;8;8;8;8;8;8;8;8","MARIO BUDRONI;A. FARRIS;MARIA GIUSEPPA SAROBBA","73;8;8","A. FARRIS;MARIA GIUSEPPA SAROBBA;MARIO BUDRONI","1;1;1","MEDICINE;BIOLOGY","2;1","GASTROENTEROLOGY;GENETICS;INTERNAL MEDICINE;ONCOLOGY;PATHOLOGY;SURGERY","1;1;1;1;1;1","CANCER;CARCINOMA;CHEMOTHERAPY;IMMUNOHISTOCHEMISTRY;REGIMEN;STROMAL CELL;TOXICITY","2;1;1;1;1;1;1","BREAST CANCER;CISPLATIN;FLUOROURACIL;MUCOSITIS;MYOEPITHELIAL CELL;TISSUE MICROARRAY","2;1;1;1;1;1","ANTHRACYCLINE;EPIRUBICIN;INVASIVE DUCTAL CARCINOMA;METASTATIC BREAST CANCER;VINORELBINE","1;1;1;1;1","BREAST NEOPLASMS;VINBLASTINE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;EPIRUBICIN;FLUOROURACIL;MYOEPITHELIOMA;BIOMARKERS, TUMOR;BREAST DISEASES;CARCINOMA, DUCTAL;CARCINOMA, DUCTAL, BREAST;CELL NUCLEUS;CYTOPLASM;EXONUCLEASES;FEMALE;HUMANS;IMMUNOHISTOCHEMISTRY;NEOPLASM PROTEINS;14-3-3 PROTEINS;ADULT;AGED","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","14-3-3 PROTEINS: STRUCTURE, FUNCTION, AND REGULATION;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT","1;1","14-3-3 PROTEINS;BREAST CANCER;CHEMOTHERAPY;EPIRUBICIN;INVASIVE LOBULAR CARCINOMA;MUCOSITIS;REGIMEN;TISSUE MICROARRAY;VINORELBINE","1;1;1;1;1;1;1;1;1","ANTHRACYCLINE-NAÏVE METASTATIC;BREAST CANCER;BREAST TISSUE;CANCER PATIENTS;COMBINATION REGIMEN;CONTINUOUS INFUSION;EPIRUBICIN VINORELBINE;FIRST-LINE CHEMOTHERAPY;FLUOROURACIL CONTINUOUS;MALIGNANT BREAST;METASTATIC BREAST;MYOEPITHELIAL MARKER;NORMAL BENIGN","1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2005,2,13.5,1.5,0,0,0,1,0,0,0,0.5,0,1,1,0,0,0.5,0.5,0,0,22,0.415535523603764,NA,0,1,0,0,0,0,"FEDERICO CAPPUZZO;ANTONIO DURANDO;ALFREDO BERRUTI;MARIA GIUSEPPA SAROBBA;FABIO PUGLISI;A. FARRIS;S. MONFARDINI;MICHELA DONADIO;DANIELE GENERALI;CLAUDIA BIGHIN;OSCAR BERTETTO;ALBERTO BOTTINI;G. GORZEGNO;DIONYSSIOS KATSAROS;MASSIMO MILANI;SILVIO DANESE;A. LAMBIASE;N. OLMEO;RAFFAELLA BITOSSI;LUCIA DEL MASTRO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FEDERICO CAPPUZZO;ANTONIO DURANDO;FABIO PUGLISI;S. MONFARDINI;CLAUDIA BIGHIN;A. LAMBIASE;N. OLMEO;LUCIA DEL MASTRO;ORNELLA NICOLETTO;M. VENTURINI;ALFREDO BERRUTI;MARIA GIUSEPPA SAROBBA;A. FARRIS;MICHELA DONADIO;DANIELE GENERALI;OSCAR BERTETTO;ALBERTO BOTTINI;G. GORZEGNO;DIONYSSIOS KATSAROS;MASSIMO MILANI","0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06","MARIA GIUSEPPA SAROBBA;A. FARRIS","1;1","MARIA GIUSEPPA SAROBBA;A. FARRIS","0.06;0.06","A. LAMBIASE;ANTONIO DURANDO;CLAUDIA BIGHIN;FABIO PUGLISI;FEDERICO CAPPUZZO;LUCIA DEL MASTRO;M. VENTURINI;N. OLMEO;ORNELLA NICOLETTO;S. MONFARDINI;A. FARRIS;ALBERTO BOTTINI;ALFREDO BERRUTI;DANIELE GENERALI;DIONYSSIOS KATSAROS;G. GORZEGNO;IRENE A. RIGAULT DE LA LONGRAIS;LUIGI DOGLIOTTI;MARA ARDINE;MARIA GIUSEPPA SAROBBA","32;32;32;32;32;32;32;32;32;32;12;12;12;12;12;12;12;12;12;12","A. FARRIS;MARIA GIUSEPPA SAROBBA","12;12","A. FARRIS;MARIA GIUSEPPA SAROBBA","1;1","MEDICINE","2","INTERNAL MEDICINE;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;ONCOLOGY;SURGERY","2;1;1;1;1","CANCER;CHEMOTHERAPY;POPULATION;REGIMEN;TOXICITY","2;2;1;1;1","BREAST CANCER;ANTIMETABOLITE;CISPLATIN;DOCETAXEL;FLUOROURACIL;MUCOSITIS;PACLITAXEL;PHASES OF CLINICAL RESEARCH","2;1;1;1;1;1;1;1","EPIRUBICIN;MAMMARY GLAND;METASTATIC BREAST CANCER;TRASTUZUMAB;VINORELBINE","1;1;1;1;1","BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BONE NEOPLASMS;LIVER NEOPLASMS;LUNG NEOPLASMS;LYMPHATIC METASTASIS;VINBLASTINE;ADULT;AGED;ANTHRACYCLINES;ANTIBIOTICS, ANTINEOPLASTIC;ANTIBODIES, MONOCLONAL;ANTIMETABOLITES, ANTINEOPLASTIC;ANTINEOPLASTIC AGENTS, PHYTOGENIC;EPIRUBICIN;FEMALE;FLUOROURACIL;HUMANS;MIDDLE AGED;PACLITAXEL","6;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT","1;1","METASTATIC BREAST CANCER;BREAST CANCER;EPIRUBICIN;MUCOSITIS;PACLITAXEL;REGIMEN;TRASTUZUMAB;TREATMENT RESPONSE;VINORELBINE","2;1;1;1;1;1;1;1;1","BREAST CANCER;ADJUVANT ANTHRACYCLINES;CANCER PATIENTS;FIRST-LINE TREATMENT;HER-OVEREXPRESSING METASTATIC;II STUDY;METASTATIC BREAST;MULTICENTER PHASE;PACLITAXEL VINORELBINE;PATIENTS PRETREATED;PHASE II","2;1;1;1;1;1;1;1;1;1;1","CONTINUOUS INFUSION;FU CONTINUOUS;PATIENTS GRADE;ADJUVANT ANTHRACYCLINES;BREAST CANCER;CANCER PATIENTS;COMBINATION REGIMEN;COMPLETE REMISSION;COMPLETE RESPONSE;COMPLETE RESPONSES;CRITERIA COMPLETE;CRITERIA OBJECTIVE;DAY CYCLES;DAYS DISEASE;DISEASE RESPONSE;DOSE-LIMITING TOXICITY;ENTIRE POPULATION;FIRST-LINE CHEMOTHERAPY;FLUOROURACIL -FU;GRADE NEUROTOXICITY;GRADE NONHAEMATOLOGIC;HEALTH ORGANIZATION;INCLUDED MUCOSITISDIARRHOEA;INFUSION ADMINISTERED;INFUSION COMBINATION;LEUCOPENIA GRADE;MANAGEABLE COMPLETE;MEDIAN DURATION;MEDIAN TIME;METASTATIC BREAST","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2006,1,18,2,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,29,0.567756810601483,NA,0,1,0,0,0,0,"MARIA COLOMBINO;MILENA CASULA;GIUSEPPE PALMIERI;ANTONIO COSSU;CORRADO CARACÒ;PAOLO A. ASCIERTO;ROSA CALEMMA;MARIO BUDRONI;MICHELE GUIDA;SERGIO CANZANELLA;C LODDO;ESTER SIMEONE;GIUSEPPE CASTELLO;ANTONIO DAPONTE;AMELIA LISSIA;GIUSEPPE COMELLA;MARÍA PAOLA SATTA;NICOLA MOZZILLO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MARIA COLOMBINO;MILENA CASULA;GIUSEPPE PALMIERI;ANTONIO COSSU;CORRADO CARACÒ;PAOLO A. ASCIERTO;ROSA CALEMMA;MARIO BUDRONI;MICHELE GUIDA;SERGIO CANZANELLA;C LODDO;ESTER SIMEONE;GIUSEPPE CASTELLO;ANTONIO DAPONTE;AMELIA LISSIA;GIUSEPPE COMELLA;MARÍA PAOLA SATTA;NICOLA MOZZILLO","0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06;0.06","ANTONIO COSSU;AMELIA LISSIA","1;1","ANTONIO COSSU;AMELIA LISSIA","0.06;0.06","AMELIA LISSIA;ANTONIO COSSU;ANTONIO DAPONTE;C LODDO;CORRADO CARACÒ;ESTER SIMEONE;GIUSEPPE CASTELLO;GIUSEPPE COMELLA;GIUSEPPE PALMIERI;MARIA COLOMBINO;MARIO BUDRONI;MARÍA PAOLA SATTA;MICHELE GUIDA;MILENA CASULA;NICOLA MOZZILLO;PAOLO A. ASCIERTO;ROSA CALEMMA;SERGIO CANZANELLA","29;29;29;29;29;29;29;29;29;29;29;29;29;29;29;29;29;29","AMELIA LISSIA;ANTONIO COSSU","29;29","AMELIA LISSIA;ANTONIO COSSU","1;1","BIOLOGY;MEDICINE","1;1","CANCER RESEARCH;GENETICS;INTERNAL MEDICINE;ONCOLOGY","1;1;1;1","CANCER;GENE;MELANOMA","1;1;1","CANDIDATE GENE;CDKN2A;GERMLINE;MUTATION","1;1;1;1","DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;GERMLINE MUTATION","1;1","MELANOMA;SKIN NEOPLASMS;GERM-LINE MUTATION;ITALY;PROTO-ONCOGENE PROTEINS B-RAF;ADULT;CHROMATOGRAPHY, HIGH PRESSURE LIQUID;DNA MUTATIONAL ANALYSIS;FEMALE;GENES, BRCA2;GENES, P16;GENETIC TESTING;HUMANS;MALE;MIDDLE AGED;REGRESSION ANALYSIS","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MELANOMA","1","CANCER GENOMICS;CANDIDATE GENE;MELANOMA","1;1;1","CANDIDATE GENES;CUTANEOUS MALIGNANT;FACTORS PREDICTING;GERMLINE MUTATIONS;MALIGNANT MELANOMA;SOUTH ITALY","1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2007,2,7.5,1.5,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0.5,0,0,27,0.511596267907265,NA,0.5,1,0.246,0,0,0,"PAOLA BALDINU;MARCELLO FILOPANTI;A. CONTU;GIUSEPPE PALMIERI;ANTONIO COSSU;A. FARRIS;MARIA CRISTINA SINI;EITAN FRIEDMAN;MARIO BUDRONI;ANNA MARIA BARBIERI;GRAZIA PALOMBA;MARINA PISANO;PAOLO BECK‐PECCOZ;FRANCESCO TANDA;GUIDO BUA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MARCELLO FILOPANTI;ANNA MARIA BARBIERI;PAOLO BECK‐PECCOZ;GUIDO BUA;PAOLA BALDINU;A. CONTU;GIUSEPPE PALMIERI;ANTONIO COSSU;A. FARRIS;MARIA CRISTINA SINI;EITAN FRIEDMAN;MARIO BUDRONI;GRAZIA PALOMBA;MARINA PISANO;FRANCESCO TANDA","0.25;0.25;0.25;0.25;0.09;0.09;0.09;0.09;0.09;0.09;0.09;0.09;0.09;0.09;0.09","A. CONTU;ANTONIO COSSU;GUIDO BUA","1;1;1","GUIDO BUA;A. CONTU;ANTONIO COSSU","0.25;0.09;0.09","ANNA MARIA BARBIERI;GUIDO BUA;MARCELLO FILOPANTI;PAOLO BECK‐PECCOZ;A. CONTU;A. FARRIS;ANTONIO COSSU;EITAN FRIEDMAN;FRANCESCO TANDA;GIUSEPPE PALMIERI;GRAZIA PALOMBA;MARIA CRISTINA SINI;MARINA PISANO;MARIO BUDRONI;PAOLA BALDINU","37;37;37;37;17;17;17;17;17;17;17;17;17;17;17","GUIDO BUA;A. CONTU;ANTONIO COSSU","37;17;17","A. CONTU;ANTONIO COSSU;GUIDO BUA","1;1;1","BIOLOGY;MATHEMATICS;MEDICINE","2;1;1","GENETICS;INTERNAL MEDICINE;MATHEMATICAL ANALYSIS;MOLECULAR BIOLOGY;ONCOLOGY","2;1;1;1;1","GENE;CANCER;DISTRIBUTION (MATHEMATICS);SURGICAL ONCOLOGY","2;1;1;1","MUTATION;BREAST CANCER;EXON","2;1;1","COMPOUND HETEROZYGOSITY;GERMLINE MUTATION;MISSENSE MUTATION","1;1;1","BREAST NEOPLASMS;BRCA2 PROTEIN;ITALY;CALCINOSIS;CANADA;FEMALE;FRANCE;GENETIC PREDISPOSITION TO DISEASE;HUMANS;HYPOPHOSPHATEMIA, FAMILIAL;ISRAEL;JEWS;MALE;N-ACETYLGALACTOSAMINYLTRANSFERASES;NEOPLASM PROTEINS;PEDIGREE;YEMEN;APOPTOSIS REGULATORY PROTEINS;CODON, NONSENSE;DNA MUTATIONAL ANALYSIS","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE","1;1","BRCA2;BRCA2 PROTEIN;COMPOUND HETEROZYGOSITY;HYPERPHOSPHATEMIA;NONSENSE MUTATION;SURGICAL ONCOLOGY","1;1;1;1;1;1","BRCA-DELAG MUTATION;BREAST CANCER;FAMILIAL TUMORAL;GALNT GENE;NONSENSE MUTATIONS;TUMORAL CALCINOSIS","1;1;1;1;1;1","BREAST CANCER;BRCA-DELAG VARIANT;FOUNDER MUTATION;GALNT GENE;HAPLOTYPE ANALYSIS;JEWISH-YEMENITE POPULATIONS;NORTH SARDINIA;ADDITIONAL GENETIC;ANALYSES REVEALED;ANALYSIS SCREENING;ANCESTRAL ORIGIN;AUTOMATED SEQUENCINGAMONG;AUTOSOMAL RECESSIVE;BRCA GENE;BRCA LOCUS;BRCA-DELAG MUTATION;BRCA-DELAG OCCURS;CALCINOSIS HFTC;CANCER FAMILIES;CANCER FAMILY;CANCER PATIENTS;CHAIN REACTION;CIRCULATING LEVELS;CLINICAL FEATURES;CODING SEQUENCE;COMMON ANCESTRAL;COMPOUND HETEROZYGOTE;CONSECUTIVELY-COLLECTED BREAST;CURRENT STUDY;DELAG MUTATION","4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.5,3,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,12,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,9,3942,33.33,0,0,262,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","BREAST CANCER;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY","1;1;1;1;1","CANCER","1",NA,NA,"BREAST CANCER","1",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2008,1,10,4,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,35,0.637849585975245,NA,0,1,0,0,0,0,"LUCA DEIANA;PAOLO BATTISTA FIORI;RENZO GINANNESCHI;SALVATORE SOTGIA;S. PETTINATO;CIRIACO CARRU;ANGELO ZINELLU;STEFANIA MAGLIONA;FLAVIA FRANCONI;SALVATORICA MANCA","1;1;1;1;1;1;1;1;1;1","LUCA DEIANA;PAOLO BATTISTA FIORI;RENZO GINANNESCHI;SALVATORE SOTGIA;S. PETTINATO;CIRIACO CARRU;ANGELO ZINELLU;STEFANIA MAGLIONA;FLAVIA FRANCONI;SALVATORICA MANCA","0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1","RENZO GINANNESCHI;S. PETTINATO;STEFANIA MAGLIONA;SALVATORICA MANCA","1;1;1;1","RENZO GINANNESCHI;S. PETTINATO;STEFANIA MAGLIONA;SALVATORICA MANCA","0.1;0.1;0.1;0.1","ANGELO ZINELLU;CIRIACO CARRU;FLAVIA FRANCONI;LUCA DEIANA;PAOLO BATTISTA FIORI;RENZO GINANNESCHI;S. PETTINATO;SALVATORE SOTGIA;SALVATORICA MANCA;STEFANIA MAGLIONA","35;35;35;35;35;35;35;35;35;35","RENZO GINANNESCHI;S. PETTINATO;SALVATORICA MANCA;STEFANIA MAGLIONA","35;35;35;35","RENZO GINANNESCHI;S. PETTINATO;SALVATORICA MANCA;STEFANIA MAGLIONA","1;1;1;1","CHEMISTRY","1","BIOCHEMISTRY;CHROMATOGRAPHY;ORGANIC CHEMISTRY","1;1;1","AMINO ACID;CAPILLARY ELECTROPHORESIS;DNA;GENE;PHOSPHORIC ACID","1;1;1;1;1","CYTOSINE;GENE EXPRESSION;GENOMIC DNA;METHIONINE;METHYLATION","1;1;1;1;1","DNA METHYLATION","1","DNA;ELECTROPHORESIS, CAPILLARY;GENOME;DNA METHYLATION;DNA, PLANT;HYDROLYSIS;TEMPERATURE","2;2;2;1;1;1;1","EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS","1","5-METHYLCYTOSINE;CYTOSINE;DNA METHYLATION;GENOMIC DNA;PHOSPHORIC ACID;RNA METHYLATION","1;1;1;1;1;1","CAPILLARY ZONE;DNA METHYLATION;GENOMIC DNA;INJECTION CAPILLARY;METHYLATION DEGREE;RAPID QUANTIFICATION;SHORT-END INJECTION;TOTAL GENOMIC;ZONE ELECTROPHORESIS","1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,1,30,25,0,0,2,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","ATHEROSCLEROSIS;CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;HYPERTENSION;KIDNEY DISEASE","1;1;1;1;1;1","CARDIOVASCULAR","1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2009,8,7.375,2.75,0.375,0.25,0.375,1.10526315789474,0.75,0.666666666666667,0.75,0.375,1,5,1,0,1,0.62,0.12,0,0.12,10.62,0.229693861619206,NA,0.25,0.875,0.263,0.267,0,0.267,"GIUSEPPE PALMIERI;ANTONIO COSSU;MARIO BUDRONI;PAOLO A. ASCIERTO;GRAZIA PALOMBA;MILENA CASULA;FABIANA TATANGELO;ASSUNTA LOMBARDI;A. CONTU;MARIO FUSILLO;A. FARRIS;CORRADO CARACÒ;CRISTIAN ALTANA;MARIA MONNE;PAOLO CASTELNUOVO;ELENA PAGANI;N LICHERI;MARIA CRISTINA SINI;O NINA;YULIYA BERD","3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FRANCISCO J.B. SAMPAIO;N LICHERI;AGOSTINO VIRDIS;A RUIU;GIUSEPPE PALMIERI;ANTONIO COSSU;MARIO BUDRONI;PAOLO A. ASCIERTO;PAOLO CASTELNUOVO;FRANCESCO MELONI;E DELEHAYE;MAURIZIO BIGNAMI;ANDREA PISTOCHINI;GRAZIA PALOMBA;FABIANA TATANGELO;ANTONELLA MANCA;CRISTINA SINI;FRANCESCO IZZO;MARIO FUSILLO;CRISTIAN ALTANA","1;0.33;0.33;0.33;0.31;0.31;0.31;0.21;0.2;0.2;0.2;0.2;0.2;0.18;0.12;0.12;0.12;0.12;0.11;0.11","GIUSEPPE PALMIERI;ANTONIO COSSU;MARIO BUDRONI;GRAZIA PALOMBA;A. CONTU;MARIO FUSILLO;A. FARRIS;MARIA MONNE;O NINA;FRANCESCO MELONI;ANTONELLA URAS;MARCO IANNUCCELLI;E DELEHAYE;ANGELA LOI;ANTONIO DESSANTI;AGOSTINO VIRDIS;MICHELE UBERTAZZI;LAURA CRISPONI;G. STRUSI","3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AGOSTINO VIRDIS;GIUSEPPE PALMIERI;ANTONIO COSSU;MARIO BUDRONI;FRANCESCO MELONI;E DELEHAYE;GRAZIA PALOMBA;MARIO FUSILLO;MARCO IANNUCCELLI;ANTONIO DESSANTI;MICHELE UBERTAZZI;G. STRUSI;A. CONTU;A. FARRIS;MARIA MONNE;ANTONELLA URAS;ANGELA LOI;LAURA CRISPONI;O NINA","0.33;0.31;0.31;0.31;0.2;0.2;0.18;0.11;0.11;0.11;0.11;0.11;0.1;0.1;0.1;0.1;0.1;0.1;0.09","ANTONIO COSSU;ANTONIO MUGGIANO;CORRADO CARACÒ;ELENA PAGANI;GIUSEPPE PALMIERI;GRAZIA PALOMBA;IGNAZIO STANGANELLI;MARIA CRISTINA SINI;MARIO BUDRONI;MILENA CASULA;PAOLO A. ASCIERTO;SERGIO CANZANELLA;ANNA R TANCA;ANTONIO DESSANTI;CRISTIAN ALTANA;DIEGO FALCHETTI;G. STRUSI;MARCO IANNUCCELLI;MARIO FUSILLO;MICHELE UBERTAZZI","46;46;46;46;46;46;46;46;46;46;46;46;26;26;26;26;26;26;26;26","ANTONIO COSSU;ANTONIO DESSANTI;G. STRUSI;MARCO IANNUCCELLI;MARIO FUSILLO;MICHELE UBERTAZZI;E DELEHAYE;FRANCESCO MELONI;A. CONTU;A. FARRIS;AGOSTINO VIRDIS;ANGELA LOI;ANTONELLA URAS;GIUSEPPE PALMIERI;GRAZIA PALOMBA;LAURA CRISPONI;MARIA MONNE;MARIO BUDRONI;O NINA","46;26;26;26;26;26;12;12;0;0;0;0;0;0;0;0;0;0;0","ANTONIO COSSU;ANTONIO DESSANTI;E DELEHAYE;FRANCESCO MELONI;G. STRUSI;MARCO IANNUCCELLI;MARIO FUSILLO;MICHELE UBERTAZZI;A. CONTU;A. FARRIS;AGOSTINO VIRDIS;ANGELA LOI;ANTONELLA URAS;GIUSEPPE PALMIERI;GRAZIA PALOMBA;LAURA CRISPONI;MARIA MONNE;MARIO BUDRONI;O NINA","3;1;1;1;1;1;1;1;0;0;0;0;0;0;0;0;0;0;0","MEDICINE;BIOLOGY;CHEMISTRY;BUSINESS;ENGINEERING;PHILOSOPHY;PSYCHOLOGY","7;5;2;1;1;1;1","GENETICS;SURGERY;BIOCHEMISTRY;ANATOMY;CANCER RESEARCH;INTERNAL MEDICINE;ONCOLOGY;PATHOLOGY;CHROMATOGRAPHY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;EPISTEMOLOGY;IMMUNOLOGY;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;MICROBIOLOGY;MOLECULAR BIOLOGY;OPERATIONS MANAGEMENT;PEDAGOGY;UROLOGY","5;5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","GENE;CANCER;MELANOMA;ORCHIOPEXY;ALLOWANCE (ENGINEERING);ALTERNATIVE MEDICINE;AMINO ACID;BACTERIA;BONE RESORPTION;CELL;CELL CULTURE;CELL GROWTH;CHEMOTHERAPY;CONCOMITANT;DEHISCENCE;ENZYME;MALIGNANCY;MEDICAL HISTORY;NOSE;OBSERVATIONAL STUDY;OSTEOLYSIS;PAPILLOMA;PARANASAL SINUSES;PATHOGENESIS;POPULATION;PREGNANCY;PROPORTIONAL HAZARDS MODEL;QUALITY (PHILOSOPHY);RECEPTOR;REPORT CARD;SAMPLE (MATERIAL);SKULL;SPERMATIC CORD;STENT;WORK (PHYSICS);ZOLEDRONIC ACID","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;MUTATION;ALKALINE PHOSPHATASE;ARGININE;CANCER REGISTRY;CDKN2A;CELL CYCLE;ESCHERICHIA COLI;GERMLINE;INFERTILITY;INFORMED CONSENT;INVERTED PAPILLOMA;OSTEOCLAST;PSEUDOMONAS AERUGINOSA;STAPHYLOCOCCUS AUREUS;WESTERN BLOT","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GERMLINE MUTATION;ARGININE DEIMINASE;CATHEPSIN K;CDKN2B;CITRULLINE;ENTEROCOCCUS FAECALIS;KLEBSIELLA PNEUMONIAE;KRAS;OSTEOCALCIN;RELATIVE SURVIVAL;VARICOCELE","2;1;1;1;1;1;1;1;1;1;1",";HUMANS;MELANOMA;SPERMATIC CORD;BRCA2 PROTEIN;CYCLIN-DEPENDENT KINASE INHIBITOR P16;NEOPLASM PROTEINS;NOSE NEOPLASMS;PAPILLOMA;PARANASAL SINUS NEOPLASMS;PROTO-ONCOGENE PROTEINS B-RAF;AGED;CRYPTORCHIDISM;INFORMED CONSENT;ITALY;MEDICAL RECORDS;NASAL MUCOSA;OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES;OXYPHIL CELLS;BIOCOMPATIBLE MATERIALS","4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;1","BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;ENGINEERING BACTERIA FOR CANCER TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;IMPACT OF HEALTHCARE ACCREDITATION ON QUALITY IMPROVEMENT;MELANOMA;OBSTETRIC VESICOVAGINAL FISTULA AND URETERAL INJURIES;TESTICULAR GERM CELL TUMORS AND TREATMENT","1;1;1;1;1;1;1;1","ORCHIOPEXY;ALLOWANCE (ENGINEERING);ARGININE DEIMINASE;ARGININE DEPRIVATION;ARGININOSUCCINATE SYNTHASE;BONE RESORPTION;BRCA1;BRCA2;BREAST CANCER;CANCER RISK;CANCER SUSCEPTIBILITY;CATHEPSIN K;CDKN2B;CLINICAL GOVERNANCE;CONCOMITANT;CRYPTORCHIDISM;ENTEROCOCCUS FAECALIS;INVERTED PAPILLOMA;MEDICAL HISTORY;MELANOMA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SPERMATIC VESSELS;BREAST CANCER;ORCHIOPEXY PRESERVING;PRESERVING SPERMATIC;SHORT SPERMATIC;STAGED ORCHIOPEXY;VESSELS STAGED;ADI TREATMENT;ANTI-NEOPLASTIC TREATMENT;ARGININE DEIMINASE;ARGININOSUCCINATE SYNTHETASE;BONE METASTASES;BONE RESORPTION;CANCER PATIENTS;CELL LINES;CLINICAL REPORTS;CONCOMITANT ANTI-NEOPLASTIC;CONTROLLED TRIAL;DEIMINASE ADI;DOUBLE-BLIND RANDOMIZED;IBRCAI MUTATIONS;INTRAORBITAL EXTENSION;KEY-REGULATOR GENES;MELANOMA CELL;MELANOMA SUSCEPTIBILITY;OBSERVATIONAL STUDY;ONCOCYTIC SCHNEIDERIAN;OPERATIVE TECHNIQUES;RANDOMIZED CONTROLLED;REPORTS OBSERVATIONAL","4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL LINES;GERMLINE MUTATIONS;MELANOMA CELL;MELANOMA SUSCEPTIBILITY;ALTERATIONS NRASBRAF;ANTERIOR SKULL;AUTOMATED DNA;BACTERIAL ADHESION;BACTERIAL ENCRUSTATION;BENIGN NEOPLASM;BIOFILM FORMATIONI;BONE DEHISCENCE;BRAF GENES;BRCA GERMLINE;CELL PAPILLOMA;CLINICALLY BEHAVIOUR;COIL STRENGTHTHIS;COLI ENTEROCOCCUS;COMMON UROLOGICAL;COMPRESSION TENSILE;CONSISTENTLY INDUCED;CONVERSELY PCDKNA;CYLINDRICAL CELL;DEVELOPING DRUGS;DHPLC ANALYSIS;DNA SEQUENCING;ENDONASAL ENDOSCOPIC;ENDOSCOPIC APPROACH;ENTEROCOCCUS FAECALIS;EPITHELIAL CELLS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2010,4,6.75,1,0.25,0.25,0.25,1,0.5,0.5,0.5,0.25,0,1,0,1,1,0.25,0,0.25,0.25,55.75,1.23366381208901,NA,0.25,0.75,0.368,0,0,0,"GIUSEPPE PALMIERI;REGINA FINK‐PUCHES;ANTONIO COSSU;VALERIA PUSCEDDU;INGRID SIMONITSCH;N LICHERI;MARIA CRISTINA SINI;MARIO BUDRONI;ANDREA SAGGINI;G. FELLIN;P. SIRIGU;AGOSTINO VIRDIS;FRANCESCO ATZORI;ANDREA GULIA;LORENZO CERRONI;GRAZIA PALOMBA;L PINNA;B. MASSIDDA;LUIS REQUENA;EDOARDO S. PESCATORI","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EDOARDO S. PESCATORI;FURIO FRANCESCO PIROZZI FARINA;N LICHERI;G. FELLIN;AGOSTINO VIRDIS;L PINNA;REGINA FINK‐PUCHES;INGRID SIMONITSCH;ANDREA SAGGINI;ANDREA GULIA;LORENZO CERRONI;LUIS REQUENA;MARIO MAGAÑA;AMELIA LISSIA;ZSOLT B. ARGÉNYI;GIUSEPPE PALMIERI;ANTONIO COSSU;VALERIA PUSCEDDU;MARIA CRISTINA SINI;MARIO BUDRONI","0.5;0.5;0.25;0.25;0.25;0.25;0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.08;0.08;0.08;0.08;0.08","ANTONIO COSSU;AGOSTINO VIRDIS;FURIO FRANCESCO PIROZZI FARINA;AMELIA LISSIA","1;1;1;1","FURIO FRANCESCO PIROZZI FARINA;AGOSTINO VIRDIS;AMELIA LISSIA;ANTONIO COSSU","0.5;0.25;0.11;0.08","AMELIA LISSIA;ANDREA GULIA;ANDREA SAGGINI;INGRID SIMONITSCH;LORENZO CERRONI;LUIS REQUENA;MARIO MAGAÑA;REGINA FINK‐PUCHES;ZSOLT B. ARGÉNYI;ANTONIO COSSU;B. MASSIDDA;FRANCESCO ATZORI;GIUSEPPE PALMIERI;GRAZIA PALOMBA;MARIA CRISTINA SINI;MARIACRISTINA DEIDDA;MARIATERESA IONTA;MARIATERESA PERRA;MARIO BUDRONI;P. SIRIGU","210;210;210;210;210;210;210;210;210;13;13;13;13;13;13;13;13;13;13;13","AMELIA LISSIA;ANTONIO COSSU;AGOSTINO VIRDIS;FURIO FRANCESCO PIROZZI FARINA","210;13;0;0","AMELIA LISSIA;ANTONIO COSSU;AGOSTINO VIRDIS;FURIO FRANCESCO PIROZZI FARINA","1;1;0;0","MEDICINE;BIOLOGY;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY","4;2;1;1;1","INTERNAL MEDICINE;BIOCHEMISTRY;PATHOLOGY;EMERGENCY MEDICINE;IMMUNOLOGY;ONCOLOGY;PALEONTOLOGY;PROGRAMMING LANGUAGE;PSYCHOANALYSIS;STATISTICS","3;2;2;1;1;1;1;1;1;1","GENE;ADVERSE EFFECT;ANTIGEN;CANCER;DOCUMENTATION;EJACULATION;IMMUNOHISTOCHEMISTRY;IN VITRO;LYMPHOMA;OBSERVATIONAL STUDY;PREDICTABILITY;PREMATURE EJACULATION;PROPORTIONAL HAZARDS MODEL;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);SURGICAL ONCOLOGY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANAPLASTIC LARGE-CELL LYMPHOMA;BREAST CANCER;CARCINOGENESIS;CD30;CD8;CHROMOSOME;CYTOTOXIC T CELL;GENE REARRANGEMENT;LYMPHOPROLIFERATIVE DISORDERS;MYCOSIS FUNGOIDES;RITUXIMAB;SURVIVIN","1;1;1;1;1;1;1;1;1;1;1;1","AGGRESSIVE LYMPHOMA;BREAST CARCINOMA;FLUORESCENCE IN SITU HYBRIDIZATION;LYMPHOMATOID PAPULOSIS","1;1;1;1","LYMPHOMATOID PAPULOSIS;LYMPHOMA, T-CELL, CUTANEOUS;BREAST NEOPLASMS;T-LYMPHOCYTES, CYTOTOXIC;BIOMARKERS, TUMOR;CARRIER PROTEINS;CYCLIN D1;HUMANS;MICROTUBULE-ASSOCIATED PROTEINS;MITOGEN-ACTIVATED PROTEIN KINASE 1;MITOGEN-ACTIVATED PROTEIN KINASE 3;TUMOR SUPPRESSOR PROTEIN P53;ADULT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FEMALE;HERPESVIRUS 4, HUMAN;HOSPITALS, GENERAL;ITALY;MIDDLE AGED","8;6;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;IMPACT OF HEALTHCARE ACCREDITATION ON QUALITY IMPROVEMENT;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;THE P53 SIGNALING NETWORK IN CANCER RESEARCH","1;1;1;1","AGGRESSIVE LYMPHOMA;ANAPLASTIC LARGE-CELL LYMPHOMA;BREAST CARCINOMA;CANCER GENOMICS;CANCER THERAPY;CD30+ LYMPHOPROLIFERATIVE DISORDERS;CLINICAL ENGINEERING;CUTANEOUS LYMPHOMAS;EJACULATION;GENE REARRANGEMENT;LOWER URINARY TRACT SYMPTOMS;LYMPHOMATOID PAPULOSIS;LYMPHOPROLIFERATIVE DISORDERS;PREDICTABILITY;PREMATURE EJACULATION;SURGICAL ONCOLOGY;SURVIVIN;T-CELL LYMPHOMA;TUMOR EVOLUTION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADVERSE EVENTS;AGGRESSIVE EPIDERMOTROPIC;BREAST CARCINOMA;CD CYTOTOXIC;CLINICAL RISK;CORPORATE PLANNING;CUTANEOUS AGGRESSIVE;CYTOTOXIC T-CELL;EPIDERMOTROPIC CD;KEY-REGULATOR GENES;LYMPHOMA DESCRIPTION;LYMPHOMATOID PAPULOSIS;MOLECULAR ALTERATIONS;OBSERVATIONAL STUDY;PAINFUL EJACULATION;PAPULOSIS SIMULATING;PRIMARY CUTANEOUS;RISK MANAGEMENT;SIMULATING PRIMARY;T-CELL LYMPHOMA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER PATIENTS;PROGNOSTIC FACTORS;ALTERATIONS INVOLVED;ANALYSIS RESULTS;ARCHIVAL PARAFFIN-EMBEDDED;ASSESS ALTERATIONS;BACKGROUND PROGNOSTIC;BREAST CARCINOMA;BREAST CARCINOMAS;CARCINOMA REPRESENTED;CARRYING INCREASED;CLINICAL ROLE;CONSECUTIVE SERIES;COX REGRESSION;EXPRESSION LEVELS;FISH ANALYSES;FOLLOW-UP PERIOD;FOUND NEGATIVE;H-PRUNE GENE;H-PRUNE GENES;HYBRIDIZATION FISH;IMMUNOHISTOCHEMISTRY IHC;INCREASED EXPRESSION;INDEPENDENT PROGNOSTIC;MAIN PARAMETERS;MOLECULAR ALTERATIONS;MOLECULAR PARAMETERS;MONTHS ARCHIVAL;MULTIVARIATE ANALYSIS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",2,0.5,0.81,1,0,0,0,0,0,0,0,1.75,0,1,1,0,0,0,0,1,0,0.75,0,41.25,42,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,9,300,25,1,1,54,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;RARE DISEASES;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION","1;1;1;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","1;1","NON-HODGKIN'S LYMPHOMA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2011,1,8,5,1,0,1,1,0.5,0,0.5,1,0,0,1,0,0,0,1,0,0,6,0.141062667937939,NA,1,1,0,0,0,0,"NICOLA GLORIOSO;EMANUELA BULLA;TAMARA DIDISHVILI;NELSON RUIZ‐OPAZO;VICTORIA L. M. HERRERA;CHIARA TROFFA;PATRIZIA BULLA;GIUSEPPE ARGIOLAS","1;1;1;1;1;1;1;1","NICOLA GLORIOSO;EMANUELA BULLA;TAMARA DIDISHVILI;NELSON RUIZ‐OPAZO;VICTORIA L. M. HERRERA;CHIARA TROFFA;PATRIZIA BULLA;GIUSEPPE ARGIOLAS","0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12","NICOLA GLORIOSO;EMANUELA BULLA;CHIARA TROFFA;PATRIZIA BULLA;GIUSEPPE ARGIOLAS","1;1;1;1;1","NICOLA GLORIOSO;EMANUELA BULLA;CHIARA TROFFA;PATRIZIA BULLA;GIUSEPPE ARGIOLAS","0.12;0.12;0.12;0.12;0.12","CHIARA TROFFA;EMANUELA BULLA;GIUSEPPE ARGIOLAS;NELSON RUIZ‐OPAZO;NICOLA GLORIOSO;PATRIZIA BULLA;TAMARA DIDISHVILI;VICTORIA L. M. HERRERA","6;6;6;6;6;6;6;6","CHIARA TROFFA;EMANUELA BULLA;GIUSEPPE ARGIOLAS;NICOLA GLORIOSO;PATRIZIA BULLA","6;6;6;6;6","CHIARA TROFFA;EMANUELA BULLA;GIUSEPPE ARGIOLAS;NICOLA GLORIOSO;PATRIZIA BULLA","1;1;1;1;1","BIOLOGY;MEDICINE","1;1","ENDOCRINOLOGY;GENETICS;IMMUNOLOGY;INTERNAL MEDICINE","1;1;1;1","BLOOD PRESSURE;GENE;PATHOGENESIS","1;1;1","ALLELE;DIASTOLE;ESSENTIAL HYPERTENSION;GENE EXPRESSION;GENOTYPE","1;1;1;1;1","PROMOTER;SINGLE-NUCLEOTIDE POLYMORPHISM","1;1","AGED;ANIMALS;BASE SEQUENCE;BLOOD PRESSURE;GENETIC ASSOCIATION STUDIES;HEART RATE;HETEROZYGOTE;HUMANS;ITALY;MALE;MICE;MOLECULAR SEQUENCE DATA;NUCLEOTIDE MOTIFS;POLYMERASE CHAIN REACTION;POLYMORPHISM, SINGLE NUCLEOTIDE;PROMOTER REGIONS, GENETIC;PSEUDOGENES;QUANTITATIVE TRAIT, HERITABLE;RECEPTORS, CELL SURFACE;TRANSCRIPTION INITIATION SITE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENOMIC STUDIES AND ASSOCIATION ANALYSES","1","ESSENTIAL HYPERTENSION;PATHOGENESIS;POLYGENIC RISK SCORES","1;1;1","DECREASES IDESPRI;IDESPRI TCATAAAA-BOX;IDESPRI TRANSCRIPTION;INCREASED BP;PROMOTER VARIANT;SARDINIAN MALES;TCATAAAA-BOX PROMOTER;VARIANT DECREASES","1;1;1;1;1;1;1;1","ESSENTIAL HYPERTENSION;CANONICAL TATAAAA-BOX;DESPR KNOCKOUT;HYPERTENSION SUSCEPTIBILITY;INCREASED BP;KNOCKOUT MALE;MALE MICE;PROMOTER VARIANTS;SUBJECTS HOMOZYGOUS;AFFECT BP;AFFECT TRANSCRIPTION;AGE RADIOTELEMETRIC;ANALYSIS DETECTED;BLOOD PRESSURE;BP MEASUREMENTS;BP REGULATION;CATAAAA-MOTIF PROMOTER-CONSTRUCT;CHALLENGE DUE;CHRONIC RENAL;COHORT ACCOUNTING;COMPLEX MULTIFACTORIAL;DECREASED DESPR;DECREASED TRANSCRIPTION;DESPR -REGULATORY;DESPR MICE;DESPR PROMOTER;DESPR RNA;DETECTED DECREASED;DIASTOLIC BP;DIASTOLIC BPS","4;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2,122,20,0,0,28,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CHRONIC PAIN;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;PAIN RESEARCH;PATIENT SAFETY","1;1;1;1;1;1",NA,NA,"5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1","NOT SITE-SPECIFIC CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2012,20,11.2,2.3,0.2,0.4,0.25,1.39393939393939,0.8,1,0.833333333333333,0.25,0,10,3,4,1,0.5,0.15,0.2,0.05,38.25,0.915765499362618,3.56,0.1,0.85,0.285,0,0.371,0.356,"ANTONIO COSSU;MARIA COLOMBINO;GIUSEPPE PALMIERI;CIRIACO CARRU;ANGELO ZINELLU;LUCA DEIANA;VINCENZO DE GIORGI;CORRADO CARACÒ;DANIELA MASSI;GERARDO BOTTI;MARIA CRISTINA SINI;PAOLO A. ASCIERTO;CORRADO RUBINO;GRAZIA PALOMBA;AMELIA LISSIA;NICOLA MOZZILLO;VITTORIO TROVA;MILENA CASULA;MARIA GIUSEPPA SAROBBA;A. CONTU","6;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2","CIRIACO CARRU;ANGELO ZINELLU;LUCA DEIANA;A. FARRIS;NICOLA FAZIO;MICHELA SQUADRONI;FRANCESCA SPADA;K. LORIZZO;ANTONIO COSSU;C. CORBU;GIANPAOLO VIDILI;GIUSEPPE DELITALA;SEBASTIANA ATZORI;PAOLO SOGGIA;MASSIMO MADONIA;MARIA COLOMBINO;GIUSEPPE PALMIERI;GIACOMINA LORIGA;SALVATORE SOTGIA;ANDREA SATTA","0.55;0.55;0.47;0.4;0.4;0.4;0.4;0.4;0.37;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.32;0.31;0.31;0.31","ANTONIO COSSU;GIUSEPPE PALMIERI;CIRIACO CARRU;ANGELO ZINELLU;LUCA DEIANA;MARIA CRISTINA SINI;AMELIA LISSIA;MILENA CASULA;MARIA GIUSEPPA SAROBBA;A. CONTU;A. FARRIS;G. BALDINO;NICOLA FAZIO;ANTONELLA MANCA;GIACOMINA LORIGA;ANTONIO PAZZOLA;ANDREA SATTA;FRANCESCO TANDA;SARA PINNA;DAMIANO SOMA","6;5;5;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1","CIRIACO CARRU;ANGELO ZINELLU;LUCA DEIANA;A. FARRIS;NICOLA FAZIO;ANTONIO COSSU;C. CORBU;GIANPAOLO VIDILI;GIUSEPPE DELITALA;SEBASTIANA ATZORI;PAOLO SOGGIA;MASSIMO MADONIA;GIUSEPPE PALMIERI;GIACOMINA LORIGA;ANDREA SATTA;DAMIANO SOMA;ANTONIO TULLIO;ROBERTA GOBBI;AGOSTINO VIRDIS;OLINDO MASSARELLI","0.55;0.55;0.47;0.4;0.4;0.37;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.31;0.31;0.25;0.25;0.25;0.25;0.25","ANTONIO COSSU;GIUSEPPE PALMIERI;MARIA COLOMBINO;AMELIA LISSIA;CORRADO CARACÒ;CORRADO RUBINO;DANIELA MASSI;GERARDO BOTTI;MARIA CRISTINA SINI;NICOLA MOZZILLO;PAOLO A. ASCIERTO;VINCENZO DE GIORGI;ANTONELLA MANCA;ELENA PAGANI;ESTER FONSATTI;MARIAELENA CAPONE;MILENA CASULA;OSCAR NAPPI;RENATO FRANCO;STEFANIA STAIBANO","473;472;472;438;438;438;438;438;438;438;438;438;437;437;437;437;437;437;437;437","ANTONELLA MANCA;GIUSEPPE PALMIERI;MARIA CRISTINA SINI;MILENA CASULA;MARIA GIUSEPPA SAROBBA;MARIO PALERMO;LUCA DEIANA;ANTONIO COSSU;ANTONIO TULLIO;DAMIANO SOMA;OLINDO MASSARELLI;ROBERTA GOBBI;A. CONTU;ANTONIO PAZZOLA;G. BALDINO;ANDREA SATTA;GIACOMINA LORIGA;GIANPAOLO VIDILI;GIUSEPPE DELITALA;SEBASTIANA ATZORI","435;435;435;435;85;56;47;38;37;37;37;37;34;34;34;30;30;17;17;17","ANTONIO COSSU;A. CONTU;A. FARRIS;AMELIA LISSIA;ANDREA SATTA;ANTONIO PAZZOLA;G. BALDINO;GIACOMINA LORIGA;LUCA DEIANA;MARIA GIUSEPPA SAROBBA;AGOSTINO VIRDIS;ANGELO ZINELLU;ANTONELLA MANCA;ANTONIO TULLIO;C. CORBU;CIRIACO CARRU;DAMIANO SOMA;GIANPAOLO VIDILI;GIOVANNI GARRUCCIU;GIUSEPPE DELITALA","5;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE","19;9;3;2;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;CANCER RESEARCH;PATHOLOGY;ENDOCRINOLOGY;SURGERY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;OPTICS;PHARMACOLOGY;RADIOLOGY;BIOINFORMATICS;COMPUTATIONAL BIOLOGY;FAMILY MEDICINE;GYNECOLOGY;IMMUNOLOGY;MACHINE LEARNING;MEDICAL EMERGENCY;MEDICAL PHYSICS;MOLECULAR BIOLOGY;NURSING;QUANTUM MECHANICS","15;9;6;5;5;4;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENE;DISEASE;MELANOMA;POPULATION;CARCINOMA;CHOLESTEROL;CLINICAL TRIAL;HEPATOCELLULAR CARCINOMA;INCIDENCE (GEOMETRY);LIVER DISEASE;OXIDATIVE STRESS;RADIOLOGICAL WEAPON;SIMVASTATIN;TOXICITY;ULTRASOUND;URIC ACID;ABDOMEN;AMINO ACID;ANTIBODY;ASCITES;ASYMPTOMATIC;CHEMOTHERAPY;CONCOMITANT;CONFIDENCE INTERVAL;ENZYME;FACIAL ARTERY;FALSE POSITIVE PARADOX;GENETIC TESTING;GLYCOPROTEIN;HOMOCYSTEINE;HORMONE;KIDNEY;KIDNEY DISEASE;LECTIN;LUNG CANCER;MANNOSE;MOLECULAR DIAGNOSTICS;PERITONEUM;PRESENTATION (OBSTETRICS);REGIMEN;RENAL FUNCTION;SCALE (RATIO);SOFT PALATE;SOFT TISSUE;TESTOSTERONE (PATCH);TUBERCULOSIS","9;7;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;MUTATION;DOCETAXEL;EPIDERMAL GROWTH FACTOR RECEPTOR;EZETIMIBE;MALONDIALDEHYDE;MUTATION RATE;SOMATIC CELL;SORAFENIB;ALLELE;ASYMPTOMATIC CARRIER;CDKN2A;CYSTATIN C;DYSLIPIDEMIA;EXON;FETUIN;GERMLINE;GLUTATHIONE;HAZARD RATIO;LIPID PROFILE;LUTEINIZING HORMONE;MANNAN-BINDING LECTIN;METASTASIS;MOLECULAR PATHOLOGY;MYCOBACTERIUM TUBERCULOSIS;NEPHELOMETRY;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;PROSTATE;PROSTATE CANCER;TAURINE;WILSON'S DISEASE","6;6;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","KRAS;GERMLINE MUTATION;ERLOTINIB;EXTRAPULMONARY TUBERCULOSIS;FOLLICLE-STIMULATING HORMONE;PRIMARY TUMOR;SANGER SEQUENCING;TRANSRECTAL ULTRASONOGRAPHY;V600E","6;3;2;1;1;1;1;1;1","HUMANS;MALE;CARCINOMA, HEPATOCELLULAR;KIDNEY FAILURE, CHRONIC;LIVER NEOPLASMS;;AGED;FEMALE;KIDNEY;MIDDLE AGED;ADENOCARCINOMA;AZETIDINES;HYPOLIPIDEMIC AGENTS;PROSTATIC NEOPLASMS;SIMVASTATIN;ALLANTOIN;ANTINEOPLASTIC AGENTS;BENZENESULFONATES;CALCINOSIS;COLONIC NEOPLASMS","13;11;8;8;8;7;7;7;7;6;5;5;5;5;5;4;4;4;4;4","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;MELANOMA;ALARM FATIGUE IN CLINICAL MONITORING SYSTEMS;CELLULAR RESPONSE TO OSMOTIC STRESS AND METABOLISM;CHOLESTEROL-LOWERING TREATMENT;COPPER AND ZINC IN HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF ABDOMINAL TUBERCULOSIS;IMMUNOLOGICAL MECHANISMS IN PREGNANCY AND FETAL-MATERNAL INTERFACE;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MICROSURGICAL RECONSTRUCTION TECHNIQUES;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;PROSTATE CANCER RESEARCH AND TREATMENT;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","KRAS MUTATIONS;MELANOMA;BRAF GENE;BRAF MUTATIONS;EZETIMIBE;HEPATOCELLULAR CARCINOMA;LIVER DISEASE;MALONDIALDEHYDE;TUMOR STAGING;ASYMPTOMATIC CARRIER;CANCER GENOMICS;CANCER RISK;CHOLESTEROL-LOWERING;CHRONIC KIDNEY DISEASE;CONCOMITANT;DIAGNOSIS;DYSLIPIDEMIA;EGFR MUTATIONS;EXTRAPULMONARY TUBERCULOSIS;FACIAL ARTERY","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESPONSE;COLORECTAL CARCINOMA;COMPARING ERLOTINIB;ELDERLY PATIENTS;HEPATOCELLULAR CARCINOMA;III TRIAL;NSCLC PATIENTS;PHASE III;SECOND-LINE TREATMENT;SOMATIC MUTATIONS;TRIAL COMPARING;WILD-TYPE WT;WT EGFR;ABSTRACT PATTERN;ARTERY MYOMUCOSAL;ATPB GENE;CANCER PATIENTS;CANDIDATE GENES;CARCINOMA CLUES;CHRONIC KIDNEY;CKD PATIENTS;COLORECTAL CANCER;CONSECUTIVE GENERATIONS;CONTRACEPTIVES MODIFY;CURRENT ROLE;DISEASE PATIENTS;DNA METHYLATION;FETUIN-A SERUM;FOLDED TUNNELIZEDFACIAL;HETEROGENEOUS PREVALENCE","2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ESTROGEN RECEPTOR;PRIMARY MELANOMAS;BRAF NRAS;LYMPH NODES;SOMATIC MUTATIONS;ANDROGENIC PROPERTIES;AUTOMATED DNA;AVOID POTENTIAL;BRAFNRAS MUTATIONS;DNA SEQUENCING;ENDOTHELIAL FUNCTION;HIGH-DENSITY LIPOPROTEIN;HORMONAL LEVELS;KRAS BRAF;PAIRED SAMPLES;PCDKNA MUTATIONS;PERITONEAL TUBERCULOSIS;RECEPTOR Α;RECEPTOR Β;SARDINIAN POPULATION;SIGNIFICANTLY LOWER;ABDOMEN PLAYED;ABNORMAL SIGNS;ACTIVITY HAPLOTYPE;ACTIVITY HAPLOTYPES;ADULT WOMEN;AKEA STUDY;ALKALINE PHOSPHATASE;ALREADY-REPORTED DISCREPANCIES;ANALYSIS AUTOMATED","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1",4,0.2,5.15,1.25,0,1,0,0,0,0,1,1.25,0,0,1,0,1,0,0,1,0,0,0,43.75,43.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,6.5,788,7.14,1,0.5,72.5,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AGING;CANCER;GENETICS;LUNG","2;2;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","2","LUNG CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2013,15,11.2666666666667,2.33333333333333,0.333333333333333,0.466666666666667,0.533333333333333,1.16666666666667,1,1,1,0.6,0,9,1,3,0,0.6,0.07,0.2,0,20.07,0.575098644788019,7.08333333333333,0.333333333333333,1,0.302,0.167,0.119,0.159,"GIUSEPPE MORGIA;C. CORBU;G GARAU;ALESSANDRO DELITALA;PAOLO SOGGIA;MASSIMO MADONIA;OLINDO MASSARELLI;SEBASTIANO CIMINO;MARIA COLOMBINO;VINCENZO DE GIORGI;STEFANO JACOBELLI;LUCA DEIANA;GIAMPIETRO GASPARINI;MONICA BOCCHIA;SPERANZA MASALA;VALENTINO GIACHÉ;IDA PAVESE;SARA PINNA;IVANA PIERRI;ALBERTO MATTEELLI","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","OLINDO MASSARELLI;GIUSEPPE MORGIA;C. CORBU;G GARAU;PAOLO SOGGIA;MASSIMO MADONIA;SEBASTIANO CIMINO;ALESSANDRO DELITALA;FERDINANDO FUSCO;DORIS ALI YOUSSEF;FURIO PIROZZI FARINA;DAMIANO SOMA;ANTONIO TULLIO;ALDO BRUNO GIANNÌ;ROBERTA GOBBI;ANDREA BIGLIO;GIOVANNI GRIMALDI;GIADA ANNA BELTRAMINI;A PISCHEDDA;A CURRELI","0.4;0.33;0.33;0.33;0.33;0.33;0.33;0.22;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","C. CORBU;G GARAU;ALESSANDRO DELITALA;PAOLO SOGGIA;MASSIMO MADONIA;OLINDO MASSARELLI;LUCA DEIANA;ROBERTA LAI;ANTONIO COSSU;DORIS ALI YOUSSEF;FURIO PIROZZI FARINA;DAMIANO SOMA;ANTONIO TULLIO;ALDO BRUNO GIANNÌ;G. SANNA;CARLA FUNDONI;ROBERTA GOBBI;ROBERTA BOSU;ANDREA BIGLIO;GIUSEPPE FANCIULLI","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OLINDO MASSARELLI;C. CORBU;G GARAU;PAOLO SOGGIA;MASSIMO MADONIA;ALESSANDRO DELITALA;DORIS ALI YOUSSEF;FURIO PIROZZI FARINA;DAMIANO SOMA;ANTONIO TULLIO;ALDO BRUNO GIANNÌ;ROBERTA GOBBI;ANDREA BIGLIO;GIADA ANNA BELTRAMINI;A PISCHEDDA;A CURRELI;ALESSANDRO BAJ;MARIO PALERMO;ROBERTA LAI;GIUSEPPE FANCIULLI","0.4;0.33;0.33;0.33;0.33;0.22;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.17;0.12;0.12","ALBERTO MATTEELLI;ALESSANDRO AMBROSI;DANIELA MARÍA CIRILLO;DELIA GOLETTI;ELIAS N. NTINGINYA;FRANCESCO ALOI;GIOVANNI SOTGIU;GRACE MWANGOKA;ILARIA C. VALENTE;KLAUS REITHER;LUCA NORBIS;LUIGI RUFFO CODECASA;NORBERT HEINRICH;PAOLO MIOTTO;ROBERTA BOSU;ALESSANDRO DELITALA;A BARALLA;ANGELO ZINELLU;CIRIACO CARRU;CLAUDIO FRANCESCHI","78;78;78;78;78;78;78;78;78;78;78;78;78;78;78;57;44;44;44;44","GIOVANNI SOTGIU;ROBERTA BOSU;LUCA DEIANA;OLINDO MASSARELLI;RAIMONDA SANNA;MARIO PALERMO;ANDREA BIGLIO;ANTONIO TULLIO;DAMIANO SOMA;ROBERTA GOBBI;ALESSANDRO DELITALA;GIUSEPPE FANCIULLI;ROBERTA LAI;A CURRELI;A PISCHEDDA;FURIO PIROZZI FARINA;CARLA FUNDONI;SIMONETTA PARDINI;ALDO BRUNO GIANNÌ;ALESSANDRO BAJ","78;78;44;35;35;32;23;23;23;23;22;22;22;21;21;21;18;16;12;12","OLINDO MASSARELLI;A CURRELI;A PISCHEDDA;ALDO BRUNO GIANNÌ;ALESSANDRO BAJ;ALESSANDRO DELITALA;ANDREA BIGLIO;ANTONIO TULLIO;CARLA FUNDONI;DAMIANO SOMA;DORIS ALI YOUSSEF;FURIO PIROZZI FARINA;GIADA ANNA BELTRAMINI;GIOVANNI SOTGIU;GIUSEPPE FANCIULLI;LUCA DEIANA;MARIO PALERMO;RAIMONDA SANNA;ROBERTA BOSU;ROBERTA GOBBI","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY","13;8;3;2;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;ONCOLOGY;UROLOGY;CANCER RESEARCH;GYNECOLOGY;OPTICS;PATHOLOGY;ANATOMY;BIOCHEMISTRY;BIOINFORMATICS;BOTANY;CARDIOLOGY;CELL BIOLOGY;DATA SCIENCE;ENDOCRINOLOGY;FAMILY MEDICINE;GASTROENTEROLOGY;MACHINE LEARNING;MEDICAL EDUCATION;MEDICAL PHYSICS;NUCLEAR PHYSICS;NURSING;PHYSICAL MEDICINE AND REHABILITATION;PHYSICAL THERAPY;SOCIAL SCIENCE","9;5;5;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENE;POPULATION;COHORT;FREE FLAP;INCIDENCE (GEOMETRY);RADIATION THERAPY;TIBIA;AMBULATORY;ANTIBODY;BACTERIA;BLOOD PRESSURE;BODY MASS INDEX;CLINICAL PRACTICE;DENERVATION;FECAL INCONTINENCE;GENUS;HEAD AND NECK;HYPERPLASIA;INTERFERON;LEUKEMIA;LOGISTIC REGRESSION;MELANOMA;MULTIDISCIPLINARY APPROACH;MYELOID LEUKEMIA;NEUROFIBROMATOSIS;PELVIC FLOOR;PHEOCHROMOCYTOMA;PLASMA;PREGNANCY;PROTEOME;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;SEXUAL DYSFUNCTION;STABILITY (LEARNING THEORY);STEM CELL;THYROID;TUBERCULOSIS;URINARY INCONTINENCE","5;5;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MUTATION;PROSTATE CANCER;COLORECTAL CANCER;FIBULA;GERMLINE;LIFE EXPECTANCY;PHENOTYPE;ALPHA INTERFERON;AMBULATORY BLOOD PRESSURE;CHRONIC MYELOGENOUS LEUKEMIA;DNA SEQUENCING;EPITOPE;EXON;FETUS;HEART RATE;IMATINIB;LINEAGE (GENETIC);MANDIBLE (ARTHROPOD MOUTHPART);MICRORNA;MOLECULAR MIMICRY;MULTIPLE ENDOCRINE NEOPLASIA;MUTANT;MYCOBACTERIUM;NEUROFIBROMIN 1;NEUROTROPHIC FACTORS;OSTEORADIONECROSIS;PELVIC FLOOR DYSFUNCTION;PELVIC FLOOR MUSCLE;PULMONARY TUBERCULOSIS;RADIATION ONCOLOGIST;RADIATION ONCOLOGY;REAL-TIME POLYMERASE CHAIN REACTION;THYROID CARCINOMA","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GERMLINE MUTATION;KRAS;PROSTATECTOMY;AMNIOTIC FLUID;CETUXIMAB;EPITOPE MAPPING;GENETIC HETEROGENEITY;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;IMATINIB MESYLATE;MEDULLARY CARCINOMA;PARATUBERCULOSIS;PENETRANCE;POINT MUTATION;TAQMAN","3;2;2;1;1;1;1;1;1;1;1;1;1;1",";PROSTATIC NEOPLASMS;HUMANS;MALE;FEMALE;LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;MIDDLE AGED;AGED;ANDROGEN ANTAGONISTS;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC AGENTS, HORMONAL;BENZAMIDES;DIABETES MELLITUS, TYPE 1;INTERFERON-ALPHA;NEUROFIBROMATOSIS 1;PIPERAZINES;PROTEIN KINASE INHIBITORS;PYRIMIDINES;THYROID DYSGENESIS;THYROID NEOPLASMS","9;7;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","MICROSURGICAL RECONSTRUCTION TECHNIQUES;PROSTATE CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EFFICACY AND RESISTANCE IN CML TREATMENT;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MASS SPECTROMETRY TECHNIQUES WITH PROTEINS;MELANOMA;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MULTIPOTENT MESENCHYMAL STEM CELLS;NATURAL KILLER CELLS IN IMMUNITY;NEUROFIBROMATOSIS TYPE 1 AND TYPE 2;PELVIC FLOOR DISORDERS","2;2;1;1;1;1;1;1;1;1;1;1;1","PROSTATE CANCER;MANDIBULAR RECONSTRUCTION;METASTATIC PROSTATE CANCER;MICROSURGICAL RECONSTRUCTION;PERFORATOR FLAP;BIOMARKER ANALYSIS;CHRONIC MYELOGENOUS LEUKEMIA;CLINICAL PRACTICE;COLD-PCR;ENDOTHELIAL CELL-LINEAGE ANALYSIS;EPITOPE MAPPING;FECAL INCONTINENCE;FREE FLAP;HEAD AND NECK RECONSTRUCTION;HEART REGENERATION;IMATINIB;IMATINIB MESYLATE;KRAS MUTATIONS;LINEAGE (GENETIC);LOWER URINARY TRACT SYMPTOMS","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARCINOMA DELLA;DELLA PROSTATA;NEI PAZIENTI;PROSTATA PROSTATECTOMIA;PROSTATECTOMIA RADICALE;RADICALE NEI;ACHIEVING COMPLETE;ACTIVE PULMONARY;AMNIOTIC FLUID;APPROACH HIGHLIGHTS;ARTERY PERFORATOR;BASED THERAPY;C-CELL HYPERPLASIA;CARDIOVASCULAR LINEAGE;CELLS MORPH;CHEMICALLY INDUCED;CHIMERIC LATERAL;CML PATIENTS;COLORECTAL CANCERS;COMPLETE CYTOGENETIC;COMPOSITE HEAD;CYTOGENETIC REMISSION;ENRICHED SEQUENCING;FIBULA FLAP;FIBULA FREE;FLUID STEM;FREE FIBULA;FREE FLAP;GERM-LINE MUTATIONS;HARBORING PATHOGENIC","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PROSTATE CANCER;RADICAL PROSTATECTOMY;FIBULA FLAP;FLOOR MUSCLES;HA BU;PELVIC FLOOR;RENAL DENERVATION;STEM CELLS;BU RA;DIAGNOSTIC ACCURACY;FIBULA FREE;FREE FIBULA;MD DEPARTMENT;ORGAN DAMAGE;PLASMA SAMPLES;PROTEIN SPOTS;SERUM MIRNA;STORAGE TEMPERATURE;VASCULAR PEDICLE;ACTIVE PULMONARY;AGEING POPULATION;ALBUMIN FIBRINOGEN;AMNIOTIC FLUID;BLOOD PRESSURE;CA GRANDA;CANCER UNDERGOING;CARDIOVASCULAR RISK;CLASSIC HARVEST;CLINICALLY LOCALIZED;COMMON MALE","8;8;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2",3,0.2,1,2.5,1,0,0,0,0,0,0,5,0,0,2,0,0,1,1,1.75,0,0,0,97,97,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,2.5,1477.67,10.34,1,0.33,59.33,0,0,0,0,2,0,0,1,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY","3;1;1;1;1","CLINICAL RESEARCH;ARTHRITIS;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;IMMUNIZATION;INFECTIOUS DISEASES;LUNG;PNEUMONIA;PNEUMONIA & INFLUENZA;PREVENTION;RARE DISEASES;RHEUMATOID ARTHRITIS;VACCINE RELATED","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","1;1","6.1 PHARMACEUTICALS;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;1;1","LUNG CANCER","1",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"PUBLIC LIBRARY OF SCIENCE","8","32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4905 STATISTICS","9;4;4;3;2;2;2","BIOTECHNOLOGY;CLINICAL RESEARCH;GENETICS;HIV/AIDS;INFECTIOUS DISEASES;LUNG;RARE DISEASES;TUBERCULOSIS","1;1;1;1;1;1;1;1","INFECTION","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE;HEALTH SERVICES RESEARCH","3;1","CERVICAL CANCER","2",NA,NA
"AOUSSN_SASSARI",2014,22,10.8181818181818,1.59090909090909,0.0909090909090909,0.181818181818182,0.272727272727273,1.20689655172414,0.666666666666667,1,1,0.727272727272727,0,9,4,2,2,0.41,0.18,0.09,0.09,26.64,0.704820446810908,5.18421052631579,0.318181818181818,1,0.252,0.167,0.267,0.222,"SILVANA SANNA;STEFANO ANDREONI;ELISABETTA BLASI;CLAUDIO FARINA;PAOLO FAZII;MARCO CONTE;ESTHER MANSO;ANTONELLA MELONI;GIUSEPPE PALMIERI;ANTONIO COSSU;ALESSIA PEPE;MARIA CRISTINA SINI;CARLO COSMI;GIANPAOLO VIDILI;PIER SERGIO SABA;GIUSEPPE DELITALA;ALESSANDRO DELITALA;GRAZIA PALOMBA;VINCENZO POSITANO;GIANLUIGI LOMBARDI","3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","SILVANA SANNA;STEFANO ANDREONI;ELISABETTA BLASI;CLAUDIO FARINA;PAOLO FAZII;MARCO CONTE;ESTHER MANSO;GIANLUIGI LOMBARDI;GIUSEPPE DELITALA;ALESSANDRO DELITALA;GIANPAOLO VIDILI;GIUSEPPE D. SANNA;G PADUA;GILDO MATTA;ANDREA BALATA;S MASIA;PIER SERGIO SABA;ANTONELLA MELONI;FRANCESCO TOLU;UPINDER KAUR MATTAR DIAL","0.34;0.34;0.34;0.34;0.34;0.34;0.34;0.25;0.24;0.24;0.22;0.2;0.2;0.2;0.2;0.2;0.18;0.17;0.17;0.17","SILVANA SANNA;ANTONIO COSSU;MARIA CRISTINA SINI;CARLO COSMI;GIANPAOLO VIDILI;PIER SERGIO SABA;GIUSEPPE DELITALA;ALESSANDRO DELITALA;FRANCESCO TOLU;UPINDER KAUR MATTAR DIAL;GIUSEPPE D. SANNA;ANTONELLO GANAU;CLAUDIO CHERCHI;ARE BM;MARIA CHIARA MANNAZZU;ROBERTO MASSAIU;RICCARDO BOCCALETTI;ANTONIO PINNA;FRANCESCO CUCCA;GIUSEPPE FANCIULLI","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","SILVANA SANNA;GIUSEPPE DELITALA;ALESSANDRO DELITALA;GIANPAOLO VIDILI;GIUSEPPE D. SANNA;PIER SERGIO SABA;FRANCESCO TOLU;UPINDER KAUR MATTAR DIAL;CARLO COSMI;GIUSEPPE FANCIULLI;ALESSANDRA MANCA;SCILLA MASTRANDREA;ANTONIO COSSU;MARIA CRISTINA SINI;ARE BM;RICCARDO BOCCALETTI;ANTONIO PINNA;CLAUDIO CHERCHI;MARIA CHIARA MANNAZZU;GIORGIO OLZAI","0.34;0.24;0.24;0.22;0.2;0.18;0.17;0.17;0.17;0.17;0.17;0.17;0.15;0.15;0.14;0.12;0.12;0.11;0.11;0.11","PIER SERGIO SABA;MARCO MATTEO CICCONE;MARIA LORENZA MUIESAN;MARIA MAIELLO;MATTEO CAMELI;PASQUALE PALMIERO;PIETRO AMEDEO MODESTI;PIETRO SCICCHITANO;ROBERTO PEDRINELLI;SALVATORE NOVO;ALESSANDRO PECCI;ANNA SAVOIA;CARLO BARONCI;CARLO L. BALDUINI;CATERINA MARCONI;CLAUDIA CAGIONI;GABRIELE BAJ;LORETTA NGU;MARCO SERI;MICHELA FALESCHINI","365;329;329;329;329;329;329;329;329;329;55;55;55;55;55;55;55;55;55;55","PIER SERGIO SABA;SIMONETTA PARDINI;RICCARDO BOCCALETTI;GIUSEPPE DELITALA;ALESSANDRO DELITALA;ANTONELLO GANAU;FABIANA FILIGHEDDU;FEDERICA DECANDIA;FRANCESCO CUCCA;GIANPAOLO VIDILI;SCILLA MASTRANDREA;ANTONIO PINNA;ALESSANDRA MANCA;GIUSEPPE FANCIULLI;UPINDER KAUR MATTAR DIAL;ANTONIO COSSU;LORENZO COPPOLA;SILVANA SANNA;AMELIA LISSIA;MARIA CRISTINA SINI","365;55;53;50;36;36;36;36;36;30;30;16;14;14;14;12;12;5;4;4","SILVANA SANNA;GIANPAOLO VIDILI;GIUSEPPE DELITALA;PIER SERGIO SABA;ALESSANDRA MANCA;ALESSANDRO DELITALA;AMELIA LISSIA;ANTONELLO GANAU;ANTONIO COSSU;ANTONIO PINNA;ARE BM;FABIANA FILIGHEDDU;FEDERICA DECANDIA;FRANCESCO CUCCA;GIUSEPPE D. SANNA;GIUSEPPE FANCIULLI;LORENZO COPPOLA;MARIA CRISTINA SINI;RICCARDO BOCCALETTI;ROBERTO MASSAIU","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHILOSOPHY;PHYSICS","21;12;2;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;MICROBIOLOGY;ENDOCRINOLOGY;ONCOLOGY;PATHOLOGY;SURGERY;CARDIOLOGY;ANATOMY;BIOCHEMISTRY;RADIOLOGY;ANESTHESIA;BIOINFORMATICS;CANCER RESEARCH;EPISTEMOLOGY;EVOLUTIONARY BIOLOGY;GASTROENTEROLOGY;GENERAL SURGERY;GERONTOLOGY;INTENSIVE CARE MEDICINE;OBSTETRICS;OPTICS;PEDIATRICS;PHARMACOLOGY;PHYSICAL THERAPY;ZOOLOGY","16;5;5;5;4;4;4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;ANTIGEN;ANTIMICROBIAL;DIABETES MELLITUS;ANTIBIOTICS;ANTIBODY;ANTIFUNGAL;CANCER;CHEMOTHERAPY;DRUG RESISTANCE;HEART FAILURE;MAGNETIC RESONANCE IMAGING;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;THALASSEMIA;ADVERSE EFFECT;ANEMIA;ASPERGILLOSIS;ASPERGILLUS;ASPERGILLUS FUMIGATUS;ASYMPTOMATIC;BACTERIA;BLOOD PRESSURE;BODY MASS INDEX;BONE MARROW;CAROTID ARTERIES;CATHETER;CELLULOSE;CHOLESTEROL;CLINICAL PRACTICE;CLINICAL TRIAL;COHORT;COMBINATION THERAPY;CONCOMITANT;CONFOUNDING;CYST;DEFEROXAMINE;DISEASE;ECHINOCOCCOSIS;ECHINOCOCCUS GRANULOSUS;FAMILY HISTORY;FUNCTIONAL FOOD;GLUCAN;GROUP B;HEART DISEASE;HEMOLYSIS;HEMOSTASIS;IN VITRO;INCIDENCE (GEOMETRY);LONGEVITY;LUNG CANCER;MECHANISM (BIOLOGY);MELANOMA;MENINGITIS;MIGRAINE;MULTIVARIATE ANALYSIS;NUTRACEUTICAL;ODDS RATIO;PAROXYSMAL NOCTURNAL HEMOGLOBINURIA;PATHOGENESIS;PLATELET;PNEUMONIA;PREGNANCY;PROPORTIONAL HAZARDS MODEL;RECEPTOR;RESPIRATORY DISTRESS;RETROSPECTIVE COHORT STUDY;RISK FACTOR;SCALP;SEPSIS;STEM CELL;THROMBOSIS;THYROID;TUBERCULOSIS;VAGINA;VENTRICLE","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIFUNGAL DRUG;CLINICAL ENDPOINT;EJECTION FRACTION;MINIMUM INHIBITORY CONCENTRATION;PHENOTYPE;ALLELE;ANTIFUNGAL DRUGS;ARTERIAL STIFFNESS;ATRIOVENTRICULAR CANAL;BETA THALASSEMIA;BREAST CANCER;CANDIDA AURIS;CANDIDA GLABRATA;CARDIAC MAGNETIC RESONANCE IMAGING;CARDIOMYOPATHY;CDKN2A;CENTRAL VENOUS CATHETER;CHELATION THERAPY;CISPLATIN;CLINDAMYCIN;CYSTIC ECHINOCOCCOSIS;CYTOPENIA;DEFERASIROX;DEFERIPRONE;DIABETIC RETINOPATHY;DNA REPAIR;DOCETAXEL;ECHINOCOCCUS;EPITOPE;ETEST;FLUCONAZOLE;GALACTOMANNAN;GEMCITABINE;GENOTYPE;GERMLINE;HAEMATOPOIESIS;HEMOGLOBINURIA;HEMOSTATIC AGENT;HYDATID CYST;IMMUNOASSAY;INTIMA-MEDIA THICKNESS;MACROCYTOSIS;METASTASIS;MUTATION;MYCOBACTERIUM;NEONATAL INFECTION;NEUROPEPTIDE;NOCICEPTION;PANCREATIC CANCER;PERFORMANCE STATUS;PROGRESSION-FREE SURVIVAL;PULSE WAVE VELOCITY;RETINOPATHY;SEROLOGY;SOMATIC CELL;STREPTOCOCCUS;THYROID CANCER;TOLERABILITY;TRANSIENT RECEPTOR POTENTIAL CHANNEL;TYPE 2 DIABETES;UNIVARIATE ANALYSIS;VOLUME OVERLOAD","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BROTH MICRODILUTION;CALCITONIN GENE-RELATED PEPTIDE;CARBOPLATIN;CASPOFUNGIN;CLINICAL PHENOTYPE;GERMLINE MUTATION;LOSS OF HETEROZYGOSITY;NUCLEOTIDE EXCISION REPAIR;PARATUBERCULOSIS;PEMETREXED;STROKE VOLUME;TRPV1;VINORELBINE","2;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;ADULT;FEMALE;AGED;MIDDLE AGED;ECHINOCOCCOSIS;MALE;THROMBOCYTOPENIA;ADOLESCENT;DIABETES MELLITUS, TYPE 1;DIABETES MELLITUS, TYPE 2;DIABETIC RETINOPATHY;SHEEP DISEASES;ACTININ;AGED, 80 AND OVER;ANTIBODIES, BACTERIAL;BLOOD PLATELETS;BREAST NEOPLASMS;CALCITONIN GENE-RELATED PEPTIDE","13;9;7;7;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3","DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;GENETIC BASIS OF PRIMARY IMMUNODEFICIENCY DISORDERS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;HEMOSTATIC AGENTS AND TECHNIQUES;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR MECHANISMS OF AGING AND LONGEVITY;MOLECULAR MECHANISMS OF DNA DAMAGE RESPONSE;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;SURGICAL VENTRICULAR RECONSTRUCTION IN MYOCARDIAL INFARCTION;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIFUNGAL RESISTANCE;ANTIFUNGAL DRUG;ANTIFUNGAL THERAPY;BROTH MICRODILUTION;CLINICAL ENDPOINT;DIAGNOSIS;ANTIFUNGAL DRUGS;AORTIC STIFFNESS;ARTERIAL STIFFNESS;ATRIOVENTRICULAR CANAL;BETA THALASSEMIA;BLOOD GROUPS;BREAST CANCER;CANCER GENOMICS;CANDIDA AURIS;CANDIDA GLABRATA;CARBOPLATIN;CATHETER-RELATED BLOODSTREAM INFECTIONS;CENTRAL VENOUS CATHETER;CENTRAL VENOUS CATHETERIZATION","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIFUNGAL SUSCEPTIBILITY;CLINICAL LABORATORY;LEFT VENTRICULAR;PATIENTS TREATED;SUSCEPTIBILITY TESTING;ABSORBABLE TOPICAL;ACTN-RELATED THROMBOCYTOPENIA;ADVANCED NON-SMALL-CELL;ANTIBODIES CROSS-REACTING;ANTIGEN ENRICHMENT;ANTIGEN ZINC;ANTIMICROBIAL ACTIVITY;ARTERIAL STIFFNESS;ASPERGILLUS SPECIES;ATRIOVENTRICULAR CANAL;AVIUM SUBSPECIES;BETA-CELL ANTIGEN;BREAST CANCER;CANCER NSCLC;CANCER PATIENTS;CANDIDATE GENES;CASTLEMAN DISEASE;CENTRAL VENOUS;CHEMOTHERAPY EPIC;CHEMOTHERAPY VERSUS;CHRONIC MIGRAINE;CLINICAL EXPERIENCES;CLINICAL PRACTICE;CLONAL POPULATIONS;CMR RELATION","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEART FAILURE;DIABETES PATIENTS;TYPE DIABETES;BREAST CANCER;ANTIFUNGAL RESISTANCE;ASPERGILLUS SPP;CAROTIDFEMORAL PWV;CI- PLT;CYSTIC ECHINOCOCCOSIS;DIABETIC RETINOPATHY;HIGH-RISK PROLIFERATIVE;MEDIAN SURVIVAL;MPM PATIENTS;PANCREATIC CARCINOMA;POSITIVE ANTIBODIES;PROLIFERATIVE DIABETIC;ADVANCED NSCLC;ANTIFUNGAL DRUG;ANTIFUNGAL DRUGS;ANTIMICROBIAL SUSCEPTIBILITY;ARTERIAL STIFFNESS;BRCA MUTATIONS;BROTH MICRODILUTION;CANCER PATIENTS;CANCER RECEIVING;CANDIDA SPP;CARDIOVASCULAR DISEASE;CARDIOVASCULAR EVENTS;CDKNA GERMLINE;CLINICAL MICROBIOLOGY","8;7;6;5;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",6,0.27,2.58,4.25,3.5,0,3,0,0,0,0,4.25,0,0,3.25,0,0,3,2,1.75,3,0,0,43.5,43.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,4,614.5,7.14,1,0.5,100,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;1;1;1","CLINICAL RESEARCH;AGING;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EYE DISEASE AND DISORDERS OF VISION;HEMATOLOGY;MACULAR DEGENERATION;NEURODEGENERATIVE;ORPHAN DRUG;RARE DISEASES","2;1;1;1;1;1;1;1;1;1","CANCER;EYE","1;1","6.1 PHARMACEUTICALS","2","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY","2;1",NA,NA,"METABOLIC AND ENDOCRINE","1",NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA
"AOUSSN_SASSARI",2015,30,15,1.8,0.2,0.233333333333333,0.266666666666667,1.28571428571429,1.2,1,1.14285714285714,0.633333333333333,0,17,6,3,2,0.57,0.2,0.1,0.07,23.63,0.63414193170959,4.57142857142857,0.466666666666667,0.966666666666667,0.346,0.25,0.241,0.288,"GIUSEPPE PALMIERI;LUCIA DEL MASTRO;MATTEO LAMBERTINI;FRANCESCA POGGIO;ANTONIO COSSU;P. PRONZATO;MARIA COLOMBINO;GABRIELE MINUTI;FABIO PUGLISI;SERENA ZILIANI;EMANUELA RISI;ANTONELLA LAI;ALESSANDRO DELITALA;DONATELLA GRASSO;VALENTINA SINI;DAVID SCHLESSINGER;GRAZIA PALOMBA;ELENA POLETTO;SILVIA MURA;PANAGIOTIS PALIOGIANNIS","6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3","ALESSANDRO DELITALA;FRANCESCO BOSCIA;ANTONIO PINNA;FRANCESCO BLASETTI;GIUSEPPE PALMIERI;LUCIA DEL MASTRO;MATTEO LAMBERTINI;DAVID SCHLESSINGER;FRANCESCA POGGIO;P. PRONZATO;FRANCESCO CUCCA;ANTONIO COSSU;PAOLO MILIA;GARRETT NIEDDU;G. MELI;MAURIZIO CONTI;GIAN LUCA ERRE;GIUSEPPE PASSIU;LILIANA LORETTU;MARCO ENRICO PIRAS","0.44;0.4;0.37;0.37;0.34;0.33;0.33;0.31;0.27;0.27;0.27;0.27;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25","ANTONIO COSSU;ANTONELLA LAI;ALESSANDRO DELITALA;FRANCESCO CUCCA;ANTONIO PAZZOLA;ANTONIO PINNA;GIUSEPPE DELITALA;FRANCESCO BLASETTI;L. CORDERO;FRANCESCO BOSCIA;T. SCOTTO;SILVANA SANNA;LUCA BRAZZI;ANDREA COSSU;MARIA GIUSEPPA SAROBBA;RITA OGGIANO;PIETRO PIRINA;PAOLO MILIA;PAOLO CASTIGLIA;MARIA GABRIELA URAS","5;4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","ALESSANDRO DELITALA;FRANCESCO BOSCIA;ANTONIO PINNA;FRANCESCO BLASETTI;FRANCESCO CUCCA;ANTONIO COSSU;PAOLO MILIA;GIAN LUCA ERRE;GIUSEPPE PASSIU;MARCO ENRICO PIRAS;GIUSEPPE DELITALA;ANTONELLA LAI;RITA OGGIANO;GIUSEPPE D’AMICO RICCI;DANIELE CARDILLO;VINCENZO MARRAS;PAOLO CASTIGLIA;CIRIACO CARRU;ANTONIO PAZZOLA;LUCA BRAZZI","0.44;0.4;0.37;0.37;0.27;0.27;0.25;0.25;0.25;0.25;0.24;0.21;0.2;0.2;0.2;0.2;0.17;0.17;0.16;0.12","FRANCESCA POGGIO;LUCIA DEL MASTRO;MATTEO LAMBERTINI;ALESSIA LEVAGGI;ANDREA MICHELOTTI;C VECCHIO;CLAUDIA BIGHIN;LUCA BONI;MONICA GIORDANO;ORNELLA GARRONE;P. PRONZATO;S. GIRAUDI;STEFANIA GORI;TERESA GAMUCCI;DAVID SCHLESSINGER;ALESSANDRO DELITALA;FRANCESCO CUCCA;MARIO ROBERTO SERTOLI;TIZIANA SCOTTO;MARISTELLA STERI","243;243;243;217;217;217;217;217;217;217;217;217;217;217;208;202;193;186;186;151","ALESSANDRO DELITALA;TIZIANA SCOTTO;ALESSANDRA MANCA;MARIA GABRIELA URAS;FRANCESCO CUCCA;MICHELE UBERTAZZI;FABIANA FILIGHEDDU;GIUSEPPE DELITALA;T. SCOTTO;ANTONELLA LAI;L. CORDERO;ANTONIO COSSU;FRANCESCO TANDA;ANTONIO PINNA;CIRIACO CARRU;PAOLO CASTIGLIA;SEBASTIANA ATZORI;CARLO COSMI;ILARIA FOTZI;ANDREA COSSU","202;186;89;89;87;57;45;45;31;26;18;15;15;13;13;13;13;12;12;11","ALESSANDRO DELITALA;ANTONELLA LAI;ANTONIO COSSU;FRANCESCO BOSCIA;FRANCESCO CUCCA;L. CORDERO;T. SCOTTO;ALESSANDRA MANCA;ANDREA COSSU;ANTONIO PINNA;BIANCA MARIA ARE;CARLO COSMI;CIRIACO CARRU;FABIANA FILIGHEDDU;FRANCESCO TANDA;GIAN LUCA ERRE;GIUSEPPE DELITALA;GIUSEPPE PASSIU;ILARIA FOTZI;LUCA BRAZZI","4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;ECONOMICS;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY","28;12;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;ENVIRONMENTAL HEALTH;PATHOLOGY;CANCER RESEARCH;ENDOCRINOLOGY;GASTROENTEROLOGY;GYNECOLOGY;SURGERY;BIOCHEMISTRY;CARDIOLOGY;IMMUNOLOGY;MACROECONOMICS;OPHTHALMOLOGY;PALEONTOLOGY;PHARMACOLOGY;ANESTHESIA;CLASSICAL MECHANICS;DERMATOLOGY;FAMILY MEDICINE;GENERAL SURGERY;INORGANIC CHEMISTRY;INTENSIVE CARE MEDICINE;LAW;MACHINE LEARNING;METALLURGY;MICROBIOLOGY;NURSING;OBSTETRICS;OPTICS;PEDIATRICS;PHYSICAL MEDICINE AND REHABILITATION;PHYSICAL THERAPY;PSYCHIATRY;PSYCHOTHERAPIST;QUANTUM MECHANICS;RADIOLOGY;SOCIAL PSYCHOLOGY;THEOLOGY","20;10;8;6;6;5;5;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENE;POPULATION;COHORT;DIABETES MELLITUS;DISEASE;CHEMOTHERAPY;CONFIDENCE INTERVAL;HORMONE;LUNG CANCER;PROPORTIONAL HAZARDS MODEL;RETROSPECTIVE COHORT STUDY;ANTIBODY;BIOPSY;DEPRESSION (ECONOMICS);STAGE (STRATIGRAPHY);THYROID;ADJUVANT;ANTIBIOTICS;ANTICOAGULANT;ARTERY;ATRESIA;BACTERIA;BAREFOOT;BLOOD PLASMA;CAROTID ARTERIES;CHORISTOMA;CHRISTIAN MINISTRY;CIRRHOSIS;CLINICAL TRIAL;COAGULATION;COHORT STUDY;COMPLICATION;COVARIATE;CROSS-SECTIONAL STUDY;DEFEROXAMINE;DENIAL;DIALYSIS;DISCONTINUATION;DNA;DRUG RESISTANCE;EMOTIONAL REACTION;EMPATHY;EPIDEMIOLOGY;FEELING;FERRITIN;FIBROSIS;FIRST LINE;GAIT;GAUGE (FIREARMS);HELICOBACTER PYLORI;HEMODIALYSIS;HEMOSTASIS;HEPARIN;HOMOCYSTEINE;IMPULSE (PHYSICS);INCIDENCE (GEOMETRY);INTERQUARTILE RANGE;KIDNEY DISEASE;KINEMATICS;LOGISTIC REGRESSION;LUNG;LYMPH;LYMPH NODE;MACULAR DEGENERATION;MELANOMA;NAUSEA;OBSERVATIONAL STUDY;ODDS RATIO;PILL;SERIOUSNESS;SHORT STATURE;SIGNAL TRANSDUCTION;SODIUM THIOSULFATE;SUBCLINICAL INFECTION;TRANSDERMAL;TREADMILL;TYPING;ULTRASOUND;VISUAL ACUITY;VOMITING;WHOLE BLOOD","13;10;6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;MUTATION;COLORECTAL CANCER;ADJUVANT THERAPY;EXON;HAZARD RATIO;ADENOCARCINOMA;EPIDERMAL GROWTH FACTOR RECEPTOR;GENOTYPE;LUTEINIZING HORMONE;ACTIVATED CLOTTING TIME;ALLELE;AUTOANTIBODY;CALCIPHYLAXIS;CDKN2A;CELL CYCLE;CHROMOSOME;CLOTTING TIME;COLISTIN;COMMON CAROTID ARTERY;CUMULATIVE INCIDENCE;DEPRESSIVE SYMPTOMS;DEVELOPED COUNTRY;DNA SEQUENCING;DOCETAXEL;ELASTOGRAPHY;FERTILITY;FOREFOOT;GENE EXPRESSION;INTIMA-MEDIA THICKNESS;LIVER BIOPSY;LOCUS (GENETICS);METHYLATION;MINIMUM INHIBITORY CONCENTRATION;OVARIAN CANCER;PHENOTYPE;PI3K/AKT/MTOR PATHWAY;PROGRESSIVE DISEASE;PROTAMINE;PROTEIN KINASE B;PSEUDOMONAS AERUGINOSA;RESEARCH METHODOLOGY;RETINOPATHY;SEROLOGY;SERUM FERRITIN;SOMATIC CELL;THYROID FUNCTION;THYROID FUNCTION TESTS;THYROID PEROXIDASE;TRACHEOESOPHAGEAL FISTULA;TRANSDERMAL PATCH;TYPE 1 DIABETES;TYPE 2 DIABETES;VIRULENCE;VITRECTOMY","8;5;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","KRAS;METASTATIC BREAST CANCER;TRASTUZUMAB;GONADOTROPIN-RELEASING HORMONE;ACINETOBACTER BAUMANNII;AKT1;ALLELE FREQUENCY;ANTI-THYROID AUTOANTIBODIES;AUTOIMMUNE DIABETES;BROTH MICRODILUTION;CAGA;DNA METHYLATION;ERLOTINIB;FAMILY PLANNING;FERTILITY PRESERVATION;FLUORESCENCE IN SITU HYBRIDIZATION;GASTRIC ADENOCARCINOMA;GENE MUTATION;GENETIC HETEROGENEITY;HAPLOTYPE;ION SEMICONDUCTOR SEQUENCING;MACULOPATHY;MOLECULAR EPIDEMIOLOGY;MULTILOCUS SEQUENCE TYPING;MUTATION TESTING;ONCOGENE;PTEN;PULSED-FIELD GEL ELECTROPHORESIS;SANGER SEQUENCING;SEROPREVALENCE;SINGLE-NUCLEOTIDE POLYMORPHISM;TRANSIENT ELASTOGRAPHY;TRIPLE-NEGATIVE BREAST CANCER","6;4;4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;;ITALY;MALE;MIDDLE AGED;BREAST NEOPLASMS;AGED;LUNG NEOPLASMS;DIABETES MELLITUS, TYPE 1;DIABETES MELLITUS, TYPE 2;HELICOBACTER INFECTIONS;YOUNG ADULT;ACINETOBACTER BAUMANNII;ADENOCARCINOMA;AGED, 80 AND OVER;BACTERIAL PROTEINS;BETA-THALASSEMIA;CARCINOMA, NON-SMALL-CELL LUNG","18;16;13;12;12;11;11;9;8;8;5;5;5;5;4;4;4;4;4;4","HER2 SIGNALING IN BREAST CANCER TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;THYROID DISEASE AND HORMONE REGULATION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANALYSIS OF ELECTROMYOGRAPHY SIGNAL PROCESSING;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CONTRACEPTION AND UNINTENDED PREGNANCY PREVENTION;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EMPATHY DECLINE AND TRAINING IN MEDICAL EDUCATION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;ESOPHAGEAL INTERVENTION TECHNIQUES;FERTILITY PRESERVATION IN CANCER PATIENTS;GASTRIC CANCER RESEARCH AND TREATMENT;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GENOMIC REARRANGEMENT DISORDERS IN SKIN DISEASES;GENOMIC STUDIES AND ASSOCIATION ANALYSES;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;TRASTUZUMAB;ADJUVANT THERAPY;CANCER THERAPY;EGFR MUTATIONS;GENE EXPRESSION REGULATION;HYPOTHYROIDISM;METASTATIC BREAST CANCER;TREATMENT RESPONSE;TRIPTORELIN;1000 GENOMES PROJECT;ACINETOBACTER BAUMANNII;ACTIVATED CLOTTING TIME;AGE-RELATED MACULOPATHY;ANTI-THYROID AUTOANTIBODIES;AUTOIMMUNE DIABETES;BAREFOOT;BLOOD PLASMA;BROTH MICRODILUTION;CAGA","7;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER PATIENTS;HER-POSITIVE METASTATIC;METASTATIC BREAST;TRASTUZUMAB-BASED THERAPY;DE NOVO;LINE TRASTUZUMAB-BASED;LINE TREATMENT;NEOADJUVANT TRASTUZUMAB;RECURRENT DISEASE;ACINETOBACTER BAUMANNII;ACOUSTIC RADIATION;ACTIVATION PATHWAYS;ADENOCARCINOMA VEGA;ADJUVANT BREAST;ADVANCED NSCLC;AGE-RELATED MACULAR;ANALOG LHRHA;ARM CLINICAL;ARTERY BYPASS;ASSOCIATION STUDY;ASYMMETRICAL DIMETHYL-SCPLSCP-ARGININE;ATHEROSCLEROTIC PLAQUE;AUTOIMMUNE DIABETES;BAUMANNII STRAINS;BLOOD DNA;CANCER CHEMOTHERAPY;CANDIDATE GENES;CAROTID INTIMA;CHELATION THERAPY","8;5;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;HR CI;OVARIAN FUNCTION;CLINICAL OUTCOMES;CANCER PATIENTS;LONG-TERM OVARIAN;NEOADJUVANT TRASTUZUMAB;TRASTUZUMAB-BASED THERAPY;EGFR MUTATIONS;KRAS MUTATIONS;DEPRESSIVE SYMPTOMS;MBC PTS;METASTATIC BREAST;CI -IPI;COMBINED HORMONAL;CUMULATIVE INCIDENCE;FIRST-LINE TRASTUZUMAB;FIRST-LINE TREATMENT;HER-POSITIVE METASTATIC;HORMONAL CONTRACEPTION;INCIDENCE ESTIMATE;MEDIAN AGE;NEOPLASTIC CELLS;RECURRENT DISEASE;AGE RANGE;AGE-ADJUSTED HR;AUTOIMMUNE DIABETES;DE NOVO;HORMONE RECEPTOR;KRAS GENE","28;15;14;9;8;8;8;8;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4",12,0.4,1.62,3.5,1.75,1.75,0,9,0,0,0,4.5,0,1,4,0,0,1,1,5,9.75,0,0,68.25,68.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,3.5,1583.5,5.26,0,0,20,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;2","CLINICAL RESEARCH;ARTHRITIS;AUTOIMMUNE DISEASE;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HIV/AIDS;PREVENTION;RHEUMATOID ARTHRITIS","2;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;INFECTION","1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;44 HUMAN SOCIETY;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;4409 SOCIAL WORK","5;2;2;1;1;1","CLINICAL RESEARCH","1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,"CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","1;1",NA,NA,NA,NA
"AOUSSN_SASSARI",2016,23,11.2608695652174,2.17391304347826,0.347826086956522,0.217391304347826,0.478260869565217,1.21951219512195,1.14285714285714,1,1.1,0.565217391304348,0,8,5,6,3,0.35,0.22,0.26,0.13,28.3,0.871358526100977,5.06451612903226,0.347826086956522,0.869565217391304,0.36,0.25,0.15,0.267,"ALESSANDRO DELITALA;GIUSEPPE PALMIERI;ANTONIO COSSU;MARGHERITA MAIOLI;GIOVANNI MARIO PES;GIUSEPPE DELITALA;ANTONIO DURANDO;C. MARCHIONI;PANAGIOTIS PALIOGIANNIS;FABIO PUGLISI;CLAUDIA BIGHIN;MICHELINO DE LAURENTIIS;PAOLO BRUZZI;GIOVANNA CAVAZZINI;FILIPPO MONTEMURRO;R. BONA;MARIO BUDRONI;MATTEO TAMPONI;MARIA PINA DORE;GIANCARLO BISAGNI","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GIOVANNI MARIO PES;FURIO PIROZZI FARINA;MARIA PINA DORE;A PISCHEDDA;ALESSANDRO DELITALA;GIUSEPPE DELITALA;MARGHERITA MAIOLI;FRANCESCO TOLU;C. MARCHIONI;R. BONA;MATTEO TAMPONI;FRANCESCO PINNA;A. POGGIU;PIERGIORGIO MARINI;MICHELE PORTOGHESE;MIRKO MURETTI;MARIO MANCA;FRANCESCO MASSI;GIUSEPPE PALMIERI;ANTONIO COSSU","0.62;0.5;0.5;0.5;0.49;0.42;0.37;0.33;0.29;0.29;0.29;0.29;0.29;0.29;0.25;0.25;0.25;0.25;0.22;0.22","ALESSANDRO DELITALA;ANTONIO COSSU;C. MARCHIONI;PANAGIOTIS PALIOGIANNIS;R. BONA;MATTEO TAMPONI;GIAN LUCA ERRE;GIOVANNI SOTGIU;FRANCESCO PINNA;A. POGGIU;PIERGIORGIO MARINI;FRANCESCO TOLU;NICOLA MUNDULA;ANTONELLO GANAU;ANGELA SPANU;CARLA CIROTTO;FRANCA SANCIU;MARIA GABRIELA URAS;MICHELE PORTOGHESE;PIER SERGIO SABA","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","FURIO PIROZZI FARINA;A PISCHEDDA;ALESSANDRO DELITALA;FRANCESCO TOLU;C. MARCHIONI;R. BONA;MATTEO TAMPONI;FRANCESCO PINNA;A. POGGIU;PIERGIORGIO MARINI;MICHELE PORTOGHESE;MIRKO MURETTI;MARIO MANCA;FRANCESCO MASSI;ANTONIO COSSU;GIOVANNI SOTGIU;PANAGIOTIS PALIOGIANNIS;GIAN LUCA ERRE;ANGELA SPANU;GIOVANNI BATTISTA MELONI","0.5;0.5;0.49;0.33;0.29;0.29;0.29;0.29;0.29;0.29;0.25;0.25;0.25;0.25;0.22;0.22;0.16;0.14;0.14;0.14","GIAN LUCA ERRE;ALBERTO MARTINI;ALESSANDRA CAROBBIO;ALESSANDRO RIMINI;ANNA CHIARA VALENTI;ANTONIO BRUCATO;DAVIDE CUMETTI;FIORENZO GAÏTA;GEORGE LAZAROS;MARA CARRARO;MARCO GATTORNO;MARIA PIA SORMANI;MARTINA FINETTI;MASSIMO IMAZIO;MONIA LORINI;NICOLINO RUPERTO;R MARCOLONGO;RICCARDO BELLI;SILVIA MAESTRONI;ALESSANDRO DELITALA","301;276;276;276;276;276;276;276;276;276;276;276;276;276;276;276;276;276;276;91","GIAN LUCA ERRE;ALESSANDRO DELITALA;GIOVANNI SOTGIU;ALESSANDRA MANCA;MARIA GABRIELA URAS;TIZIANA SCOTTO;ANTONIO COSSU;MICHELE UBERTAZZI;ALESSANDRA PIRAS;ANTONELLO GANAU;GIUSEPPE PASSIU;LOREDANA TARAS;MARCO PIRAS;MARIA GIOVANNA LONGU;NICOLA MUNDULA;PIER SERGIO SABA;SILVIA MURA;FRANCESCO TANDA;PANAGIOTIS PALIOGIANNIS;FRANCA SANCIU","301;91;46;41;41;41;33;30;25;25;25;25;25;25;25;25;25;23;23;17","ALESSANDRO DELITALA;GIAN LUCA ERRE;ALESSANDRA MANCA;ALESSANDRA PIRAS;ANTONELLO GANAU;ANTONIO COSSU;FRANCA SANCIU;FRANCESCO MASSI;FRANCESCO TANDA;FRANCESCO TOLU;GIOVANNI SANNA;GIOVANNI SOTGIU;GIUSEPPE PASSIU;LOREDANA TARAS;MARCO PIRAS;MARIA GABRIELA URAS;MARIA GIOVANNA LONGU;MARIO MANCA;MARIO PALA;MARISTELLA SALVATORA MASALA","4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;BUSINESS;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY","22;6;3;3;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;CARDIOLOGY;CANCER RESEARCH;ENDOCRINOLOGY;IMMUNOLOGY;ONCOLOGY;BIOCHEMISTRY;CELL BIOLOGY;GASTROENTEROLOGY;GENETICS;PHARMACOLOGY;SURGERY;ENVIRONMENTAL HEALTH;GYNECOLOGY;NUCLEAR MEDICINE;ALGORITHM;ANATOMY;BIOTECHNOLOGY;CRYSTALLOGRAPHY;DATABASE;DERMATOLOGY;FINANCE;INTENSIVE CARE MEDICINE;LAW;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;MEDICAL PHYSICS;MICROBIOLOGY;NURSING;OPERATING SYSTEM;PEDIATRICS;PHYSIOLOGY;PROGRAMMING LANGUAGE;RADIOLOGY;WORLD WIDE WEB","17;6;5;4;4;4;4;3;3;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENE;ALTERNATIVE MEDICINE;ANTIBODY;DIABETES MELLITUS;DISEASE;RANDOMIZED CONTROLLED TRIAL;REGIMEN;THYROID;CHEMOTHERAPY;THALASSEMIA;ADNEXAL MASS;ADVERSE EFFECT;AMINO ACID;ANTIBIOTICS;ARTERY;ATRIAL FIBRILLATION;BETA (PROGRAMMING LANGUAGE);BLOOD PRESSURE;CELL;CELL GROWTH;CENTER (CATEGORY THEORY);CHOLESTEROL;COHORT;CONFIDENCE INTERVAL;CONFOUNDING;CONSERVATIVE MANAGEMENT;CORTICOSTEROID;COVER (ALGEBRA);DEFEROXAMINE;DICOM;EMERGENCY DEPARTMENT;ENDOTHELIAL DYSFUNCTION;EPIDEMIOLOGY;ETIOLOGY;HELICOBACTER PYLORI;HORMONE;HYALURONIC ACID;IN VITRO;IN VIVO;INFLAMMATION;INSULIN;INVASIVE SURGERY;KINASE;LAPAROSCOPY;LAPAROTOMY;LEPROSY;MATLAB;MEDLINE;MELANOMA;MELATONIN;MENOPAUSE;ODDS RATIO;ORDER (EXCHANGE);OVARIAN TORSION;PATHOLOGICAL;PATIENT DATA;PECTUS EXCAVATUM;PERICARDITIS;POPULATION;PROPORTIONAL HAZARDS MODEL;PROSTHESIS;PULP (TOOTH);RED BLOOD CELL DISTRIBUTION WIDTH;RENAL CELL CARCINOMA;RETROSPECTIVE COHORT STUDY;RHEUMATOID ARTHRITIS;SIDEROSIS;SIGNAL TRANSDUCTION;STEM CELL;SUBCLINICAL INFECTION;SUBJECT (DOCUMENTS);TACHYCARDIA;THORACOTOMY;TUBERCULOSIS","5;5;3;3;3;3;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;AUTOANTIBODY;CHEMOTHERAPY REGIMEN;THYROID PEROXIDASE;ACUTE PERICARDITIS;ANAKINRA;ARGININE;ARTERIAL STIFFNESS;AUTOIMMUNITY;BETA THALASSEMIA;CELL CYCLE;CLEAR CELL RENAL CELL CARCINOMA;CLINICAL ENDPOINT;CLOFAZIMINE;COLORECTAL CANCER;CONTRAINDICATION;CRITICAL APPRAISAL;CYCLOPHOSPHAMIDE;DEFERASIROX;DEFERIPRONE;DENTAL PULP STEM CELLS;EPIDERMAL GROWTH FACTOR RECEPTOR;EXON;GENE SILENCING;GENETIC EPIDEMIOLOGY;GENETIC PREDISPOSITION;GRAVES' DISEASE;HAZARD RATIO;HIGH-DENSITY LIPOPROTEIN;ISONIAZID;LIPID PROFILE;MANAGEMENT OF ATRIAL FIBRILLATION;MOXIFLOXACIN;MULTICENTER STUDY;MYCOBACTERIUM TUBERCULOSIS;NOTCH SIGNALING PATHWAY;PI3K/AKT/MTOR PATHWAY;PLACEBO;PROTEIN KINASE B;PULSE WAVE VELOCITY;RETINOIC ACID;SUPRAVENTRICULAR TACHYCARDIA;THYROID CANCER;THYROIDITIS;TRIGLYCERIDE;VIRULENCE","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTI-THYROID AUTOANTIBODIES;EPIRUBICIN;ASYMMETRIC DIMETHYLARGININE;AUTOIMMUNE THYROIDITIS;BEDAQUILINE;CAGA;DOUBLE BLIND;ETHAMBUTOL;JAG1;KRAS;MAMMOGRAPHY;ONCOGENE;PYRAZINAMIDE;RADIOIODINE THERAPY","2;2;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;ADULT;MIDDLE AGED;BETA-THALASSEMIA;ITALY;AUTOANTIBODIES;DIABETES MELLITUS;FUNNEL CHEST;HEMOSIDEROSIS;MELANOMA;SKIN NEOPLASMS;5-ALPHA REDUCTASE INHIBITORS;ADOLESCENT;AGED;ANTICOAGULANTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ATRIAL FIBRILLATION","13;10;9;8;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ATRIAL FIBRILLATION;BREAST CANCER SCREENING TECHNOLOGY;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CHOLANGIOCARCINOMA;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MELANOMA;MINIMALLY INVASIVE REPAIR OF PECTUS EXCAVATUM;MOLECULAR RESEARCH ON BREAST CANCER;MULTIPOTENT MESENCHYMAL STEM CELLS;ROLE OF NITRIC OXIDE IN HEALTH AND DISEASE;STANDARDISATION OF LOWER URINARY TRACT FUNCTION","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","REGIMEN;ANTI-THYROID AUTOANTIBODIES;CHEMOTHERAPY REGIMEN;EGFR MUTATIONS;EPIRUBICIN;NEOADJUVANT THERAPY;THYROID PEROXIDASE;ACUTE PERICARDITIS;ADNEXAL MASS;ARRHYTHMIAS;ASYMMETRIC DIMETHYLARGININE;ATRIAL FIBRILLATION;AUTOIMMUNE THYROIDITIS;BEDAQUILINE;BETA (PROGRAMMING LANGUAGE);BETA THALASSEMIA;BREAST CANCER;CAGA;CAGA PROTEIN;CENTER (CATEGORY THEORY)","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","ADJUVANT CHEMOTHERAPY;BREAST CANCER;CANCER PATIENTS;DOSE-DENSE ADJUVANT;GIM PHASE;POOLED ANALYSIS;PREMENOPAUSAL BREAST;ADVERSE EVENTS;ANTI-THYROID PEROXIDASE;ARTERIAL STIFFNESS;ARTERY BYPASS;ASYMMETRIC DIMETHYLARGININE;ATRIAL FIBRILLATION;AUTOIMMUNE DIABETES;BANGLADESH REGIMEN;BETA-THALASSEMIA MAJOR;BREAST TOMOSYNTHESIS;CAGA ANTIBODIES;CARDIAC IRON;CASECONTROL STUDY;CELL CARCINOMA;CELL RENAL;CHEMOTHERAPY TREATMENT-INDUCED;CHOLANGIOCARCINOMA DEVELOPMENT;COLCHICINE RESISTANCE;COLORECTAL CARCINOMA;CONDITIONED MEDIUM;CORONARY ARTERY;CORTICOSTEROID DEPENDENCE;COSMETIC PROSTHESIS","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RECURRENT PERICARDITIS;ARTERIAL STIFFNESS;BREAST CANCER;RHEUMATOID ARTHRITIS;TREATMENT-INDUCED AMENORRHEA;AKTJAG MICE;ADMA CONCENTRATION;CONTROL SUBJECTS;DOSE-DENSE CHEMOTHERAPY;HEALTHY CONTROL;HUMAN ICC;INCIDENCE RATE;INCREASED RISK;KRAS MUTATIONS;MENOPAUSAL STATUS;NOTCH SIGNALLING;PREMENOPAUSAL BREAST;TDM PATIENTS;Β-T MAJOR;ADVERSE EVENTS;AORTIC AUGMENTATION;ARTHRITIS COMPARED;AUGMENTATION PRESSURE;BU RA;C-REACTIVE PROTEIN;CANCER PATIENTS;CELL LINES;CHEMOTHERAPY REGIMEN;CLOFAZIMINE PYRAZINAMIDE;COLCHICINE RESISTANCE","7;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2",6,0.26,5.34,7.75,3.25,1,3,7,3.5,0,0,8,0,0,6,0,0,1,7,5.25,4,0,0,125,125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,1.5,1200,5,0,0,11.5,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY","2;1;1","CLINICAL RESEARCH;AGING;EYE DISEASE AND DISORDERS OF VISION;MACULAR DEGENERATION;NEURODEGENERATIVE","2;1;1;1;1","EYE","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2017,36,16.6388888888889,1.77777777777778,0.194444444444444,0.0555555555555556,0.25,1.42222222222222,1.16666666666667,0.666666666666667,1.28571428571429,0.583333333333333,0,17,11,2,3,0.47,0.31,0.06,0.08,24.69,0.837809049721428,4.8641975308642,0.305555555555556,1,0.522,0.233,0.2,0.211,"ANTONIO COSSU;GIOVANNI MARIO PES;GIUSEPPE PALMIERI;ANTONELLA MELONI;ALESSIA PEPE;ALBERTO PORCU;ALESSANDRO DELITALA;PANAGIOTIS PALIOGIANNIS;MARIA G. PILO;MARIA CRISTINA SINI;AURELIO MAGGIO;GIANPAOLO VIDILI;FRANK DOMBROWSKI;ANTONIO PINNA;LI CHE;ANTONIO CIGLIANO;LAURA PISTOIA;FRANCESCO COGNETTI;ROSA M. PASCALE;ANTONIO FRASSOLDATI","7;7;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","GIOVANNI MARIO PES;ANTONIO COSSU;ANTONIO PINNA;FRANCESCO BOSCIA;GIUSEPPE PALMIERI;ALESSANDRO DELITALA;ALESSANDRA ERRIGO;GIUSEPPE DELITALA;ANTONELLA MELONI;ALESSIA PEPE;LEONARDO A. SECHI;ANGELA BITTI;MARIA PINA DORE;AURELIO MAGGIO;LAURA PISTOIA;ALBERTO PORCU;MARIA COLOMBINO;GERARDO BOTTI;PAOLO A. ASCIERTO;PANAGIOTIS PALIOGIANNIS","0.82;0.58;0.57;0.57;0.53;0.52;0.45;0.4;0.33;0.33;0.28;0.25;0.25;0.24;0.24;0.24;0.24;0.24;0.24;0.23","ANTONIO COSSU;ALESSANDRO DELITALA;ANTONIO PINNA;GIUSEPPE PASSIU;FRANCESCO BOSCIA;ALESSANDRO G. FOIS;PIETRO PIRINA;MARIA GRAZIA SANNA;CARLO COSMI;ALESSIO ALIGI COGONI;GIAN LUCA ERRE;MG LONGU;ML CADONI;ALESSANDRA ERRIGO;ANGELA BITTI;B. VINCIS;PIERFRANCO SPANO;ALDO PISCHEDDA;CARLA CIROTTO;CLAUDIA SPADA","7;4;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","ANTONIO COSSU;ANTONIO PINNA;FRANCESCO BOSCIA;ALESSANDRO DELITALA;ALESSANDRA ERRIGO;ANGELA BITTI;GIUSEPPE PASSIU;FRANCA SANCIU;MARIA ALMA POSADINU;MARIA GRAZIA SANNA;CARLO COSMI;ANGELA MARIA MURETTI;GIAN LUCA ERRE;MG LONGU;ML CADONI;ANDREA MONTELLA;LUCIA ULGHERI;SIMONA RICCIO;ALDO PISCHEDDA;MARIO MAIORE","0.58;0.57;0.57;0.52;0.45;0.25;0.21;0.2;0.2;0.18;0.17;0.17;0.14;0.14;0.14;0.12;0.12;0.12;0.11;0.11","ALESSANDRO DELITALA;ALESSANDRO MATHIEU;MATTEO PIGA;ALESSANDRA MELONI;ANA SUÁREZ;ANDREA ANGIUS;ANDREA MASCHIO;ANTONELLA MULAS;ANTONELLO PANI;ANTONIO GONZÁLEZ;BERTA MARTINS DA SILVA;CARLO SIDORE;DAVID SCHLESSINGER;DAVIDE FIRINU;EDOARDO FIORILLO;ELEONORA COCCO;ELEONORA PORCU;FABIO BUSONERO;FAUSTO PODDIE;FRANCA ROSA GUERINI","419;345;345;344;344;344;344;344;344;344;344;344;344;344;344;344;344;344;344;344","GABRIELE FARINA;ANTONIO COSSU;ALESSANDRO DELITALA;ALESSANDRO G. FOIS;ANTONIO PINNA;FRANCESCO BOSCIA;CARLO COSMI;B MARIANI;B. VINCIS;CLAUDIA SPADA;DAVID CUESTA–FRAU;ELISABETTA ZINELLU;F. UDA;FRANCISCA SERRA;P.P. MAUREDDU;PIERFRANCO SPANO;PIETRO PIRINA;ANDREA MONTELLA;LUCIA ULGHERI;MARIANNA CONTU","344;322;75;30;27;27;25;19;19;19;19;19;19;19;19;19;19;12;12;12","ANTONIO COSSU;ALESSANDRO DELITALA;ANTONIO PINNA;FRANCESCO BOSCIA;ALESSANDRO G. FOIS;CARLO COSMI;GIAN LUCA ERRE;MARIA GRAZIA SANNA;MG LONGU;ML CADONI;ALDO PISCHEDDA;ALESSANDRA ERRIGO;ANDREA MONTELLA;ANGELA BITTI;ANGELA MARIA MURETTI;ANTONELLO SERRA;B MARIANI;B. VINCIS;CLAUDIA SPADA;DAVID CUESTA–FRAU","7;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY","32;14;5;3;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;CANCER RESEARCH;SURGERY;ENDOCRINOLOGY;IMMUNOLOGY;PEDIATRICS;BIOCHEMISTRY;CARDIOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;NURSING;PALEONTOLOGY;PATHOLOGY;CELL BIOLOGY;DERMATOLOGY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;MACHINE LEARNING;OPHTHALMOLOGY;OPTICS;PHYSICAL THERAPY;PSYCHIATRY","27;8;7;6;6;5;5;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;COHORT;GENE;DISEASE;ANTIBODY;IMMUNE SYSTEM;RETROSPECTIVE COHORT STUDY;THALASSEMIA;DIABETES MELLITUS;HEART FAILURE;RHEUMATOID ARTHRITIS;ADVERSE EFFECT;APOPTOSIS;ASTHMA;CHEMOTHERAPY;CLINICAL TRIAL;INSULIN;MELANOMA;POPULATION;PROPORTIONAL HAZARDS MODEL;SIGNAL TRANSDUCTION;STAGE (STRATIGRAPHY)","7;7;7;6;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","IMMUNOTHERAPY;ALLELE;AUTOANTIBODY;AUTOIMMUNITY;BETA THALASSEMIA;CLINICAL ENDPOINT;COLORECTAL CANCER;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;EJECTION FRACTION;GENOTYPE;IMMUNOGENICITY;MUTATION;PI3K/AKT/MTOR PATHWAY;TYPE 2 DIABETES;ACANTHAMOEBA KERATITIS;ADENOCARCINOMA;ADIPOCYTE;ADIPOGENESIS;ARTERIAL STIFFNESS;ASTHMA MANAGEMENT;AUTOIMMUNE DISEASE;AUTOPHAGY;B CELL;BASAL (MEDICINE);BIRTH WEIGHT;BONE MINERAL;BREAST CANCER;CADHERIN;CARCINOGENESIS;CARDIAC FUNCTION CURVE;CARDIAC MAGNETIC RESONANCE;CELLULAR DIFFERENTIATION;CHEMOTHERAPY REGIMEN;CHROMOSOME;CLINICAL DISEASE;CUMULATIVE INCIDENCE;DEHYDROGENASE;DOCETAXEL;EMOTIONAL SUPPORT;EXON;FAMILIAL HYPERCHOLESTEROLEMIA;FETUS;FLUOROURACIL;GEMCITABINE;GENE EXPRESSION;GENETIC PREDISPOSITION;GERMLINE;GLUTAMINE;HAZARD RATIO;HUMAN LEUKOCYTE ANTIGEN;HYPERAEMIA;INSULIN RESISTANCE;JUVENILE MYOCLONIC EPILEPSY;LAMA;LEPTIN;LIVER CANCER;MAPK/ERK PATHWAY;MESENTERIC ISCHEMIA;MESSENGER RNA;METASTATIC MELANOMA;MUCOCUTANEOUS ZONE;MUCOSAL MELANOMA;MYOCARDIAL FIBROSIS;MYOCLONIC EPILEPSY;MYOCLONIC JERK;PARKINSON'S DISEASE;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PLASMAPHERESIS;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;PROINFLAMMATORY CYTOKINE;PROINSULIN;PROTEIN KINASE B;RADIAL STRESS;REACTIVE HYPEREMIA;RESTENOSIS;RETINAL DETACHMENT;RITUXIMAB;SOMATIC CELL;SPIROMETRY;SPLENECTOMY;SYMBLEPHARON;SYSTEMIC LUPUS ERYTHEMATOSUS;TOLERABILITY;TYPE 1 DIABETES;UNIVARIATE ANALYSIS;VITRECTOMY","3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MTORC1;NIVOLUMAB;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ABATACEPT;ADIPOKINE;ADIPONECTIN;B-CELL ACTIVATING FACTOR;BONE HEALTH;CANCER IMMUNOTHERAPY;CDH1;DELETION SYNDROME;DISEASE MANAGEMENT;GERMLINE MUTATION;GLUCOSE-6-PHOSPHATE DEHYDROGENASE;HEAD CIRCUMFERENCE;INTRAUTERINE GROWTH RESTRICTION;KRAS;LONG ARM;MECHANISTIC TARGET OF RAPAMYCIN;MICROARRAY;MICROSATELLITE;P70-S6 KINASE 1;RETINAL TEAR;SIGNET RING CELL CARCINOMA;SINGLE-NUCLEOTIDE POLYMORPHISM;SPECKLE TRACKING ECHOCARDIOGRAPHY;TAMOXIFEN;TRAMETINIB;TRANSLATION (BIOLOGY);VEMURAFENIB","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;RETROSPECTIVE STUDIES;CARCINOMA, SIGNET RING CELL;CARDIOMYOPATHIES;GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY;IRON OVERLOAD;ITALY;LATENT AUTOIMMUNE DIABETES IN ADULTS;STOMACH NEOPLASMS;ADULT STEM CELLS;AMEBIASIS;CONJUNCTIVITIS;CORNEAL DISEASES;EPILEPSIES, MYOCLONIC","20;16;15;14;10;8;7;6;5;5;5;5;5;5;5;4;4;4;4;4","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ASTHMA;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CANCER IMMUNOTHERAPY;CHALLENGES AND OPPORTUNITIES IN TRANSLATIONAL RESEARCH;CHOLANGIOCARCINOMA;CHOLESTEROL-LOWERING TREATMENT;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;EPILEPSY AND SEIZURES;FAMILY-CENTERED CARE IN INTENSIVE CARE UNITS;GASTRIC CANCER RESEARCH AND TREATMENT;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;HYPERSENSITIVITY REACTIONS TO DRUGS AND MEDICATIONS;INTERACTIONS OF LEGIONELLA AND AMOEBAE IN DISEASE;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS","4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BETA THALASSEMIA;CANCER GENOMICS;CLINICAL ENDPOINT;THALASSEMIA;TYPE 1 DIABETES;ABATACEPT;ACANTHAMOEBA KERATITIS;ANASTROZOLE;ANTIEPILEPTIC DRUGS;AROMATASE INHIBITOR;ARTIFICIAL TEARS;ASTHMA;ASTHMA MANAGEMENT;AUTOIMMUNE DISEASE EPIDEMIOLOGY;BASAL (MEDICINE);BIOMARKERS FOR IMMUNOTHERAPY;BLEPHARITIS;BONE HEALTH;BRAF GENE;BRAIN METASTASES","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AUTOIMMUNE DIABETES;EXPANDED ACCESS;LATENT AUTOIMMUNE;RHEUMATOID ARTHRITIS;THALASSEMIA MAJOR;ABSENCE SEIZURE;ACCESS PROGRAM;ACCESS PROGRAMME;ACTIVITY INDEX;ACTIVITY US-CLARA;ACUTE EYE;ADENOCARCINOMA MGA;ADIPOGENIC FATE;ADIPOSE-DERIVED STEM;ADJUVANT ANASTROZOLE;ADVANCED SQ-NSCLC;ADVANCED SQUAMOUS;AGE PERIOD;AGGRESSIVE SIGNET-RING;AMOEBAE KERATITIS;ANTI-APOPTOTIC BAG;ARTHRITIS ACTIVITY;ARTHRITIS PATIENTS;ASTHMA MANAGEMENT;AUTOIMMUNITY RISK;AUTOLOGOUS SERUM;AUTOSOMAL RECESSIVE;BAG PROTEIN;BETA-THALASSAEMIA MAJOR;BONE HEALTH","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PERIPHERAL ED;RA PATIENTS;SASSARI ITALY;DISEASE CONTROL;MOUSE MODEL;ADVERSE EVENTS;AKTYAPSA ICC;BRAIN METASTASES;CHOLANGIOCARCINOMA ICC;CLINICAL TRIALS;COPD HF;ENV-SU SUBSUB;GASTRIC CANCER;HEPATOCELLULAR CARCINOMA;HF PATIENTS;ICC CELL;ICC DEVELOPMENT;ICC MOUSE;LATE STAGE;MEDIAN FOLLOW-UP;MULTIPLE SCLEROSIS;REGRESSION ANALYSIS;SMOKING HABIT;SQUAMOUS NSCLC;ACTIVATED AKTMTOR;ACTIVATED FORMS;BIRTH COHORTS;CATCH-UP GROWTH;CAUSAL VARIANT;CELL LINES","7;7;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3",13,0.36,4.1,8,11.5,1,1,15,1,0,0,8,0,1,7,0,4,1,5.5,3.5,10.25,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,2.38,689.86,18.18,2,0.25,37.5,0,0,2,0,1,0,0,5,0,4,4,0,0,0,0,0,0,7,1,0,8,0,0,0,0,0,0,0,0,0,"Italy;Germany","6;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","6;5;3;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;PATIENT SAFETY;RARE DISEASES;CANCER;HEART DISEASE;LUNG;AGING;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BREAST CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;COMPLEMENTARY AND INTEGRATIVE HEALTH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETICS;HEALTH SERVICES;HEART DISEASE - CORONARY HEART DISEASE","8;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;CANCER;INFECTION;RESPIRATORY","3;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS","4;1;1","LUNG CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_SASSARI",2018,35,15.1142857142857,2.65714285714286,0.285714285714286,0.228571428571429,0.4,1.40909090909091,1.11111111111111,0.888888888888889,1.07692307692308,0.6,0,13,10,4,5,0.37,0.29,0.11,0.14,24.91,0.816640817545791,4.82075471698113,0.257142857142857,0.914285714285714,0.401,0.288,0.316,0.304,"GIAN LUCA ERRE;ALESSANDRO DELITALA;CIRIACO CARRU;GIUSEPPE PASSIU;ANTONIO COSSU;LEONARDO A. SECHI;RICCARDO BOCCALETTI;ERMETE GIANCIPOLI;DOMENICO POLICICCHIO;ANTONELLA MELONI;ALESSANDRO G. FOIS;PIETRO PIRINA;ZAFER CEBECI;ROBERTO GALLUS;ANAT LOEWENSTEIN;MARCO BO;ALESSIA PEPE;DINAH ZUR;MATTHIAS EVERT;E. SGARAMELLA","5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ALESSANDRO DELITALA;RICCARDO BOCCALETTI;DOMENICO POLICICCHIO;LEONARDO A. SECHI;GIAN LUCA ERRE;GIOSUÉ DIPELLEGRINI;GIAMPIERO MUGGIANU;GIUSEPPE PASSIU;CIRIACO CARRU;E. SGARAMELLA;FILIPPO VENEZIANI SANTONIO;GIUSEPPE D’AMICO RICCI;ANTONIO PINNA;FRANCESCO BOSCIA;ERMETE GIANCIPOLI;MICHELE MARONGIU;DAVID SCHLESSINGER;EDOARDO FIORILLO;GIUSEPPE D. SANNA;ROBERTO MANETTI","0.59;0.56;0.56;0.4;0.4;0.39;0.39;0.37;0.33;0.31;0.31;0.27;0.27;0.27;0.26;0.25;0.25;0.25;0.25;0.25","GIAN LUCA ERRE;ALESSANDRO DELITALA;CIRIACO CARRU;GIUSEPPE PASSIU;ANTONIO COSSU;RICCARDO BOCCALETTI;ERMETE GIANCIPOLI;DOMENICO POLICICCHIO;ALESSANDRO G. FOIS;PIETRO PIRINA;E. SGARAMELLA;ELISABETTA ZINELLU;ANTONIO PINNA;GIOSUÉ DIPELLEGRINI;MARIA GIOVANNA LONGU;FRANCESCO BUSSU;MARCO PIRAS;ANGELO ZINELLU;GIOVANNI SOTGIU;FILIPPO VENEZIANI SANTONIO","5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","ALESSANDRO DELITALA;RICCARDO BOCCALETTI;DOMENICO POLICICCHIO;GIAN LUCA ERRE;GIOSUÉ DIPELLEGRINI;GIAMPIERO MUGGIANU;GIUSEPPE PASSIU;CIRIACO CARRU;E. SGARAMELLA;FILIPPO VENEZIANI SANTONIO;ANTONIO PINNA;FRANCESCO BOSCIA;ERMETE GIANCIPOLI;ROBERTO MANETTI;ALESSANDRO G. FOIS;PIETRO PIRINA;ELISABETTA ZINELLU;MARIA GIOVANNA LONGU;MARCO PIRAS;ANGELO ZINELLU","0.59;0.56;0.56;0.4;0.39;0.39;0.37;0.33;0.31;0.31;0.27;0.27;0.26;0.25;0.24;0.24;0.24;0.24;0.24;0.24","LEONARDO A. SECHI;CIRIACO CARRU;ERMETE GIANCIPOLI;GIANCARLO BISAGNI;ADRIAN T. FUNG;ANAT LOEWENSTEIN;AUDE COUTURIER;CATHARINA BUSCH;DINAH ZUR;JAY CHHABLANI;MALI OKADA;MARCO LUPIDI;MATÍAS IGLICKI;MATÚŠ REHÁK;MICHAELLA GOLDSTEIN;MIRIANA MARIUSSI;PATRICIO J. RODRÍGUEZ‐VALDÉS;SAMANTHA FRASER‐BELL;VORAPORN CHAIKITMONGKOL;ZAFER CEBECI","178;157;154;138;133;133;133;133;133;133;133;133;133;133;133;133;133;133;133;133","ERMETE GIANCIPOLI;GIAN LUCA ERRE;GIUSEPPE PASSIU;KAI PAULUS;ANTONIO COSSU;MARCO PIRAS;MARIA GIOVANNA LONGU;ALESSANDRO DELITALA;ALESSANDRA MANCA;VINCENZO MARRAS;ALESSIO ALIGI COGONI;ANTONELLA LAI;MARIA GIUSEPPA SAROBBA;GIOVANNI SOTGIU;ANTONIO PINNA;FRANCESCO BOSCIA;LOREDANA TARAS;CIRIACO CARRU;ALESSANDRA PALMIERI;ANDREA PIANA","133;115;115;100;87;78;78;77;75;75;69;69;69;64;52;52;52;49;43;43","GIAN LUCA ERRE;GIUSEPPE PASSIU;ALESSANDRO DELITALA;ANTONIO COSSU;DOMENICO POLICICCHIO;ANTONIO PINNA;CIRIACO CARRU;E. SGARAMELLA;ELISABETTA ZINELLU;ERMETE GIANCIPOLI;FILIPPO VENEZIANI SANTONIO;FRANCESCO BOSCIA;FRANCESCO BUSSU;GIAMPIERO MUGGIANU;GIOSUÉ DIPELLEGRINI;GIOVANNI SOTGIU;MARCO PIRAS;MARIA GIOVANNA LONGU;PIETRO PIRINA;A BARALLA","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;ART;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY","33;12;4;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;RADIOLOGY;IMMUNOLOGY;ONCOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;OPHTHALMOLOGY;CANCER RESEARCH;CARDIOLOGY;ENVIRONMENTAL HEALTH;NEUROSCIENCE;PSYCHIATRY;BIOINFORMATICS;CELL BIOLOGY;INTENSIVE CARE MEDICINE;VIROLOGY","24;10;8;7;7;6;6;5;4;4;4;3;3;3;3;3;2;2;2;2","CANCER;DISEASE;GENE;RANDOMIZED CONTROLLED TRIAL;ANTIGEN;APOPTOSIS;CHEMOTHERAPY;DEXAMETHASONE;IMMUNE SYSTEM;INFLAMMATION;MAGNETIC RESONANCE IMAGING;POPULATION;RHEUMATOID ARTHRITIS;ANTIBODY;ARTHRITIS;BLOOD TRANSFUSION;CELL GROWTH;DIABETES MELLITUS;EDEMA;ISCHEMIA;LYMPH NODE;LYMPHOMA;MACULAR DEGENERATION;MALIGNANCY;MYOCARDIAL INFARCTION;PERCEPTION;PROPORTIONAL HAZARDS MODEL;REFRACTORY (PLANETARY SCIENCE);THALASSEMIA;VIRUS;VISUAL ACUITY","6;6;6;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","AUTOIMMUNITY;BREAST CANCER;GENOTYPE;BETA THALASSEMIA;CARCINOGENESIS;DIABETIC RETINOPATHY;EPITOPE;INNATE IMMUNE SYSTEM;METASTASIS;MOLECULAR MIMICRY;PI3K/AKT/MTOR PATHWAY;ACUTE CORONARY SYNDROME;ADIPOGENESIS;ALCOHOL CONSUMPTION;ALLELE;AMYOTROPHIC LATERAL SCLEROSIS;ANTERIOR COMMUNICATING ARTERY;APOLIPOPROTEIN B;AUTOIMMUNE DISEASE;BEVACIZUMAB;BIG FIVE PERSONALITY TRAITS;CARBAPENEM;CDKN2A;CELLULAR DIFFERENTIATION;CEREBRAL ANGIOGRAPHY;CHELATION THERAPY;CLINICAL ENDPOINT;CLOPIDOGREL;COLORECTAL CANCER;COMPLETE REMISSION;CYCLOPHOSPHAMIDE;DEFERASIROX;DEFERIPRONE;DIENOGEST;EPIGENETICS;EPSTEIN–BARR VIRUS;ESCHERICHIA COLI;EUTHYROID;FLUORESCEIN ANGIOGRAPHY;GROWTH INHIBITION;HAZARD RATIO;HEAD AND NECK CANCER;HUMAN LEUKOCYTE ANTIGEN;IGG4-RELATED DISEASE;IMAGE NOISE;IMAGE QUALITY;INSULIN RESISTANCE;INTRACRANIAL BLEEDING;ISCHEMIC STROKE;LEPTIN;LIPOPROTEIN;MACULAR EDEMA;MAGNETIC RESONANCE ANGIOGRAPHY;MAPK/ERK PATHWAY;MEAN PLATELET VOLUME;MEDIASTINAL LYMPHADENOPATHY;MICRORNA;MIDDLE CEREBRAL ARTERY;MULTICENTER STUDY;MUTATION;MYCOBACTERIUM;NEURORADIOLOGY;NEUTROPHIL TO LYMPHOCYTE RATIO;NONPROBABILITY SAMPLING;PARKINSON'S DISEASE;PERSONALITY ASSESSMENT INVENTORY;PHENOTYPE;PLATELET AGGREGATION INHIBITOR;PROINFLAMMATORY CYTOKINE;PROTEIN KINASE B;PROTOCOL (SCIENCE);REACTIVE HYPEREMIA;RHEUMATOID FACTOR;RITUXIMAB;THROMBOLYSIS;THYROGLOBULIN;THYROID FUNCTION;THYROID FUNCTION TESTS;THYROID PEROXIDASE;TRANSFUSION THERAPY;VASCULITIS;WARFARIN","4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DIABETIC MACULAR EDEMA;INTERFERON REGULATORY FACTORS;ADIPOKINE;ADIPONECTIN;ALLELE FREQUENCY;ANTERIOR CEREBRAL ARTERY;ANTIPLATELET DRUG;APOLIPOPROTEIN A1;AROMATASE;DABIGATRAN;DUCTAL CARCINOMA;EXTRAVERSION AND INTROVERSION;GRANULOMATOSIS WITH POLYANGIITIS;HAPLOTYPE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;KLEBSIELLA PNEUMONIAE;KRAS;LEVODOPA;LYMPHOVASCULAR INVASION;MEK INHIBITOR;METASTATIC BREAST CANCER;MICROSCOPIC POLYANGIITIS;MIR-155;MODIFIED RANKIN SCALE;MOLECULAR EPIDEMIOLOGY;MTORC1;PARATUBERCULOSIS;PRASUGREL;PRIMARY TUMOR;PTEN;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN;TICAGRELOR;TRIPLE-NEGATIVE BREAST CANCER;VITAMIN K ANTAGONIST","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;;MIDDLE AGED;MALE;AGED;ADULT;CHOLANGIOCARCINOMA;ITALY;AGED, 80 AND OVER;ARTHRITIS, RHEUMATOID;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BACTEREMIA;CROSS INFECTION;KLEBSIELLA INFECTIONS;ACRYLONITRILE;ADIPOCYTES;AUTOIMMUNITY;BREAST NEOPLASMS;CARBAPENEM-RESISTANT ENTEROBACTERIACEAE","22;14;13;13;12;11;8;8;8;6;6;5;5;5;5;4;4;4;4;4","AGE-RELATED MACULAR DEGENERATION RESEARCH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;THYROID DISEASE AND HORMONE REGULATION;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;CHOLANGIOCARCINOMA;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFLAMMATORY DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;FUNCTIONS AND REGULATION OF RNA EDITING BY ADARS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;IMPORTANCE OF COGNITIVE ERRORS IN DIAGNOSIS AND STRATEGIES;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MACULAR DEGENERATION;BETA THALASSEMIA;DIABETIC MACULAR EDEMA;DIABETIC RETINOPATHY;IMAGING IN VASCULITIS;INTRAHEPATIC CHOLANGIOCARCINOMA;INTRAVITREAL INJECTION;IRF5;MOLECULAR MIMICRY;REFRACTORY (PLANETARY SCIENCE);THYROID HORMONE;TRANSFUSION THERAPY;ANASTROZOLE;ANTERIOR CEREBRAL ARTERY;ANTERIOR COMMUNICATING ARTERY;ANTIPLATELET DRUG;APTITUDE;AROMATASE INHIBITOR;ATHEROSCLEROTIC CARDIOVASCULAR RISK;AUTOIMMUNITY","4;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","RHEUMATOID ARTHRITIS;AGE-RELATED MACULAR;BREAST CANCER;DEXAMETHASONE IMPLANT;DIABETIC MACULAR;EPIDEMIOLOGICAL STUDY;MACULAR DEGENERATION;MACULAR EDEMA;REFRACTORY EYES;THYROID FUNCTION;ACCURATE COMPILING;ACUTE CORONARY;ACUTE ISCHEMIC;ADIPOCYTOKINE CORRELATIONS;ADIPOSE DERIVED;ADJUVANT ANASTROZOLE;AIF- GENE;ALCOHOL CONSUMPTION;ALVEOLAR HAEMORRHAGEIN;AMERICANUSI INFECTION;ANASTROZOLE VERSUS;ANCA-ASSOCIATED VASCULITIS;ANDI NECATOR;ANTERIOR CEREBRAL;ANTIBODIES HIGHLY;ANTIPLATELET THERAPY;ARTHRITIS INVESTIGATING;ARTHRITIS PATIENT;ARTHRITIS PATIENTS;AUTOIMMUNE RESPONSE","3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HOMOZYGOUS ΒΒ;SASSARI SASSARI;AROMATASE INHIBITORS;BD PATIENTS;IRON OVERLOAD;EXPERIMENTAL MEDICINE;MEDICINE UNIVERSITY;SASSARI ITALYSEARCH;SIGNIFICANTLY LOWER;DISEASE-FREE SURVIVAL;HR CI;LYMPH NODE;RS RS;SWITCH STRATEGY;ALCOHOL CONSUMPTION;AZIENDA OSPEDALIERO-UNIVERSITARIA;BREAST CANCER;CELL LINES;CLINICA MEDICA;DI SASSARI;HEALTHY CONTROLS;ICC CELL;IL- IL-;MEK INHIBITORS;RA PATIENTS;REGRESSION ANALYSIS;ΒΒ GENOTYPE;ANTI-VEGF THERAPY;AUTHOR ALESSANDRO;HLA REGION","8;8;7;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3",14,0.4,3,3,1,0,1,1,1,0,1,3,0,0,3,0,0,1,0,3,0,0,0,48.5,40.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,1.5,814,6.25,1,0.25,87.25,0,0,1,0,1,0,0,2,0,2,2,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Italy;United States;Germany","5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;2;2;2","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;GENETICS;HEART DISEASE;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER DISEASE","4;3;2;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;INFECTION","1;1","6.1 PHARMACEUTICALS","2","COLON AND RECTAL CANCER","1","5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,"PUBLIC LIBRARY OF SCIENCE","4","32 BIOMEDICAL AND CLINICAL SCIENCES;50 PHILOSOPHY AND RELIGIOUS STUDIES;3204 IMMUNOLOGY;5005 THEOLOGY","2;2;1;1",NA,NA,NA,NA,NA,NA,"CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA
"AOUSSN_SASSARI",2019,40,13.975,1.875,0.25,0.125,0.5,1.5625,1.42857142857143,1,1.33333333333333,0.725,1,18,6,1,3,0.45,0.15,0.03,0.07,17.7,0.727889215968451,4.87313432835821,0.475,0.95,0.459,0.352,0.3,0.366,"ALESSANDRO DELITALA;ANTONIO COSSU;GIAN LUCA ERRE;CIRIACO CARRU;ANGELO ZINELLU;GIUSEPPE PASSIU;GIOVANNI SOTGIU;MILENA CASULA;MARIA R. MURONI;GIUSEPPE PALMIERI;MARIA CRISTINA SINI;LEONARDO A. SECHI;FRANCESCO BUSSU;GIOVANNA PIRA;ARDUINO A. MANGONI;LAURA SADERI;FRANCESCA SANGES;MARIA R. DE MIGLIO;MARIA COLOMBINO;ANTONELLA MELONI","6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2","ALESSANDRO DELITALA;GIAN LUCA ERRE;CIRIACO CARRU;GIUSEPPE PASSIU;LEONARDO A. SECHI;ANTONIO COSSU;ANGELO SCUTERI;FRANCESCO BUSSU;ANGELO ZINELLU;MARCO BO;PIERA ANGELA MANCHIA;GIOVANNI SOTGIU;ARDUINO A. MANGONI;MILENA CASULA;GIUSEPPE PALMIERI;MARIA CRISTINA SINI;GIUSEPPE D’AMICO RICCI;ANTONIO PINNA;FRANCESCO BOSCIA;EDWARD G. LAKATTA","1.7;0.6;0.43;0.43;0.41;0.38;0.37;0.36;0.34;0.31;0.31;0.3;0.29;0.26;0.26;0.26;0.23;0.23;0.23;0.23","ALESSANDRO DELITALA;ANTONIO COSSU;GIAN LUCA ERRE;CIRIACO CARRU;GIUSEPPE PASSIU;FRANCESCO BUSSU;PAOLA CRIVELLI;CARLO COSMI;PIER SERGIO SABA;VALENTINA DONEDDU;ANTONIO PINNA;PIERA ANGELA MANCHIA;CARLO PUTZU;ALESSANDRA MANCA;FRANCESCO BOSCIA;EGLE MILIA;VALERIA SANNA;GIOVANNI SPANÓ;DAVIDE RIZZO;MARIA LAURA SEDDA","6;5;5;5;4;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","ALESSANDRO DELITALA;GIAN LUCA ERRE;CIRIACO CARRU;GIUSEPPE PASSIU;ANTONIO COSSU;FRANCESCO BUSSU;PIERA ANGELA MANCHIA;ANTONIO PINNA;FRANCESCO BOSCIA;SARA SERDINO;ROBERTO MANETTI;GIOSUÉ DIPELLEGRINI;ARTAN DODA;GIAMPIERO MUGGIANU;DOMENICO POLICICCHIO;PIER SERGIO SABA;VALERIA SANNA;VALENTINA DONEDDU;PAOLA CRIVELLI;EGLE MILIA","1.7;0.6;0.43;0.43;0.38;0.36;0.31;0.23;0.23;0.2;0.2;0.2;0.2;0.2;0.2;0.19;0.18;0.18;0.17;0.16","GIOVANNI SOTGIU;FRANCESCA SANGES;GIOVANNA PIRA;MARIA R. DE MIGLIO;MARIA R. MURONI;CARLO PUTZU;FERDINANDO RICCARDI;SAVERIO CINIERI;CIRIACO CARRU;LAURA SADERI;GIAN LUCA ERRE;ANTONIO COSSU;ALESSANDRO DELITALA;A M SCANU;ALESSANDRA MANCA;ANDREA ANGIUS;ANTONINA DOLEI;CATERINA SERRA;ELENA ULERI;GABRIELE IBBA","113;102;102;102;102;99;99;99;95;82;78;77;73;70;70;70;70;70;70;70","CARLO PUTZU;GIAN LUCA ERRE;ANTONIO COSSU;ALESSANDRO DELITALA;ALESSANDRA MANCA;EGLE MILIA;GIUSEPPE PASSIU;FRANCESCO BUSSU;ANTONELLA BORTONE;VALERIA SANNA;ANTONIO PINNA;FRANCESCO BOSCIA;S. E. DORE;PIERA ANGELA MANCHIA;CARLA FONNESU;CATERINA KIHLGREN;DAVIDE RIZZO;MARIA RITA PIRAS;DARIA DELRIO;MARIA LAURA SEDDA","99;78;77;73;70;66;64;59;54;53;44;44;41;40;34;34;34;31;21;21","ALESSANDRO DELITALA;ANTONIO COSSU;GIAN LUCA ERRE;GIUSEPPE PASSIU;FRANCESCO BUSSU;ALESSANDRA MANCA;ANTONIO PINNA;CARLO COSMI;CARLO PUTZU;EGLE MILIA;FRANCESCO BOSCIA;PIERA ANGELA MANCHIA;VALENTINA DONEDDU;VALERIA SANNA;ALESSANDRA ERRIGO;AMELIA LISSIA;ANTONELLA BORTONE;ARTAN DODA;CARLA FONNESU;CATERINA KIHLGREN","6;5;5;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;CHEMISTRY;MATHEMATICS;COMPUTER SCIENCE;ECONOMICS;GEOGRAPHY;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY","36;16;3;3;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;GENETICS;ONCOLOGY;CANCER RESEARCH;CARDIOLOGY;IMMUNOLOGY;SURGERY;ENDOCRINOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;PATHOLOGY;MICROBIOLOGY;CELL BIOLOGY;GERONTOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;NEUROSCIENCE;NUCLEAR MEDICINE;OPHTHALMOLOGY;PALEONTOLOGY;PEDIATRICS;PSYCHIATRY;RADIOLOGY;THERMODYNAMICS","26;10;9;7;7;7;7;5;5;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2","CANCER;GENE;POPULATION;ANTIBODY;CONFIDENCE INTERVAL;RHEUMATOID ARTHRITIS;THALASSEMIA;BLOOD PRESSURE;CHEMOTHERAPY;COHORT;DIABETES MELLITUS;DISEASE;HEART FAILURE;HOMOGENEOUS;IMMUNE SYSTEM;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;ADJUVANT;ANTIMICROBIAL;BACTERIA;CONTEXT (ARCHAEOLOGY);HEMOGLOBIN;MULTISLICE;PATHOGENESIS;SIGNAL TRANSDUCTION;STROKE (ENGINE)","10;7;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","BREAST CANCER;MUTATION;SOMATIC CELL;ALLELE;AUTOANTIBODY;CARDIAC FUNCTION CURVE;CLINICAL ENDPOINT;COLORECTAL CANCER;EJECTION FRACTION;METASTASIS;MICRORNA;MYCOBACTERIUM;PROTEIN KINASE B;TYPE 1 DIABETES;ADENOCARCINOMA;ADJUVANT THERAPY;AGAR;AGAR PLATE;ANTICOAGULANT DRUG;AUTOIMMUNE DISEASE;AUTOIMMUNITY;BRACHYTHERAPY;CARCINOGENESIS;CARDIAC AMYLOIDOSIS;CAROTID ENDARTERECTOMY;CELL CYCLE;CISPLATIN;CLOPIDOGREL;CONTRAINDICATION;DEFERASIROX;DEFERIPRONE;DENTIN HYPERSENSITIVITY;DIASTOLE;DNA DAMAGE;DNA REPAIR;DYSLIPIDEMIA;ECOLOGICAL STUDY;EPIDERMAL GROWTH FACTOR RECEPTOR;EPIGENETICS;EUTHYROID;FETUS;GENE EXPRESSION;GENOTYPE;GESTATION;HAZARD RATIO;IMMUNE DYSREGULATION;IMMUNOGENICITY;INNATE IMMUNE SYSTEM;INSULIN RESISTANCE;ISLET;LARYNGECTOMY;LENALIDOMIDE;LEPTIN;LIPID PROFILE;LIPOPROTEIN;LIVER FIBROSIS;MESSENGER RNA;METABOLIC SYNDROME;MOLECULAR MIMICRY;MUCOSAL MELANOMA;OVARIAN CANCER;PHENOTYPE;PLATELET AGGREGATION INHIBITOR;PSEUDOMONAS AERUGINOSA;RADIATION TREATMENT PLANNING;REVASCULARIZATION;RHEUMATOID FACTOR;SLEEP QUALITY;STAPHYLOCOCCUS AUREUS;SUPPRESSOR;TARGETED THERAPY;TORTUOSITY;TRANSFUSION THERAPY;UBIQUITIN;WAIST;WARFARIN","5;4;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GERMLINE MUTATION;KRAS;PARATUBERCULOSIS;ADIPOKINE;ADIPONECTIN;ANTIPLATELET DRUG;AROMATASE;BRAIN METASTASIS;CAROTID ARTERY DISEASE;CETUXIMAB;DEBULKING;DNA MISMATCH REPAIR;EXOME SEQUENCING;GENE EXPRESSION PROFILING;GENOME INSTABILITY;GNAQ;INTERFERON REGULATORY FACTORS;LEFT ATRIAL APPENDAGE OCCLUSION;MASTECTOMY;METASTATIC BREAST CANCER;METHYLENETETRAHYDROFOLATE REDUCTASE;MICROSATELLITE;ONCOGENE;PEMETREXED;PITTSBURGH SLEEP QUALITY INDEX;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;SENTINEL LYMPH NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;STAPHYLOCOCCUS EPIDERMIDIS;TAMOXIFEN;TRANSCRIPTOME;UBIQUITIN LIGASE;VERY LOW-DENSITY LIPOPROTEIN","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;BREAST NEOPLASMS;FEMALE;AGED;MIDDLE AGED;MALE;COLORECTAL NEOPLASMS;ADULT;BIOMARKERS, TUMOR;ITALY;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOGENESIS;GENE EXPRESSION REGULATION, NEOPLASTIC;MICRORNAS;ARTHRITIS, RHEUMATOID;ATRIAL FIBRILLATION;CARDIOMYOPATHIES;CASE-CONTROL STUDIES","23;17;14;14;13;12;11;7;6;6;6;5;5;5;5;5;4;4;4;4","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;THYROID DISEASE AND HORMONE REGULATION;ADVANCEMENTS IN LUNG CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;ANTIMICROBIAL PROPERTIES OF ESSENTIAL OILS IN FOODS;ATRIAL FIBRILLATION;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLANGIOCARCINOMA;DENTAL EROSION AND TOOTH WHITENING;DETECTION AND MANAGEMENT OF RETINAL DISEASES;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF VOICE DISORDERS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFECTIONS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETIC AND DEVELOPMENTAL STUDIES OF LIMB MALFORMATIONS","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CLINICAL ENDPOINT;HYPOTHYROIDISM;IRON OVERLOAD;LETROZOLE;MULTISLICE;PATHOGENESIS;STROKE (ENGINE);TRANSFUSION THERAPY;ADJUVANT THERAPY;ANTICOAGULANT DRUG;ANTICOAGULANT THERAPY;ANTIMICROBIAL ACTIVITY;ANTIPLATELET DRUG;AROMATASE INHIBITOR;ARRHYTHMIAS;ATRIAL FIBRILLATION;ATRIAL FLUTTER;BRAF GENE;BRAIN METASTASES","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","RHEUMATOID ARTHRITIS;BREAST CANCER;MASSETERIC REFLEX;ABERRANT FBXW;AC POLYMORPHISMS;ACOUSTIC MASSETERIC;ACTIVATED AKT;ACTIVE RHEUMATOID;ADJUVANT THERAPY;ADJUVANT ZOLEDRONIC;ADVANCED BREAST;AFFECTS BRAFRASMAPK;AGE-RELATED MACULAR;AKT SIGNALING;ALZHEIMER DISEASE;ANTICARBAMYLATED PROTEIN;ANTICOAGULANT DRUG;ANTIMICROBIAL ACTIVITY;ANTIMICROBIAL EFFECT;APPENDAGE OCCLUSION;ARTHRITIS PATIENTS;ARTHRITIS RESULTS;ATRIAL APPENDAGE;AUTOIMMUNE DIABETES;AVIUM SUBSP;AVIUMLTEMGT SUBSP;BLEEDING RISK;BRAF MUTATIONS;BRAFRASMAPK PATHWAYS;BRAIN METASTASES","5;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GLOBAL HEART;IRON OVERLOAD;BLOOD PRESSURE;BREAST CANCER;CARDIAC IRON;RA PATIENTS;CHELATION THERAPY;DIAGNOSTIC ACCURACY;HUMAN ICCA;REGULAR BT;TM PATIENTS;GPD DEFICIENCY;HEART FAILURE;MYOCARDIAL IRON;PROGRESSION-FREE SURVIVAL;ANTIPLATELET THERAPY;EF DIFFERENCE;HETEROGENEOUS MIO;KRAS-MUTATED CRC;LIVER STIFFNESS;LT MS;MS HETEROGENEOUS;MTHFR GENE;MTX-TREATED RA;PATIENTS DIED;PP POPULATION;RHEUMATOID ARTHRITIS;SIGNIFICANT DIFFERENCES;SIGNIFICANT LOWER;SIGNIFICANTLY LOWER","11;9;7;7;7;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",16,0.4,2.58,4,2,0,0,1.5,0,1,0,4.25,0,0,4,0,0,2,6.75,4,4.25,0,0,48.5,48.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,4.6,922.6,11.11,0,0,71.4,0,0,0,0,1,0,0,4,0,2,3,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"Italy;Belgium;United Kingdom","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","5;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LUNG;PATIENT SAFETY;PEDIATRIC;PEDIATRIC CANCER;REHABILITATION;TUBERCULOSIS","5;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;RESPIRATORY","2;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","2;1;1;1;1","LEUKEMIA / LEUKAEMIA","1","6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,"PUBLIC LIBRARY OF SCIENCE","7","31 BIOLOGICAL SCIENCES;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4301 ARCHAEOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;44 HUMAN SOCIETY;4401 ANTHROPOLOGY;49 MATHEMATICAL SCIENCES","3;3;3;2;1;1;1;1","AGING;BEHAVIORAL AND SOCIAL SCIENCE;EYE DISEASE AND DISORDERS OF VISION;NEUROSCIENCES","1;1;1;1",NA,NA,NA,NA,NA,NA,"BASIC SCIENCE","2",NA,NA,NA,NA
"AOUSSN_SASSARI",2020,76,13.9210526315789,2.06578947368421,0.236842105263158,0.210526315789474,0.289473684210526,1.74444444444444,1.28571428571429,1.45454545454545,1.375,0.710526315789474,0,30,14,10,2,0.39,0.18,0.13,0.03,18.92,0.75087813428615,5.71165644171779,0.355263157894737,0.947368421052632,0.477,0.429,0.488,0.445,"FRANCESCO BUSSU;GIAN LUCA ERRE;DAVIDE RIZZO;PAOLA CRIVELLI;ALBERTO PORCU;CIRIACO CARRU;FABIOLA ATZENI;ALESSANDRO FANCELLU;ANDREINA MANFREDI;ANGELO ZINELLU;PIETRO PIRINA;MATTEO PIGA;ARDUINO A. MANGONI;JACOPO GALLI;GIUSEPPE PASSIU;ALESSANDRA MANCA;CATERINA VACCHI;MARIA R. MURONI;ELENA BARTOLONI;ELISA BARATELLA","10;10;7;6;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3","GIAN LUCA ERRE;FRANCESCO BUSSU;FRANCESCO BURRAI;VALENTINA MICHELUZZI;ARDUINO A. MANGONI;DAVIDE RIZZO;LUIGI APUZZO;PAOLA CRIVELLI;GIOVANNI MARIO PES;MARIA PINA DORE;ALBERTO PORCU;CIRIACO CARRU;ALESSANDRO FANCELLU;RICCARDO BOCCALETTI;GIOSUÉ DIPELLEGRINI;ARTAN DODA;DOMENICO POLICICCHIO;ANGELO ZINELLU;JACOPO GALLI;GIUSEPPE FANCIULLI","1.24;1.13;1;1;0.83;0.73;0.67;0.65;0.62;0.62;0.59;0.58;0.53;0.5;0.5;0.5;0.5;0.49;0.48;0.45","FRANCESCO BUSSU;GIAN LUCA ERRE;DAVIDE RIZZO;PAOLA CRIVELLI;CIRIACO CARRU;PIETRO PIRINA;GIUSEPPE PASSIU;ALESSANDRA MANCA;SALVATORE RUBINO;RICCARDO BOCCALETTI;GIUSEPPE FANCIULLI;GIOSUÉ DIPELLEGRINI;ARTAN DODA;ALESSANDRO DELITALA;LUCA SABA;VALENTINA MICHELUZZI;FLORIANA CASTAGNA;ANTONIO PIRAS;DOMENICO POLICICCHIO;LUIGI CUGIA","10;10;7;6;6;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","GIAN LUCA ERRE;FRANCESCO BUSSU;VALENTINA MICHELUZZI;DAVIDE RIZZO;PAOLA CRIVELLI;CIRIACO CARRU;RICCARDO BOCCALETTI;GIOSUÉ DIPELLEGRINI;ARTAN DODA;DOMENICO POLICICCHIO;GIUSEPPE FANCIULLI;GIUSEPPE PASSIU;PIETRO PIRINA;MARIO PALERMO;ANTONIO PIRAS;ALESSANDRA MANCA;MICHELE PORTOGHESE;LUIGI CUGIA;ALESSANDRO DELITALA;SALVATORE RUBINO","1.24;1.13;1;0.73;0.65;0.58;0.5;0.5;0.5;0.5;0.45;0.42;0.42;0.4;0.4;0.38;0.37;0.37;0.37;0.36","FRANCESCO BUSSU;DAVIDE RIZZO;PAOLA CRIVELLI;SALVATORE RUBINO;LUCA SABA;SILVANA SANNA;ABDELKADER MAHAMMEDI;ACHALA VAGAL;ALESSANDRO CARRIERO;ALESSANDRO PADOVANI;ALESSIO PASCHÈ;ALICE BUSELLI;ANDREA ROSSI;BIN ZHANG;CORRADO LIPERI;DANIELA PASERO;DAVIDE PIREDDA;ENRICO PREMI;GIAN PIETRO BRANCA;LORENZO CASADIO","349;299;270;243;206;179;174;174;174;174;174;174;174;174;174;174;174;174;174;174","DAVIDE RIZZO;PAOLA CRIVELLI;SILVANA SANNA;ABDELKADER MAHAMMEDI;ACHALA VAGAL;ALESSANDRO CARRIERO;ALESSANDRO PADOVANI;ALESSIO PASCHÈ;ANDREA ROSSI;BIN ZHANG;CORRADO LIPERI;DANIELA PASERO;DAVIDE PIREDDA;ENRICO PREMI;GIAN PIETRO BRANCA;LUCA SABA;MARY F. GASKILL;MICHELA LEALI;ROBERTO GASPAROTTI;SALVATORE RUBINO","299;270;179;174;174;174;174;174;174;174;174;174;174;174;174;174;174;174;174;174","GIAN LUCA ERRE;FRANCESCO BUSSU;DAVIDE RIZZO;PAOLA CRIVELLI;GIUSEPPE PASSIU;PIETRO PIRINA;V. SANNA;VALERIA SANNA;ANTONIO PIRAS;ARTAN DODA;DOMENICO POLICICCHIO;GIOSUÉ DIPELLEGRINI;MARIO PALERMO;RICCARDO BOCCALETTI;VALENTINA MICHELUZZI;ALESSANDRA MANCA;ALESSANDRO DELITALA;ANDREA MELIS;FLORIANA CASTAGNA;GIAMPIERO MUGGIANU","10;8;7;6;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;PHYSICS;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;ART;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY","71;14;6;6;6;5;4;2;2;1;1;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;GASTROENTEROLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;CARDIOLOGY;GENETICS;INTENSIVE CARE MEDICINE;DEMOGRAPHY;PHYSICAL THERAPY;VIROLOGY;ANESTHESIA;OPTICS;PEDIATRICS;PHARMACOLOGY","54;25;12;11;10;10;9;9;8;8;7;6;6;5;5;5;4;4;4;4","DISEASE;CANCER;POPULATION;RETROSPECTIVE COHORT STUDY;COHORT;GENE;RHEUMATOID ARTHRITIS;ASYMPTOMATIC;CONFIDENCE INTERVAL;LUNG;RHEUMATOLOGY;COPD;DIABETES MELLITUS;INCIDENCE (GEOMETRY);INFLAMMATION;OBSERVATIONAL STUDY;OUTBREAK;ADVERSE EFFECT;CASE-CONTROL STUDY;HEART FAILURE;LYMPHOCYTE;MYOCARDIAL INFARCTION;ODDS RATIO;OTORHINOLARYNGOLOGY;PROSTHESIS;PULMONARY DISEASE;RADIOLOGICAL WEAPON;STENT","17;14;9;9;6;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;INTERSTITIAL LUNG DISEASE;PERCUTANEOUS CORONARY INTERVENTION;SYSTEMIC INFLAMMATION;2019-20 CORONAVIRUS OUTBREAK;BRACHYTHERAPY;COLORECTAL CANCER;CONVENTIONAL PCI;EPITOPE;LARYNGECTOMY;LIVER CANCER;MALONDIALDEHYDE;NASAL VESTIBULE;PHENOTYPE;SAMPLING (SIGNAL PROCESSING);ADENOID CYSTIC CARCINOMA;ADJUVANT THERAPY;AGAR;AGAR PLATE;ALLELE;ANTIBACTERIAL ACTIVITY;ARGININE;BALLOON DILATION;BENIGN PAROXYSMAL POSITIONAL VERTIGO;BILIARY STENT;BOTULINUM NEUROTOXIN;BRAIN ANATOMY;C-REACTIVE PROTEIN;CARCINOGENESIS;CEREBRAL VEINS;CEREBROSPINAL FLUID LEAKAGE;CHARLSON COMORBIDITY INDEX;CHELATION THERAPY;CISPLATIN;CLINICAL ENDPOINT;COHORT EFFECT;CORONARY ANGIOGRAPHY;CRACKLES;CRANIOPLASTY;CROHN'S DISEASE;CROSS REACTIONS;CRYOABLATION;CYTOTOXICITY;DEFERASIROX;DEFERIPRONE;DIASTOLE;DOCETAXEL;EJECTION FRACTION;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;ENDOTHELIAL ACTIVATION;EOSINOPHIL;EPICARDIAL FAT;ESCHERICHIA COLI;EUROSCORE;FIBULA;GENE EXPRESSION;GENE ISOFORM;GENOTYPE;HAZARD RATIO;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;HISTIOCYTOSIS;HOMOLOGOUS CHROMOSOME;HOSPITAL ANXIETY AND DEPRESSION SCALE;HOST RESPONSE;INFLAMMATORY BOWEL DISEASE;INTRACRANIAL HYPOTENSION;LUNG FUNCTION;MEAN PLATELET VOLUME;METASTASIS;MINIMUM INHIBITORY CONCENTRATION;MUCOCILIARY CLEARANCE;MULTICENTER STUDY;NEURORADIOLOGY;NEUTROPHIL TO LYMPHOCYTE RATIO;OPIOID;OVERWEIGHT;PISTACIA LENTISCUS;PLATELET ACTIVATION;POLYMERASE CHAIN REACTION;POSTOPERATIVE NAUSEA AND VOMITING;PSEUDOMONAS AERUGINOSA;QUARTILE;RADIOFREQUENCY ABLATION;RATE RATIO;REACTIVE HYPEREMIA;RELAPSING REMITTING;RESTENOSIS;RESTRICTIVE LUNG DISEASE;RHEUMATOID FACTOR;RHEUMATOID NODULE;RHINOMANOMETRY;RITUXIMAB;SINUS RHYTHM;SOLEUS MUSCLE;SPIROMETRY;STAPHYLOCOCCUS AUREUS;SURGICAL MESH;TELEMEDICINE;THYROID DISEASE;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS;UNSTABLE ANGINA;VIRAL DISEASE;VITAMIN D DEFICIENCY;WARFARIN","11;9;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORONAVIRUS DISEASE 2019 (COVID-19);BREAST SURGERY;METASTATIC BREAST CANCER;ABATACEPT;ALTERNATIVE SPLICING;ANTHRACYCLINE;ANTISYNTHETASE SYNDROME;ASYMMETRIC DIMETHYLARGININE;ATRIAL APPENDAGE;CLINICAL PHENOTYPE;COLONOSCOPY;CROSS-REACTIVITY;DIFFUSING CAPACITY;DOPPLER IMAGING;DRUG-ELUTING STENT;ERDHEIM–CHESTER DISEASE;EXTERNAL BEAM RADIOTHERAPY;GENE EXPRESSION PROFILING;KLEBSIELLA PNEUMONIAE;LEFT ATRIAL APPENDAGE OCCLUSION;LYMPHOVASCULAR INVASION;MASTECTOMY;METAPLASTIC CARCINOMA;METHYLENETETRAHYDROFOLATE REDUCTASE;OPPORTUNISTIC INFECTION;P2Y12;PERCUTANEOUS ETHANOL INJECTION;SENTINEL LYMPH NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;STAPHYLOCOCCUS EPIDERMIDIS;TAXANE;TELEHEALTH;TRANSCRIPTOME;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;VOICE PROSTHESIS","11;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;ITALY;FEMALE;MALE;MIDDLE AGED;AGED;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;ADULT;COVID-19;RETROSPECTIVE STUDIES;BIOMARKERS;AGED, 80 AND OVER;ARTHRITIS, RHEUMATOID;INFLAMMATION;LUNG;BLOOD PLATELETS;CROSS-SECTIONAL STUDIES;GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY;LYMPHOCYTES","51;25;21;20;18;17;10;9;8;8;8;7;6;6;6;6;5;5;5;5","STANDARDISATION AND MANAGEMENT OF COPD;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RHEUMATOID ARTHRITIS;DIAGNOSIS AND TREATMENT OF VOICE DISORDERS;DIAGNOSTIC METHODS FOR COVID-19 DETECTION;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEPATOCELLULAR CARCINOMA;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MOLECULAR RESEARCH ON BREAST CANCER;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;BIOLOGICAL ACTIVITIES OF TRITERPENOIDS AND SAPONINS;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COCHLEAR NEUROPATHY AND HEARING LOSS MECHANISMS;CORONAVIRUS DISEASE 2019;CORONAVIRUS DISEASE 2019 RESEARCH;CULTURAL STUDIES AND INNOVATION IN HUMANITIES AND SOCIAL SCIENCES","4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","COPD;BREAST CANCER;CARDIOVASCULAR RISK;INTERSTITIAL LUNG DISEASE;PANDEMIC;PULMONARY DISEASE;2019-20 CORONAVIRUS OUTBREAK;ATHEROSCLEROTIC CARDIOVASCULAR RISK;BREAST CANCER SCREENING;CORONA VIRUS;CORONAVIRUS;DIAGNOSIS;FALSE NEGATIVE REACTIONS;HEPATOCELLULAR CARCINOMA;HYPERTHYROIDISM;HYPOTHYROIDISM;INFLAMMATION;LIVER CANCER;MALONDIALDEHYDE;NASAL VESTIBULE","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;RHEUMATOID ARTHRITIS;CARDIOVASCULAR RISK;BLOOD BIOMARKERS;CASE-CONTROL STUDY;COMPARATIVE STUDY;INTERSTITIAL LUNG;LUNG DISEASE;BREAST UNIT;CARDIOVASCULAR OBESITY;CHRONIC OBSTRUCTIVE;CORDIS STUDY;COVID- OUTBREAK;DISEASE CORDIS;DUODENOSCOPE-RELATED INFECTIONS;GASTRIC CANCER;HEPATOCELLULAR CARCINOMA;INTERVENTIONAL RADIOTHERAPY;ITALIAN BREAST;ITALIAN PICK;ITALIAN SOCIETY;LUNG INVOLVEMENT;MONOCENTRIC CROSS-SECTIONAL;MULTICENTER RETROSPECTIVE;NASAL VESTIBULE;NORTH SARDINIA;OBSTRUCTIVE PULMONARY;PRE-COVID ERA;REDUCED LEVEL;RHEUMATIC DISEASE","7;7;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RA PATIENTS;CV RISK;RELEVANT RELATIONSHIPS;BREAST CANCER;SPEAKERS BUREAU;RHEUMATOID ARTHRITIS;CORONAVIRUS DISEASE;HOSPITALIZED PATIENTS;PATIENTS TREATED;SLE PATIENTS;COVID- PANDEMIC;NEUROLOGIC IMAGING;RHEUMATIC DISEASES;ROCHE PFIZER;ARTHRITIS RA;BUREAU ABBVIE;ELECTRONIC CIGARETTES;FAT DENSITY;HEALTHY CONTROLS;LUNG DISEASE;PERIVASCULAR FAT;RISK FACTORS;SARS-COV- INFECTION;SIGNIFICANT DIFFERENCES;STATISTICALLY SIGNIFICANT;VASODILATORY CAPACITY;VOICE PROSTHESIS;CONTRAST PLAQUE;CROSSREF MEDLINE;DISEASE DURATION","19;15;15;14;13;11;9;9;9;8;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6;5;5;5",32,0.42,4.79,5.25,0,0,0,1,1,1,1,5.75,0,0,4.5,1,0,1,1,4,2,0,0,57.25,57.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,3.42,1774.92,14.12,6,0.5,41.08,0,0,1,0,3,0,1,7,0,5,7,0,0,0,0,0,0,11,1,0,12,0,0,0,0,0,0,0,0,0,"Italy;Germany;United Kingdom;United States","6;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;52 PSYCHOLOGY","12;7;2;2;2;2;1;1;1","CLINICAL RESEARCH;CANCER;HEMATOLOGY;PATIENT SAFETY;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;DIGESTIVE DISEASES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PREVENTION;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;AGING;ATHEROSCLEROSIS;BIOENGINEERING;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN CANCER","12;8;5;5;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","6;3","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;8.1 ORGANISATION AND DELIVERY OF SERVICES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","4;2;2;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;BLOOD CANCER;BRAIN TUMOR;BREAST CANCER;COLON AND RECTAL CANCER;OVARIAN CANCER;PANCREATIC CANCER","4;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","7;1","32 BIOMEDICAL AND CLINICAL SCIENCES;38 ECONOMICS;3202 CLINICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;3801 APPLIED ECONOMICS;3803 ECONOMIC THEORY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","8;5;2;2;1;1;1;1;1;1;1;1;1;1;1","AGING;BREAST CANCER;CANCER;CLINICAL RESEARCH;GENETICS","1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","2;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER","1;1",NA,NA
"AOUSSN_SASSARI",2021,58,21.1724137931034,2.13793103448276,0.172413793103448,0.241379310344828,0.46551724137931,1.58974358974359,1,1.55555555555556,1.6875,0.672413793103448,0,20,20,5,2,0.34,0.34,0.09,0.03,13.62,0.883272453955125,5.72052401746725,0.275862068965517,0.982758620689655,0.489,0.32,0.332,0.303,"GIANPAOLO VIDILI;FRANCESCO AZZAROLI;EDOARDO G. GIANNINI;GIANLUCA SVEGLIATI‐BARONI;FRANCO TREVISANI;ALBERTO MASOTTO;ANDREA MEGA;GIOVANNI RAIMONDO;EUGENIO CATURELLI;FABIO FARINATI;FRANCESCO GIUSEPPE FOSCHI;MARCO ZOLI;RODOLFO SACCO;GERARDO NARDONE;GIUSEPPE CABIBBO;FABIO MARRA;GIAN LUDOVICO RAPACCINI;MARIA GUARINO;MAURIZIA ROSSANA BRUNETTO;MARIA DI MARCO","11;10;10;10;10;10;10;10;10;9;9;9;9;9;8;8;7;7;7;7","FRANCESCO BURRAI;VALENTINA MICHELUZZI;LEONARDO A. SECHI;DAVIDE RIZZO;FRANCESCO BUSSU;ANTONIO PIRAS;ANTONIO PINNA;FRANCESCO BOSCIA;S. E. DORE;GIAN LUCA ERRE;GIANPAOLO VIDILI;PAOLO SOLLA;RITA SERRA;ROBERTO GALLUS;FRANCESCO AZZAROLI;EDOARDO G. GIANNINI;GIANLUCA SVEGLIATI‐BARONI;FRANCO TREVISANI;ALBERTO MASOTTO;ANDREA MEGA","0.83;0.83;0.8;0.55;0.55;0.55;0.54;0.54;0.54;0.5;0.45;0.44;0.41;0.38;0.33;0.33;0.33;0.33;0.33;0.33","GIANPAOLO VIDILI;DAVIDE RIZZO;LEONARDO A. SECHI;FRANCESCO BUSSU;ANTONIO PIRAS;ANTONIO PINNA;PAOLO SOLLA;ALESSIO ALIGI COGONI;GIAN LUCA ERRE;S. E. DORE;IGNAZIO ROBERTO ZARBO;SERGIO UZZAU;GUIDO PARODI;DANIELA PASERO;SALVATORE RUBINO;ANTONELLO SERRA;MATTHEW GAVINO DONADU;CARLO PUTZU;GABRIELE IBBA;DAVIDE CORDA","11;5;5;5;5;4;4;4;4;4;3;3;3;2;2;2;2;2;2;2","VALENTINA MICHELUZZI;LEONARDO A. SECHI;DAVIDE RIZZO;FRANCESCO BUSSU;ANTONIO PIRAS;ANTONIO PINNA;S. E. DORE;GIAN LUCA ERRE;GIANPAOLO VIDILI;PAOLO SOLLA;IGNAZIO ROBERTO ZARBO;CIRIACO CARRU;GUIDO PARODI;SERGIO UZZAU;MATTHEW GAVINO DONADU;DANIELA PASERO;ALESSIO ALIGI COGONI;DAVIDE CORDA;ELIA SECHI;SALVATORE RUBINO","0.83;0.8;0.55;0.55;0.55;0.54;0.54;0.5;0.45;0.44;0.3;0.27;0.25;0.24;0.24;0.23;0.21;0.21;0.21;0.2","PAOLO SOLLA;ANTONIO PIRAS;DAVIDE RIZZO;FRANCESCO BUSSU;IGNAZIO ROBERTO ZARBO;LEONARDO A. SECHI;GIANPAOLO VIDILI;ALBERTO MASOTTO;ANDREA MEGA;ANTONIO GASBARRINI;EDOARDO G. GIANNINI;EUGENIO CATURELLI;FRANCESCO AZZAROLI;FRANCESCO GIUSEPPE FOSCHI;FRANCO TREVISANI;GIANLUCA SVEGLIATI‐BARONI;GIOVANNI RAIMONDO;MARCO ZOLI;ROBERTO GALLUS;FABIO FARINATI","110;107;107;107;91;91;89;79;79;79;79;79;79;79;79;79;79;79;76;71","ANTONIO PIRAS;FRANCESCO BUSSU;LEONARDO A. SECHI;GIANPAOLO VIDILI;DAVIDE RIZZO;ALESSIO ALIGI COGONI;PAOLO SOLLA;ANDREA MELIS;GIOVANNI MARIA SORO;LAURA MARIA DE LUCA;PIERANGELA TRAMALONI;GUIDO PARODI;IGNAZIO ROBERTO ZARBO;SERGIO UZZAU;DANIELA PASERO;GIAN LUCA ERRE;MATTHEW GAVINO DONADU;MAURIZIO CONTI;PAOLA CRIVELLI;PAOLA MARIA GRAZIA SANNA","107;107;91;89;76;69;68;60;60;60;60;49;49;49;47;46;40;37;37;36","GIANPAOLO VIDILI;ANTONIO PIRAS;LEONARDO A. SECHI;ALESSIO ALIGI COGONI;ANTONIO PINNA;DAVIDE RIZZO;FRANCESCO BUSSU;GIAN LUCA ERRE;CARLO PUTZU;CIRIACO CARRU;DANIELA PASERO;FLAVIA ANGIOJ;GUIDO PARODI;LAURA MARIA DE LUCA;LUIGI CUGIA;MATTHEW GAVINO DONADU;PAOLO SOLLA;S. E. DORE;SERGIO UZZAU;ALESSANDRA MADEDDU","11;5;5;4;4;4;4;4;2;2;2;2;2;2;2;2;2;2;2;1","MEDICINE;BIOLOGY;MATHEMATICS;POLITICAL SCIENCE;COMPUTER SCIENCE;SOCIOLOGY;BUSINESS;ECONOMICS;PHYSICS;PSYCHOLOGY;CHEMISTRY;ENGINEERING;GEOGRAPHY","53;14;4;4;3;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GASTROENTEROLOGY;SURGERY;PATHOLOGY;VIROLOGY;IMMUNOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;GENETICS;LAW;NURSING;ENDOCRINOLOGY;GYNECOLOGY;INTENSIVE CARE MEDICINE;PALEONTOLOGY;ANESTHESIA;EMERGENCY MEDICINE;FAMILY MEDICINE;MICROBIOLOGY;MOLECULAR BIOLOGY;NEUROSCIENCE;OPERATING SYSTEM;OPHTHALMOLOGY;PEDIATRICS;PHARMACOLOGY;STATISTICS","40;15;12;11;9;9;8;6;6;6;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","DISEASE;HEPATOCELLULAR CARCINOMA;CANCER;CONFIDENCE INTERVAL;PROPORTIONAL HAZARDS MODEL;POPULATION;ANTIBODY;COHORT;OUTBREAK;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;BACTERIA;CARCINOMA;GENE;HEALTH CARE;HEART FAILURE;IMMUNE SYSTEM;RHEUMATOID ARTHRITIS;SURVIVAL ANALYSIS;AKAIKE INFORMATION CRITERION;ANTIBIOTICS;ANTIGEN;ANTIMICROBIAL;BODY MASS INDEX;CLINICAL TRIAL;COMPLETE BLOOD COUNT;CONFOUNDING;DIABETES MELLITUS;ENDOSCOPIC ULTRASOUND;ENDOSCOPY;ERYTHROCYTE SEDIMENTATION RATE;GLYCOPROTEIN;HORMONE;INFLAMMATION;INTENSIVE CARE UNIT;INTERQUARTILE RANGE;LUMEN (ANATOMY);LYMPHOCYTE;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;OBSERVATIONAL STUDY;OVERALL SURVIVAL;PANCREATITIS;PLATELET;PROCESS (COMPUTING);QUALITY OF LIFE (HEALTHCARE);RED BLOOD CELL DISTRIBUTION WIDTH;REGIMEN;STAGE (STRATIGRAPHY);STENT;TOXICITY;TRANSPLANTATION;VACCINATION;WHITE BLOOD CELL","16;10;8;7;7;6;5;5;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;BREAST CANCER;CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;ANTIBIOTIC RESISTANCE;CANCER REGISTRY;CISPLATIN;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;GENOME;IMMUNOTHERAPY;LIVER CANCER;LUTEINIZING HORMONE;MEAN PLATELET VOLUME;MULTIPLE DRUG RESISTANCE;NEUTROPENIA;NEUTROPHIL TO LYMPHOCYTE RATIO;SORAFENIB;UNIVARIATE ANALYSIS;ACINETOBACTER;ADJUVANT THERAPY;AMYOTROPHIC LATERAL SCLEROSIS;ANTERIOR ISCHEMIC OPTIC NEUROPATHY;ANTIEMETIC;AORTIC VALVE STENOSIS;AUTOIMMUNITY;BIOFILM;BRACHYTHERAPY;CARDIAC HYPERTROPHY;CARDIAC MAGNETIC RESONANCE;CAUSE OF DEATH;CD19;CD8;CHEMOKINE;CHEMOTHERAPY REGIMEN;CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY;CIPROFLOXACIN;COLORECTAL CANCER;CRITICAL ILLNESS;CRONBACH'S ALPHA;CYCLOPHOSPHAMIDE;DIABETIC RETINOPATHY;DIMETHYL FUMARATE;EHEALTH;EJECTION FRACTION;ENCEPHALOMYELITIS;ENDOSCOPIC ULTRASONOGRAPHY;EPITOPE;ETOPOSIDE;EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;EXPLORATORY FACTOR ANALYSIS;FACE PERCEPTION;FATTY LIVER;FERTILITY;FINE NEEDLE ASPIRATION CYTOLOGY;FINE-NEEDLE ASPIRATION;FINGOLIMOD;FIRST LINE TREATMENT;GENOTYPE;GENTAMICIN;GLATIRAMER ACETATE;HCCS;HUMORAL IMMUNITY;HUNTINGTON'S DISEASE;HYPERAEMIA;INTERIM ANALYSIS;INTRACLASS CORRELATION;LEVOFLOXACIN;LIVER TRANSPLANTATION;MACULAR EDEMA;MICROGLIA;MULTICENTER STUDY;MYCOBACTERIUM;MYIASIS;MYOCARDIAL FIBROSIS;NASAL VESTIBULE;NATALIZUMAB;NEUROINFLAMMATION;OPTIC NEUROPATHY;ORGAN DONATION;PARKINSON'S DISEASE;PENICILLIN;PERIPHERAL BLOOD MONONUCLEAR CELL;PHENOTYPE;POLYMERASE CHAIN REACTION;PORTAL VEIN THROMBOSIS;PROINFLAMMATORY CYTOKINE;PSEUDOMONAS AERUGINOSA;PSORIATIC ARTHRITIS;RELIABILITY (SEMICONDUCTOR);RITUXIMAB;SACROILIITIS;SEROLOGY;STAPHYLOCOCCUS AUREUS;SULFAMETHOXAZOLE;T CELL;TELEMEDICINE;TETRACYCLINE;TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION;TYPE 1 DIABETES;ULCERATIVE COLITIS;UNIVERSAL PRECAUTIONS;VASCULAR INVASION;VENTRICULAR ASSIST DEVICE;VESTIBULE;VOLUME OVERLOAD","8;6;5;5;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORONAVIRUS DISEASE 2019 (COVID-19);ABSOLUTE NEUTROPHIL COUNT;GONADOTROPIN-RELEASING HORMONE;METASTATIC BREAST CANCER;PEMBROLIZUMAB;ACINETOBACTER BAUMANNII;AORTIC VALVULOPLASTY;AROMATASE;AXIAL SPONDYLOARTHRITIS;BASDAI;CAPECITABINE;CARBOPLATIN;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;DIABETIC MACULAR EDEMA;DIGITAL POLYMERASE CHAIN REACTION;ENDOGENOUS RETROVIRUS;EXTERNAL BEAM RADIOTHERAPY;FERTILITY PRESERVATION;HEREDITARY SPASTIC PARAPLEGIA;IMPELLA;IPILIMUMAB;MEROPENEM;MYELIN OLIGODENDROCYTE GLYCOPROTEIN;NIVOLUMAB;OCRELIZUMAB;OESTRUS OVIS;PALONOSETRON;PARATUBERCULOSIS;PARKIN;PRESSURE OVERLOAD;STAPHYLOCOCCUS EPIDERMIDIS;STROKE VOLUME;SULFASALAZINE;SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS;TAMOXIFEN;TAXANE;TERIFLUNOMIDE;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;VINORELBINE","8;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;COVID-19;ITALY;MIDDLE AGED;RETROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED;PROSPECTIVE STUDIES;SARS-COV-2;ADULT;ANTINEOPLASTIC AGENTS;ANTIRHEUMATIC AGENTS;PROGNOSIS;SORAFENIB;STAPHYLOCOCCUS","30;26;16;13;11;11;10;10;10;9;8;7;6;6;5;4;4;4;4;4","HEPATOCELLULAR CARCINOMA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;RHEUMATOID ARTHRITIS;SALIVARY GLAND TUMORS AND CARCINOMAS;AGE-RELATED MACULAR DEGENERATION RESEARCH;APPLICATION OF 3D PRINTING IN MEDICAL ANATOMY EDUCATION;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CORONAVIRUS DISEASE 2019;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;DIAGNOSTIC METHODS FOR COVID-19 DETECTION;ECONOMIC BURDEN OF CANCER TREATMENT;ECTOPARASITIC DISEASES IN HUMANS AND ANIMALS;EFFECTS OF DIETARY SODIUM ON HEALTH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;FAMILY-CENTERED CARE IN INTENSIVE CARE UNITS;FERTILITY PRESERVATION IN CANCER PATIENTS","10;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEPATOCELLULAR CARCINOMA;CLINICAL ENDPOINT;BREAST CANCER;LIVER CANCER;2019-20 CORONAVIRUS OUTBREAK;ABSOLUTE NEUTROPHIL COUNT;AKAIKE INFORMATION CRITERION;CLINICAL CHARACTERISTICS;COMPLETE BLOOD COUNT;ENDOSCOPIC ULTRASOUND;ERYTHROCYTE SEDIMENTATION RATE;INFLAMMATION;INTERQUARTILE RANGE;LUMEN (ANATOMY);MEAN PLATELET VOLUME;METAL STENTS;METASTATIC BREAST CANCER;NEUTROPHIL-TO-LYMPHOCYTE RATIO;PORTAL VEIN THROMBOSIS;REGIMEN","7;6;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HEPATOCELLULAR CARCINOMA;BREAST CANCER;CARCINOMA PATIENTS;RHEUMATOID ARTHRITIS;SARDINIA ITALY;ADVANCED HEPATOCELLULAR;ALS PATIENTS;BILIARY OBSTRUCTION;BLOOD CELL;CLINICAL OUTCOME;COMPLETE BLOOD;COVID- PATIENTS;CRITICALLY ILL;DISTAL BILIARY;HUMORAL RESPONSE;III TRIAL;IMMUNE RESPONSE;LUMEN-APPOSING METAL;MACROVASCULAR INVASION;MALIGNANT DISTAL;METAL STENT;MULTICENTER STUDY;OBSERVATIONAL STUDY;PATIENTS UNDERGOING;PHASE III;RISK FACTORS;TRANSARTERIAL CHEMOEMBOLIZATION;ACCURATE PREDICTOR;ACINETOBACTER BAUMANNII;ACTIVE EXPERIMENTAL","9;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","BREAST CANCER;PATIENTS TREATED;RHEUMATOID ARTHRITIS;HEPATOCELLULAR CARCINOMA;IVERMECTIN SOLUTION;HEALTHY CONTROLS;HERV-K ENV;MAXIMUM TUMOR;PORTAL VEIN;TUMOR DIAMETER;VEIN THROMBOSIS;ENDOTHELIAL FUNCTION;HAZARD RATIO;HCC PATIENTS;NOSE VESTIBULE;PROPYLENE GLYCOL;SEVERE STEATOSIS;ALS PATIENTS;CONFIDENCE INTERVAL;IMMUNE RESPONSE;MONTHS CI;PATIENTS UNDERGOING;PLATELET COUNT;PRETACEPREDICT MODEL;SARS-COV- POSITIVE;SIGNIFICANT DIFFERENCE;SIGNIFICANTLY LOWER;AID USAGE;AUDIOVESTIBULAR SYMPTOMS;BODY MASS","10;10;10;8;8;7;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4",28,0.48,10.27,13.25,1,1.5,0,9.75,0,0,0,20.5,0,0,11.25,0,0,2,11.5,7,4.5,0,0,27.25,27.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,3.83,4062,16.67,4,0.33,107.17,0,0,0,0,5,0,0,7,0,5,7,0,0,0,0,0,0,12,0,0,12,0,0,0,0,0,0,0,0,0,"Italy;Japan;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;50 PHILOSOPHY AND RELIGIOUS STUDIES;5002 HISTORY AND PHILOSOPHY OF SPECIFIC FIELDS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","11;6;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;PATIENT SAFETY;RARE DISEASES;AUTOIMMUNE DISEASE;CANCER;HEMATOLOGY;ATHEROSCLEROSIS;CARDIOVASCULAR;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEALTH SERVICES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HIV/AIDS;INFECTIOUS DISEASES;LYMPHOMA;NEURODEGENERATIVE;PREVENTION","12;7;4;4;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1","RESPIRATORY;CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;INFECTION","2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","8;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE","1;1","30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3009 VETERINARY SCIENCES;3202 CLINICAL SCIENCES","2;2;1;1","ATHEROSCLEROSIS;CARDIOVASCULAR;PREVENTION","1;1;1",NA,NA,NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","1",NA,NA,"3 GOOD HEALTH AND WELL BEING","1"
"AOUSSN_SASSARI",2022,85,19.4117647058824,2.04705882352941,0.176470588235294,0.294117647058824,0.305882352941176,1.5,1.15384615384615,1.66666666666667,1.36842105263158,0.717647058823529,1,31,17,7,4,0.36,0.2,0.08,0.05,9.75,1.09254513686665,5.43346007604563,0.305882352941176,0.941176470588235,0.467,0.356,0.433,0.403,"LEONARDO A. SECHI;FRANCESCO BUSSU;ELENA RITA SIMULA;GIUSEPPE DE LUCA;MARTA NOLI;STEFANO RUBERTO;DAVIDE RIZZO;ROBERTO GALLUS;ALESSANDRO FUGAZZA;ALESSANDRO REPICI;PAOLO CASTIGLIA;STEFANIA ZANETTI;MATTHEW GAVINO DONADU;ANDREA ANDERLONI;MARIA ANTONIETTA MANCA;MÁRIÓ GAJDÁCS;ILARIA TARANTINO;MONICA VERDOIA;SEYEDESOMAYE JASEMI;SERGIO UZZAU","10;8;7;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4","LEONARDO A. SECHI;G. RIZZO;ELENA RITA SIMULA;MARTA NOLI;STEFANO RUBERTO;FRANCESCO BUSSU;ALBERTO PORCU;NICOLA LOI;FRANCESCA GINATEMPO;FRANCA DERIU;TERESA PERRA;SEYEDESOMAYE JASEMI;GIUSEPPE DE LUCA;MARIA ANTONIETTA MANCA;DAVIDE RIZZO;PAOLO CASTIGLIA;ROBERTO GALLUS;GIOVANNA DEIANA;ANDREA MANCA;DAVIDE COSSU","1.15;1;0.81;0.73;0.73;0.65;0.58;0.57;0.57;0.57;0.5;0.5;0.48;0.46;0.43;0.42;0.4;0.38;0.37;0.37","LEONARDO A. SECHI;FRANCESCO BUSSU;GIUSEPPE DE LUCA;DAVIDE RIZZO;PAOLO CASTIGLIA;MATTHEW GAVINO DONADU;SERGIO UZZAU;LUIGI CUGIA;GIOVANNA DEIANA;SALVATORE RUBINO;GIANPAOLO VIDILI;LAURA MARIA DE LUCA;CLAUDIA CRESCIO;FRANCA DERIU;ANTONIO COSSU;ALBERTO PORCU;MARCO DETTORI;GINA CASU;RICCARDO BOCCALETTI;GIOSUÉ DIPELLEGRINI","10;8;6;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2","LEONARDO A. SECHI;G. RIZZO;FRANCESCO BUSSU;ALBERTO PORCU;FRANCA DERIU;TERESA PERRA;GIUSEPPE DE LUCA;DAVIDE RIZZO;PAOLO CASTIGLIA;GIOVANNA DEIANA;MATTHEW GAVINO DONADU;VALENTINA MICHELUZZI;MARCO DETTORI;ANTONELLA ARGHITTU;SERGIO UZZAU;GIANPAOLO VIDILI;ANDREA MONTELLA;SALVATORE RUBINO;GINA CASU;RICCARDO BOCCALETTI","1.15;1;0.65;0.58;0.57;0.5;0.48;0.43;0.42;0.38;0.35;0.33;0.32;0.32;0.31;0.3;0.29;0.28;0.27;0.27","GIANPAOLO VIDILI;ADELAIDA LA CASTA;ALEJANDRO FORNER;ALEXANDER SCHEITER;ANA LANDA-MAGDALENA;ANA LLEÓ;ANNA SABOROWSKI;ARNDT VOGEL;BAS GROOT KOERKAMP;CHIARA BRACONI;DOMENICO ALVARO;FLORA LÓPEZ-LÓPEZ;GIAN LUCA GRAZI;GUIDO CARPINO;HEINZ‐JOSEF KLÜMPEN;JAN N.M. IJZERMANS;JAN PHILIPP JONAS;JESPER B. ANDERSEN;JESÚS M. BAÑALES;JORGE ADEVA","193;177;177;177;177;177;177;177;177;177;177;177;177;177;177;177;177;177;177;177","GIANPAOLO VIDILI;LEONARDO A. SECHI;MATTHEW GAVINO DONADU;LUIGI CUGIA;FRANCESCO BUSSU;ANTONELLA ARGHITTU;ANTONIO AZARA;GIOVANNA DEIANA;MARCO DETTORI;PAOLO CASTIGLIA;GIUSEPPE DE LUCA;SALVATORE RUBINO;MARIA GRAZIA ALICICCO;PIETRO MANCA;SERGIO UZZAU;GABRIELE FARINA;A. PACIFICO;P. BRIZZI;MASSIMO MADONIA;TATIANA SOLINAS","193;103;75;63;50;48;48;48;48;48;36;36;32;29;29;21;20;20;19;19","LEONARDO A. SECHI;FRANCESCO BUSSU;GIUSEPPE DE LUCA;DAVIDE RIZZO;GIANPAOLO VIDILI;LUIGI CUGIA;MATTHEW GAVINO DONADU;CLAUDIA CRESCIO;FRANCA DERIU;LAURA MARIA DE LUCA;SALVATORE RUBINO;ALESSANDRA MANCA;ANDREA MELIS;ANDREA MONTELLA;ARTAN DODA;CLAUDIA PIU;DOMENICO POLICICCHIO;EMILIA DEGNI;FILIPPO VENEZIANI SANTONIO;FRANCESCO LONGU","10;7;6;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PSYCHOLOGY;PHYSICS;POLITICAL SCIENCE;COMPUTER SCIENCE;SOCIOLOGY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY;PHILOSOPHY","76;28;7;7;5;4;4;3;3;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GENETICS;RADIOLOGY;IMMUNOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;MICROBIOLOGY;ONCOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;NEUROSCIENCE;VIROLOGY;MECHANICAL ENGINEERING;LAW;PEDIATRICS;PSYCHIATRY","49;19;14;14;12;11;11;10;9;8;8;7;6;6;6;6;5;4;4;4","DISEASE;CANCER;GENE;MYOCARDIAL INFARCTION;BACTERIA;POPULATION;ANTIBODY;COHORT;CLINICAL TRIAL;DIABETES MELLITUS;IMMUNE SYSTEM;RETROSPECTIVE COHORT STUDY;STROKE (ENGINE);ADVERSE EFFECT;ALTERNATIVE MEDICINE;ANTIMICROBIAL;HEART FAILURE;ANTIBIOTICS;BIOPSY;CONFIDENCE INTERVAL;ENDOSCOPY;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);THALASSEMIA","15;13;10;10;8;8;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BIOFILM;BREAST CANCER;PERCUTANEOUS CORONARY INTERVENTION;ANTIBIOTIC RESISTANCE;AUTOANTIBODY;CLINICAL ENDPOINT;COLORECTAL CANCER;CONVENTIONAL PCI;STAPHYLOCOCCUS AUREUS;VIRULENCE;2019-20 CORONAVIRUS OUTBREAK;ACUTE CORONARY SYNDROME;CARCINOGENESIS;CLINDAMYCIN;CLOPIDOGREL;EPITOPE;ERYTHROMYCIN;HAZARD RATIO;INTRACEREBRAL HEMORRHAGE;LARYNGECTOMY;LIPOPROTEIN;MYCOBACTERIUM;MYOCARDIAL FIBROSIS;PARKINSON'S DISEASE;SEROLOGY;SULFAMETHOXAZOLE;TRANSCRANIAL MAGNETIC STIMULATION;TRANSCRIPTION FACTOR;TRIMETHOPRIM;TYPE 1 DIABETES;VIABILITY ASSAY","7;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);P2Y12;PARATUBERCULOSIS;STAPHYLOCOCCUS;STAPHYLOCOCCUS EPIDERMIDIS;ABTS;ADAMTS13;AROMATASE;BIFIDOBACTERIUM;BOOSTER DOSE;BROTH MICRODILUTION;CAROTID STENTING;CASPOFUNGIN;CETUXIMAB;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;COACTIVATOR;CROSSOVER STUDY;DIABETES MANAGEMENT;EPIRUBICIN;GRANISETRON;HPV INFECTION;IRINOTECAN;LEFT ATRIAL APPENDAGE OCCLUSION;LIPOPROTEIN(A);METAPROTEOMICS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MOLECULAR MEDICINE;MYELIN OLIGODENDROCYTE GLYCOPROTEIN;N100;NEUROTYPICAL;ODDBALL PARADIGM;ONCOGENE;PALONOSETRON;PARKIN;POSACONAZOLE;PRASUGREL;PRIMARY MOTOR CORTEX;REPRESSOR;RNA SPLICING;RNA-BINDING PROTEIN;SENTINEL NODE;SILENT PERIOD;SINGLE-NUCLEOTIDE POLYMORPHISM;TRANSLATION (BIOLOGY);VIRULENCE FACTOR","7;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;COVID-19;FEMALE;SARS-COV-2;MALE;ACUTE CORONARY SYNDROME;PERCUTANEOUS CORONARY INTERVENTION;BILE DUCT NEOPLASMS;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;AGED;CHOLESTASIS;HEMORRHAGE;MULTIPLE SCLEROSIS;MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS;PANDEMICS;ANIMALS;CHOLANGIOCARCINOMA;DIABETES MELLITUS","42;41;15;11;9;8;7;7;6;6;6;5;5;5;5;5;5;4;4;4","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;ANTIMICROBIAL PROPERTIES OF ESSENTIAL OILS IN FOODS;COCHLEAR NEUROPATHY AND HEARING LOSS MECHANISMS;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ATRIAL FIBRILLATION;AUTISM SPECTRUM DISORDERS;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY","4;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","PANDEMIC;STROKE (ENGINE);ANTICOAGULANT THERAPY;CLINICAL ENDPOINT;ENDOSCOPIC ULTRASOUND;2019-20 CORONAVIRUS OUTBREAK;CORTICAL EXCITABILITY;ECHOCARDIOGRAPHY;ELECTIVE SURGERY;HEPATOCELLULAR CARCINOMA;HILAR CHOLANGIOCARCINOMA;HPV INFECTION;MYOCARDIAL FIBROSIS;PATHOGENESIS;PRIMARY SCLEROSING CHOLANGITIS;SULFAMETHOXAZOLE;TRANSCRANIAL DIRECT CURRENT STIMULATION;TRANSCRANIAL MAGNETIC STIMULATION;TRANSFUSION THERAPY;TRIMETHOPRIM","5;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COVID- PANDEMIC;ACUTE CORONARY;ANTIBIOTIC RESISTANCE;ENDOGENOUS RETROVIRUS;MULTICENTER STUDY;MYOCARDIAL INFARCTION;THALASSEMIA MAJOR;ACUTE ISCHEMIC;BILIO-PANCREATIC DISEASES;BREAST CANCER;CLINICAL PRACTICE;COLORECTAL CANCER;CORONARY INTERVENTION;CORONARY SYNDROMES;DIGITAL SINGLE-OPERATOR;DISEASE PATIENTS;HEARING SCREENING;HEPATOCELLULAR CARCINOMA;HUMAN ENDOGENOUS;HUMORAL RESPONSE;INTERVENTIONAL RADIOTHERAPY;ISCHEMIC STROKE;ITALIAN MULTICENTER;LARYNGEAL SQUAMOUS;MULTIPLE SCLEROSIS;MYCOBACTERIUM AVIUM;NEWBORN HEARING;PAEDIATRIC PATIENTS;PARKINSONS DISEASE;PERCUTANEOUS CORONARY","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GLOBAL HEART;ECV VALUES;HEART FAILURE;HR CI;PATIENTS UNDERGOING;PRIMARY OUTCOME;RISK FACTORS;SIGNIFICANT DIFFERENCES;GLOBAL ECV;MYOCARDIAL INFARCTION;SENTINEL NODE;BIOFILM FORMATION;BIOFILM-FORMING CAPACITY;PATIENTS AFFECTED;SIGNIFICANT DIFFERENCE;SIGNIFICANT MIO;COLONIC LUMINAL;HEALTHY CONTROLS;HML ENV;IQR MONTHS;LPA LEVELS;LUNG BIOPSY;MYOCARDIAL FIBROSIS;NODE BIOPSY;PATIENTS TREATED;PD PATIENTS;STAPHYLOCOCCUS SPP;TM PATIENTS;ADAMTS REMISSION;ADJUSTED HR","17;13;10;10;9;8;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4",41,0.48,2.85,5,1,1.75,0,9.5,0,1,0,5,0,0,4,0,0,1,4,3,3.5,0,0,18,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,788,0.9,0,0,61,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CLINICAL RESEARCH;PATIENT SAFETY","1;1",NA,NA,"6.4 SURGERY","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"FRONTIERS;KARGER PUBLISHERS","9;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3107 MICROBIOLOGY","12;8;6;5;4","CANCER;DIGESTIVE DISEASES;COLO-RECTAL CANCER;GENETICS;HUMAN GENOME;BIODEFENSE;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;LUNG;PNEUMONIA;PREVENTION;VACCINE RELATED;BIOENGINEERING;DENTAL/ORAL AND CRANIOFACIAL DISEASE;RARE DISEASES","6;6;5;5;5;4;4;4;4;4;4;4;1;1;1","CANCER;ORAL AND GASTROINTESTINAL;INFECTION","6;5;4",NA,NA,NA,NA,NA,NA,"COLON AND RECTAL CANCER;HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","5;1;1;1",NA,NA
"AOUSSN_SASSARI",2023,104,19.3461538461538,1.61538461538462,0.125,0.230769230769231,0.221153846153846,1.90909090909091,1.08333333333333,2,1.53333333333333,0.730769230769231,0,47,27,7,1,0.45,0.26,0.07,0.01,3.77,0.85994840594931,5.27863777089783,0.403846153846154,0.951923076923077,0.515,0.258,0.37,0.392,"ALBERTO PORCU;FRANCESCO BUSSU;LEONARDO A. SECHI;LUIGI CUGIA;THOMAS RUSSELL;ELIZABETH PANDO;PARTHI SRINIVASAN;KEITH ROBERTS;GABRIELE MARANGONI;FABIO AUSANIA;BRIAN R DAVIDSON;MANUEL MAGLIONE;VASILEIOS MAVROEIDIS;PETER LABIB;CARLO FABBRI;ILARIA TARANTINO;ANDREW M. SMITH;AMBAREEN KAUSAR;ADAM E. FRAMPTON;DUNCAN SPALDING","10;10;9;9;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8","LEONARDO A. SECHI;ALBERTO PORCU;TERESA PERRA;FRANCESCO BUSSU;FRANCA DERIU;DAVIDE COSSU;RICCARDO BOCCALETTI;NICOLA LOI;CLAUDIA CRESCIO;GIOSUÉ DIPELLEGRINI;DOMENICO POLICICCHIO;PIER LUIGI FIORI;GIOVANNI MARIO PES;MARIA PINA DORE;FRANCESCA GINATEMPO;FABIO SCARPA;DARIA SANNA;ALESSANDRO FANCELLU;LUIGI CUGIA;CORRADO RUBINO","1.59;1.29;1.03;1.02;1.01;0.95;0.75;0.66;0.65;0.65;0.65;0.65;0.64;0.64;0.62;0.53;0.53;0.52;0.5;0.49","ALBERTO PORCU;FRANCESCO BUSSU;LEONARDO A. SECHI;LUIGI CUGIA;PIER LUIGI FIORI;FRANCA DERIU;CLAUDIA CRESCIO;CLAUDIO FOZZA;DAVIDE RIZZO;ANTONIO COSSU;RICCARDO BOCCALETTI;ANDREA MEGA;PIERLUIGI MERELLA;TERESA PERRA;ALESSANDRO FANCELLU;GIOSUÉ DIPELLEGRINI;GIANPAOLO VIDILI;ANTONIO PAZZOLA;GAVINO CASU;LUCA MUREDDU","10;10;9;9;7;7;6;5;4;4;4;4;3;3;3;3;3;3;3;3","LEONARDO A. SECHI;ALBERTO PORCU;TERESA PERRA;FRANCESCO BUSSU;FRANCA DERIU;RICCARDO BOCCALETTI;CLAUDIA CRESCIO;GIOSUÉ DIPELLEGRINI;DOMENICO POLICICCHIO;PIER LUIGI FIORI;ALESSANDRO FANCELLU;LUIGI CUGIA;DAVIDE RIZZO;ANTONIO COSSU;SIMONE VENERONI;SILVIA PORZANI;GIUSEPPE FANCIULLI;LUCA MUREDDU;ANGELA BITTI;CORRADO LIPERI","1.59;1.29;1.03;1.02;1.01;0.75;0.65;0.65;0.65;0.65;0.52;0.5;0.42;0.4;0.33;0.33;0.33;0.33;0.31;0.29","FRANCESCO BUSSU;DARIA SANNA;FABIO SCARPA;PIER LUIGI FIORI;ILENIA AZZENA;MARCO CASU;MARTA GIOVANETTI;MASSIMO CICCOZZI;STEFANO PASCARELLA;ELENA IMPERIA;JACOPO GALLI;ANDREA CIOFALO;ANGELO GHIDINI;CARLO CAVALIERE;CARLOTTA PIPOLO;CLAUDIO MONTUORI;DANIELA LUCIDI;ELENA CANTONE;ERNESTO PASQUINI;EUGENIO DE CORSO","94;79;79;78;77;77;77;77;77;56;56;54;54;54;54;54;54;54;54;54","FRANCESCO BUSSU;PIER LUIGI FIORI;CLAUDIA CRESCIO;ALBERTO PORCU;LEONARDO A. SECHI;DAVIDE RIZZO;LUIGI CUGIA;QIAN WANG;CORRADO LIPERI;GIANPAOLO VIDILI;PIERLUIGI MERELLA;DANIELE DELOGU;GAVINO CASU;MATTHEW GAVINO DONADU;PAOLO CARACENI;PAOLO GIUFFRIDA;FRANCA DERIU;A. MANUNTA;ANGELA BITTI;GIUSEPPE D. SANNA","86;78;27;21;21;18;18;17;16;16;11;10;10;10;10;10;9;8;8;8","LEONARDO A. SECHI;LUIGI CUGIA;ALBERTO PORCU;FRANCESCO BUSSU;PIER LUIGI FIORI;FRANCA DERIU;CLAUDIA CRESCIO;CLAUDIO FOZZA;PAOLA MARIA GRAZIA SANNA;ANTONIO PAZZOLA;DAVIDE RIZZO;GAVINO CASU;GIOSUÉ DIPELLEGRINI;PIERLUIGI MERELLA;QIAN WANG;RICCARDO BOCCALETTI;TERESA PERRA;ANGELA BITTI;CORRADO LIPERI;DOMENICO POLICICCHIO","9;9;8;8;7;7;6;5;3;3;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;CHEMISTRY;ENGINEERING;GEOGRAPHY;SOCIOLOGY;ECONOMICS;MATHEMATICS;PHILOSOPHY;ART;MATERIALS SCIENCE;POLITICAL SCIENCE","99;28;7;7;5;4;4;4;4;3;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;RADIOLOGY;ONCOLOGY;PATHOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;VIROLOGY;EVOLUTIONARY BIOLOGY;GENERAL SURGERY;PEDIATRICS;ECOLOGY;ENDOCRINOLOGY;NEUROSCIENCE;ANATOMY;BIOCHEMISTRY;DEMOGRAPHY;MICROBIOLOGY;OPTICS;PSYCHIATRY","59;39;19;17;15;14;13;11;9;8;8;7;6;6;6;5;5;5;4;4;4;4;4;4","CANCER;RETROSPECTIVE COHORT STUDY;GENE;POPULATION;DISEASE;COHORT;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ANTIBODY;CHEMOTHERAPY;OBSERVATIONAL STUDY;STENT;IMMUNE SYSTEM;HEPATOCELLULAR CARCINOMA;MULTIPLE SCLEROSIS;BACTERIA;CONFIDENCE INTERVAL;ENDOSCOPIC ULTRASOUND;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;MYELOID LEUKEMIA;PROPENSITY SCORE MATCHING;RADIATION THERAPY;STIMULATION","21;17;16;13;11;10;9;8;8;7;7;7;6;5;5;4;4;4;4;4;4;4;4;4","BREAST CANCER;GENOTYPE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);LINEAGE (GENETIC);MULTICENTER STUDY;CLINICAL ENDPOINT;GENETIC VARIATION;GENOME;COLORECTAL CANCER;EPITOPE;MYCOBACTERIUM;NASAL VESTIBULE;PANCREATICODUODENECTOMY;SEROLOGY;TRANSCRANIAL MAGNETIC STIMULATION;ALLELE;BETA THALASSEMIA;BILIARY STENT;BRACHYTHERAPY;CANCER REGISTRY;CUMULATIVE INCIDENCE;EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;HAZARD RATIO;IMATINIB;IMMUNOTHERAPY;LIVER CANCER;MOTOR CORTEX;PANCREATIC CANCER;PROSTATE CANCER;SALVAGE THERAPY;TOLERABILITY;VIRULENCE;WARFARIN","7;7;7;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);PARATUBERCULOSIS;SINGLE-NUCLEOTIDE POLYMORPHISM;AROMATASE;BREAST RECONSTRUCTION;HAPLOTYPE;LEFT ATRIAL APPENDAGE OCCLUSION;MASTECTOMY;REGORAFENIB;TAMOXIFEN;ADJUVANT CHEMOTHERAPY;ADVANCED CARDIAC LIFE SUPPORT;ALCOHOLIC HEPATITIS;AMNIOTIC FLUID;ARTERY DISSECTION;AUTOMATED EXTERNAL DEFIBRILLATOR;BASIC LIFE SUPPORT;BREAST SURGERY;CAPECITABINE;CARFILZOMIB;CEREBRAL AMYLOID ANGIOPATHY;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CRYPTOCOCCAL MENINGITIS;DARATUMUMAB;DASATINIB;EFFECTIVE POPULATION SIZE;EXTERNAL BEAM RADIOTHERAPY;FENFLURAMINE;GENETIC VARIABILITY;GENOTYPING;IMATINIB MESYLATE;INTERFERON REGULATORY FACTORS;INVASIVE CANDIDIASIS;KLEBSIELLA PNEUMONIAE;METASTATIC BREAST CANCER;MILAN CRITERIA;MULTICENTER TRIAL;MYELIN OLIGODENDROCYTE GLYCOPROTEIN;NILOTINIB;PANCREATIC DUCTAL ADENOCARCINOMA;PERIAMPULLARY CANCER;PNEUMOCYSTIS PNEUMONIA;POMALIDOMIDE;PRIMARY MOTOR CORTEX;QUORUM SENSING;SILENT PERIOD;TERIFLUNOMIDE;TIMI;TRANSCRIPTOME;TRASTUZUMAB;VINCRISTINE;VIRAL PHYLODYNAMICS","7;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;RETROSPECTIVE STUDIES;FEMALE;COVID-19;SARS-COV-2;TREATMENT OUTCOME;BREAST NEOPLASMS;MALE;PANCREATIC NEOPLASMS;AGED;ANTI-BACTERIAL AGENTS;RISK FACTORS;CANDIDEMIA;CARCINOMA, PANCREATIC DUCTAL;CASE-CONTROL STUDIES;ENDOGENOUS RETROVIRUSES;GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY;INFLAMMATION;ISCHEMIA","53;49;14;12;10;9;8;7;7;7;6;5;5;4;4;4;4;4;4;4","PANCREATIC CANCER RESEARCH AND TREATMENT;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEPATOCELLULAR CARCINOMA;ATRIAL FIBRILLATION;BODY CONTOURING TECHNIQUES AND PROCEDURES;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GLIOMAS;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MANAGEMENT OF HYPERBILIRUBINEMIA IN NEWBORN INFANTS;MANAGEMENT OF MESENTERIC ISCHEMIA AND ANEURYSMS;SALIVARY GLAND TUMORS AND CARCINOMAS;ACUTE MYELOID LEUKEMIA","8;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1","ENDOSCOPIC ULTRASOUND;HEPATOCELLULAR CARCINOMA;LINEAGE (GENETIC);METAL STENTS;BILIARY DRAINAGE;CLINICAL ENDPOINT;ENDOSCOPIC DRAINAGE;LIVER CANCER;NASAL VESTIBULE;PANDEMIC;SQUAMOUS-CELL CARCINOMA;STROKE (ENGINE);SURGICAL COMPLICATIONS;ACUTE PANCREATITIS;ANTICOAGULANT THERAPY;AROMATASE INHIBITORS;ATRIAL FIBRILLATION;BETA THALASSEMIA;BILIARY STENT;BREAST CANCER","5;5;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","HEPATOCELLULAR CARCINOMA;METAL STENTS;BREAST CANCER;MULTIPLE SCLEROSIS;CELL CARCINOMA;DEDICATED METAL;ENDOSCOPIC ULTRASOUND-GUIDED;INTERNATIONAL MULTICENTRE;MYCOBACTERIUM AVIUM;MYELOID LEUKEMIA;NASAL VESTIBULE;OBSERVATIONAL STUDY;PROPENSITY SCORE-MATCHED;PROSPECTIVE STUDY;SCORE-MATCHED COMPARISON;ULTRASOUND-GUIDED DRAINAGE;ALCOHOL-RELATED HEPATOCELLULAR;AMNIOTIC FLUID;APPENDAGE OCCLUSION;ATRIAL APPENDAGE;ATRIAL FIBRILLATION;AVIUM SUBSPECIES;BILIARY OBSTRUCTIONS;CANCER RISK;CHRONIC MYELOID;CLINICAL PRACTICE;CML CAMPUS;COVID- PANDEMIC;DEHYDROGENASE DEFICIENCY;ENDOGENOUS RETROVIRUS","5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LAA OCCLUSION;BREAST CANCER;NASAL VESTIBULE;PATIENTS TREATED;MEDIAN AGE;MS PATIENTS;PROSTATE CANCER;RETROSPECTIVE STUDY;RISK FACTORS;SIGNIFICANT DIFFERENCES;STATISTICALLY SIGNIFICANT;Β Β;EO MNDS;FOOD INTAKE;GENETIC VARIABILITY;JUNIPER EO;MEDIAN TIME;MYELOID LEUKEMIA;POPULATION SIZE;SURVIVAL OS;WARTHIN TUMORS;CELL CARCINOMA;CML PATIENTS;CML RELATED;COVID- PANDEMIC;GPD DEFICIENCY;MULTIPLE SCLEROSIS;PD OUTCOMES;RS RS;VIRAL POPULATION","10;9;9;9;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6",45,0.43,3.45,6,1,1,0,0,0,1,0,6,0,0,6.5,0,0,1,3,5,2,0,0,6,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,5.67,541,3.53,0,0,27.33,0,0,0,0,0,0,0,3,0,1,2,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Switzerland","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES","3;2;1;1;1","CANCER;CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;HEMATOLOGY;LYMPHOMA;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);REHABILITATION","2;2;2;2;2;2;2;1;1;1;1;1;1","CARDIOVASCULAR;CANCER","2;1","2.4 SURVEILLANCE AND DISTRIBUTION;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","1;1;1","NON-HODGKIN'S LYMPHOMA","2",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"ZENODO","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","4;2","CANCER;CLINICAL RESEARCH;DIGESTIVE DISEASES;PANCREATIC CANCER;RARE DISEASES","2;2;2;2;2",NA,NA,NA,NA,"CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","2","PANCREATIC CANCER","2",NA,NA
"AOUSSN_SASSARI",2024,74,24.8378378378378,1.89189189189189,0.135135135135135,0.324324324324324,0.243243243243243,1.4,0.909090909090909,1.26315789473684,1.125,0.648648648648649,0,31,12,8,4,0.42,0.16,0.11,0.05,0.82,0.862530519243518,4.21159420289855,0.513513513513513,0.959459459459459,0.507,0.3,0.366,0.348,"LEONARDO A. SECHI;VALERIA TERRUSO;CINZIA ROBERTI;RUGGIERO LEONE;ROBERTO TARLETTI;GIOVANNI FRISULLO;ANTONELLA BONI;ANDREA ZINI;DANIELE ORSUCCI;GIAMPIETRO RUZZA;PAOLO CANDELARESI;SILVIA CENCIARELLI;GINO VOLPI;FRANCESCA PISTOIA;MARIA GUARINO;EMANUELE ALESSANDRO CAGGIA;MAURIZIO PACIARONI;ANNA CAVALLINI;GASPARE SCAGLIONE;MICHELE ROMOLI","9;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5","LEONARDO A. SECHI;GIOSUÉ DIPELLEGRINI;DOMENICO POLICICCHIO;ALBERTO PORCU;RICCARDO BOCCALETTI;FRANCESCO BUSSU;TERESA PERRA;SILVANA SANNA;MARIA LUISA LAMPUS;ELENA RITA SIMULA;ARDUINO A. MANGONI;ANGELO ZINELLU;JACOPO GALLI;GIAN LUCA ERRE;PIER LUIGI FIORI;DAVIDE RIZZO;ROBERTO GALLUS;SEYEDESOMAYE JASEMI;PAOLO SOLLA;PAOLO RAGGI","1.27;0.68;0.68;0.64;0.63;0.57;0.51;0.5;0.5;0.5;0.43;0.4;0.4;0.4;0.39;0.38;0.38;0.36;0.35;0.33","LEONARDO A. SECHI;ANTONELLA BONI;ALESSANDRA SANNA;FRANCESCO BUSSU;SALVATORE RUBINO;ALBERTO PORCU;RICCARDO BOCCALETTI;PAOLO SOLLA;ANGELO ZINELLU;DAVIDE RIZZO;PIER LUIGI FIORI;GIOSUÉ DIPELLEGRINI;GIANPAOLO VIDILI;GIAN LUCA ERRE;CIRIACO CARRU;GAVINO CASU;CORRADO LIPERI;DOMENICO POLICICCHIO;FRANCA DERIU;IGNAZIO ROBERTO ZARBO","9;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","LEONARDO A. SECHI;GIOSUÉ DIPELLEGRINI;DOMENICO POLICICCHIO;ALBERTO PORCU;RICCARDO BOCCALETTI;FRANCESCO BUSSU;TERESA PERRA;SILVANA SANNA;MARIA LUISA LAMPUS;ANGELO ZINELLU;GIAN LUCA ERRE;PIER LUIGI FIORI;DAVIDE RIZZO;PAOLO SOLLA;ELIANO PIO NAVARESE;MARIA LAURA BECCIU;FRANCA DERIU;CIRIACO CARRU;CORRADO LIPERI;MARCO BO","1.27;0.68;0.68;0.64;0.63;0.57;0.51;0.5;0.5;0.4;0.4;0.39;0.38;0.35;0.33;0.33;0.29;0.28;0.27;0.25","ADELINA GIMENO;ANA BUDIMIR;ANA VERÓNICA HALPERIN;ANDRÉ ALMEIDA;ANNA GIAMMANCO;ANNA MICHALSKA-FALKOWSKA;ASGER NELLEMANN RASMUSSEN;ASSAF MIZRAHI;AXEL HAMPRECHT;BIANCA PAGLIETTI;BRANKA BEDENIĆ;CHANTAL QUIBLIER;CLÉMENCE MASSIP;CLÉMENT ZANCANARO;CORINA MUŞUROI;CORNELIU OVIDIU VRÂNCIANU;CRISTINA COSTA;DANIEL NUNES;DANIELA TĂLĂPAN;DELPHINE CHAINIER","8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8","BIANCA PAGLIETTI;LEONARDO A. SECHI;SALVATORE RUBINO;CORRADO LIPERI;GIANPAOLO VIDILI;ALESSIO ALIGI COGONI;FRANCESCO BUSSU;GAVINO CASU;ALBERTO PORCU;ANGELO ZINELLU;DANIELA PASERO;ELIANO PIO NAVARESE;FILIPPO VENEZIANI SANTONIO;GIOVANNI FADDA;GIUSEPPE D. SANNA;M.G. ALICICCO;MARIA LAURA BECCIU;PAOLA MARIA GRAZIA SANNA;PIETRO CARMELO MANCA;RICCARDO BOCCALETTI","8;8;8;6;6;5;4;4;3;2;2;2;2;2;2;2;2;2;2;2","LEONARDO A. SECHI;FRANCESCO BUSSU;GIANPAOLO VIDILI;ALBERTO PORCU;CORRADO LIPERI;GAVINO CASU;DAVIDE RIZZO;FRANCA DERIU;PIER LUIGI FIORI;RICCARDO BOCCALETTI;SALVATORE RUBINO;DANIELA PASERO;PIETRO CARMELO MANCA;ALESSIO ALIGI COGONI;ANDREA COSSU;ANDREA TONDO;ANGELA MURONI;ANGELO ZINELLU;ANTONELLO PIPPIA;BIANCA PAGLIETTI","9;5;4;3;3;3;3;3;3;3;3;2;2;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;SOCIOLOGY;CHEMISTRY;ECONOMICS;GEOGRAPHY;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;GEOLOGY","71;26;9;4;4;4;4;3;2;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GENETICS;PATHOLOGY;RADIOLOGY;ONCOLOGY;IMMUNOLOGY;GENERAL SURGERY;MECHANICAL ENGINEERING;PALEONTOLOGY;VIROLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;GASTROENTEROLOGY;PSYCHIATRY;BIOINFORMATICS;MICROBIOLOGY;ANATOMY;ANESTHESIA;DEMOGRAPHY;ECOLOGY;EVOLUTIONARY BIOLOGY;INTENSIVE CARE MEDICINE;MEDICAL PHYSICS;PEDIATRICS","45;20;16;15;10;10;9;8;7;6;6;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3","GENE;CANCER;DISEASE;ISCHEMIA;STROKE (ENGINE);CHEMOTHERAPY;RADIATION THERAPY;COHORT;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);STENOSIS;BODY MASS INDEX;EPIDEMIOLOGY;IMMUNE SYSTEM;OBSERVATIONAL STUDY;POPULATION;RHEUMATOID ARTHRITIS;VIRUS","13;12;11;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;COLORECTAL CANCER;GENOME;ISCHEMIC STROKE;CLINICAL ENDPOINT;HEAD AND NECK CANCER;MINOR STROKE;16S RIBOSOMAL RNA;ANTIBIOTIC RESISTANCE;BRACHYTHERAPY;CONVENTIONAL PCI;DOWNREGULATION AND UPREGULATION;GENOTYPE;LINEAGE (GENETIC);MICRORNA;MYOCARDIAL ISCHEMIA;PANCREATICODUODENECTOMY;PERCUTANEOUS CORONARY INTERVENTION;2019-20 CORONAVIRUS OUTBREAK;ACUTE RESPIRATORY DISTRESS;AMYOTROPHIC LATERAL SCLEROSIS;AORTIC ARCH;AORTIC VALVE REPLACEMENT;AORTIC VALVE STENOSIS;ARDS;BACTEROIDES;BILE LEAK;BILIARY TRACT SURGICAL PROCEDURES;BLOOD MANAGEMENT;BRAIN ABSCESS;BREAST AUGMENTATION;CARDIAC MAGNETIC RESONANCE IMAGING;CATHEPSIN B;CEPHALOSPORIN;CHEMORADIOTHERAPY;CHONDROITIN;CHRONIC HEPATITIS;CHRONIC LIVER DISEASE;CORONARY ANGIOGRAPHY;CORONARY ARTERIES;DEMYELINATING DISEASE;ELASTOGRAPHY;ELECTRONIC HEALTH RECORD;ELITE;ESCHERICHIA COLI;EXTERNAL VENTRICULAR DRAIN;FAECALIBACTERIUM PRAUSNITZII;FEATURE TRACKING;FLUOROURACIL;GEMCITABINE;GENE EXPRESSION;GENE KNOCKDOWN;GENE SILENCING;GENETIC DIVERSITY;GLUCURONIC ACID;GLYCAN;HEALTH RECORDS;HEPATIC FIBROSIS;HEPATITIS B VIRUS;IMMUNE DYSREGULATION;INSULIN RESISTANCE;LACTOBACILLUS;LINALOOL;LIVER FIBROSIS;LIVER TRANSPLANTATION;MASTOPEXY;MEDITERRANEAN ISLANDS;METASTASIS;MIDDLE CEREBRAL ARTERY;MYCOBACTERIUM;MYCOPLASMA HOMINIS;NAD+ KINASE;NASAL VESTIBULE;NEURODEGENERATION;NEURONAVIGATION;NEURORADIOLOGY;OCCULT;PACLITAXEL;PALLIATIVE CHEMOTHERAPY;PANCREATIC CANCER;PARKINSON'S DISEASE;PERFORMANCE STATUS;PERINEURAL INVASION;PET-CT;PHASES OF CLINICAL RESEARCH;PHYLOGENETIC TREE;PHYLOGENETICS;POLYMERASE CHAIN REACTION;POST PARTUM;PREDICTIVE MARKER;PROGRESSION-FREE SURVIVAL;PROTEIN KINASE B;PROTOCOL (SCIENCE);RADIATION TREATMENT PLANNING;RECOMBINANT DNA;REVASCULARIZATION;RIGHT VENTRICULAR FAILURE;SEROMA;SINUS RHYTHM;SKIN CANCER;SORAFENIB;THROMBOLYSIS;TIC DISORDER;TITER;TRICHOMONAS;TROPONIN;TYPE 1 DIABETES;VENTRICULITIS;VESTIBULE;WARFARIN","6;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORONAVIRUS DISEASE 2019 (COVID-19);ENDOGENOUS RETROVIRUS;ADJUVANT CHEMOTHERAPY;AKKERMANSIA;FIRMICUTES;GENETIC VARIANTS;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IRINOTECAN;ANTERIOR CEREBRAL ARTERY;ANTIBODY TITER;ATRIAL APPENDAGE;AUGMENTATION MAMMOPLASTY;BACTEROIDETES;BREAST RECONSTRUCTION;BREAST SURGERY;CAPECITABINE;CETUXIMAB;CIRCULAR RNA;CLADE;DEMOGRAPHIC HISTORY;DEOXYCYTIDINE;ENTEROBACTER;ENTEROBACTER AEROGENES;ENTEROBACTERIACEAE;FOLD CHANGE;FRACTIONAL FLOW RESERVE;HBSAG;IDURONIC ACID;ISCHEMIA-MODIFIED ALBUMIN;KRAS;LEFT ATRIAL APPENDAGE OCCLUSION;LYMPHOVASCULAR INVASION;MASTECTOMY;MICROARRAY;MODIFIED RANKIN SCALE;MULTIPLEX POLYMERASE CHAIN REACTION;NEOADJUVANT THERAPY;NICOTINAMIDE ADENINE DINUCLEOTIDE;PARATUBERCULOSIS;POLYCYSTIC OVARY;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL HAIRPIN RNA;TRANSIENT ELASTOGRAPHY;VACCINIA;WHIPPLE PROCEDURE","6;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;RETROSPECTIVE STUDIES;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;COVID-19;RISK FACTORS;SARS-COV-2;TIME FACTORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BIOMARKERS;LIVER NEOPLASMS;MULTIPLE SCLEROSIS;NEOPLASM RECURRENCE, LOCAL","42;32;21;19;16;13;12;10;7;7;5;4;4;4;4;3;3;3;3;3","RHEUMATOID ARTHRITIS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CHOLANGIOCARCINOMA;CHOLESTEROL-LOWERING TREATMENT;CORONAVIRUS DISEASE 2019 RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MOLECULAR RESEARCH ON BREAST CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ATRIAL FIBRILLATION;BIOGENESIS AND FUNCTIONS OF CIRCULAR RNAS;BIOTECHNOLOGICAL PRODUCTION OF VANILLIN;BODY CONTOURING TECHNIQUES AND PROCEDURES","3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","STROKE (ENGINE);INFARCTION TREATMENT;CLINICAL ENDPOINT;MINOR STROKE;ADJUVANT CHEMOTHERAPY;AKKERMANSIA;BODY MASS INDEX;BREAST CANCER SCREENING;CHOLANGIOCARCINOMA;CHOLESTEROL-LOWERING;DIAGNOSIS;DYSREGULATION;ENDOGENOUS RETROVIRUS;FUSOBACTERIA;IDENTIFICATION (BIOLOGY);INTRACRANIAL ANEURYSMS;LACHNOSPIRACEAE;LEFT VENTRICULAR FUNCTION;LINEAGE (GENETIC);MENDELIAN RANDOMIZATION","6;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;ISCHEMIC STROKE;ANTIPLATELET TREATMENT;AORTIC VALVE;BODY MASS;CELL CARCINOMA;COLORECTAL CANCER;DUAL ANTIPLATELET;LEFT ATRIAL;MASS INDEX;MULTIPLE SCLEROSIS;PHASE III;READAPT STUDY;RHEUMATOID ARTHRITIS;SQUAMOUS CELL;ADJUVANT CHEMOTHERAPY;ANTIMICROBIAL RESISTANCE;APPENDAGE OCCLUSION;ARTHRITIS PATIENTS;ATRIAL APPENDAGE;CARDIOVASCULAR EVENTS;CHEMOTHERAPY SCHEDULES;ENDOGENOUS RETROVIRUSES;GIM TRIAL;III GIM;INTERNATIONAL MULTICENTER;INTERVENTIONAL RADIOTHERAPY;LOCAL ANESTHESIA;MATCHED ANALYSIS;MINOR ISCHEMIC","4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ISCHEMIC STROKE;PATIENTS TREATED;PSYCHOBIOSOCIAL EXPERIENCES;SELFEVALUATED PERFORMANCE;ARDS PATIENTS;CUT-OFF VALUES;DRIVING PRESSURE;ISCHEMIC ATTACK;MAJOR HEALTH;MODERATE ARDS;MS PATIENTS;RHEUMATIC DISEASES;TRANSIENT ISCHEMIC;ADVANCED CAD;ANTITHROMBOTIC REGIMEN;BLOOD CELL;CARBAPENEMS RESISTANCE;CMH NA;CONCENTRATION DISRUPTION;DE POINTES;DISEASE PROGRESSION;DUAL ANTIPLATELET;F-FDG PETCT;HUMAN ENDOGENOUS;LIVER DISEASE;MAP INFECTION;OCULAR TICS;RA PATIENTS;RATIO CI;RENAL FUNCTION","8;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",1,0.01,20.3,25,0,0,0,1,0,0,0,27,0,0,24,0,0,1,8,14,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,2,552,1.1,0,0,41,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","1;1;1","BEHAVIORAL AND SOCIAL SCIENCE;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DEPRESSION;HEMATOLOGY;LYMPHOMA;MENTAL HEALTH;PREVENTION;RARE DISEASES;REHABILITATION","1;1;1;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE","1","7.1 INDIVIDUAL CARE NEEDS","1","COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA","1;1","6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"FRONTIERS","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","4;2;2","CANCER;CHILDHOOD LEUKEMIA;CLINICAL RESEARCH;HEMATOLOGY;PEDIATRIC;PEDIATRIC CANCER;RARE DISEASES","2;2;2;2;2;2;2","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2",NA,NA,"CLINICAL MEDICINE AND SCIENCE","2","LEUKEMIA / LEUKAEMIA","2",NA,NA
